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ABSTRACT

Trauma diagnostics and management are major aims of research for implantable
amperometric enzyme biosensor technology [1-3]. Biosensors are capable of monitoring
metabolic variables in a minimally invasive manner [4] and have great potential to
augment current wireless vital sign monitoring technologies [5] in order to make a more
robust physiologic status monitoring platform [3]. The dual responsive Electrochemical
Cell-on-a-Chip Microdisc Electrode Array (ECC MDEA 5037) is a recently developed
electrochemical transducer for use in a wireless, implantable biosensor system for the
continuous measurement of interstitial glucose and lactate. Hyperglycemia arising from
insulin resistance and hyperlactatemia arising from anaerobic metabolism both occur
following trauma and hemorrhage. The extent of trauma can be correlated to the
magnitude of the hyperglycemic response [6]. Rate of production and final concentration
of lactate in both interstitial and blood compartments have also been observed to correlate
to various stages and endpoints of trauma [3, 7-9]. Applying the integrated metabolic
response of these analytes to direct lifesaving interventions may decrease mortality and
other complications of hemorrhage and shock.
The Pinnacle dual potentiostat (A) and MDEA 5037 biotransducer (B) form a
system (C) intended to demonstrate the value of advanced point-of-care diagnostic
technology. When configured as an ASIC, this minimally invasive implantable device
may be used by first responders to initiate early and continuous monitoring of patient
physiologic status. Development of the bioactive membrane and both in vitro and in vivo
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characterization of the MDEA 5037 have been performed. Using the mediator ferrocene
monocarboxylic acid (FcCOOH) as a redox probe, the steady state dose response of the
MDEA 5037 was 1.9 times greater than the theoretical response as determined by the
Cottrell relationship for multi-disc array electrodes. Electrochemical impedance
spectroscopic analysis of the MDEA 5037 fits a standard Randle’s equivalent circuit
model with error <9% when probed with FcCOOH. The oxidoreductase enzymes glucose
oxidase (GOx) and lactate oxidase (LOx) have been immobilized onto MDEA 5037
transducer working electrodes via electro-co-polymerization of pyrrole (Py) and pyrrole
butyric acid (PyBA) (7:1 feed) (p(Py-co-PyBA copolymer). Biotransducers were shown
to have a sensitivity of 4.75 (±0.93) µA/mM/cm2, a KMapp of 7.20 (±2.59) mM, an Imax of
76.75 (25.50) µA/cm2, a response time of 16.5 (±5) s, and a detection limit of 0.05
(±0.03) mM. The foregoing use of the p(Py-co-PyBA) co-polymer yielded a fivefold
increase in sensitivity (p < 0.001) and a threefold increase in maximum current (p < 0.01)
compared to biotransducers fabricated with polypyrrole (PPy) only. A Sprague-Dawley
hemorrhage model was instrumented with indwelling biotransducers and externalized
wireless potentiostat. Resection after 4 h and subsequent in vitro testing showed a
decreased sensitivity from 0.68 (±0.40) to 0.22 (±0.17) µA/mM/cm2 with an average
change of 56 (±48) %, and a change in the in limit of detection from 0.05 (±0.03) to 0.27
(±0.27) mM with an average change of 298 (±298) %. Response time of resected
biotransducers was 244 (±193) s, 6 times greater than pre-implanted biotransducers with
a response time of 41 (±18). This is likely due to biofouling and/or protease related
enzyme denaturation. For long duration implantable devices [10] an electroconductive
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hydrogel [11] has been developed to confer its antifouling properties [11, 12]. In addition
to mitigating inflammation and fibrous encapsulation, these hydrogels maintain the
stability of the enzymes far more effectively when compared to system fabricated with
just polypyrrole and show increasing sensitivity during storage for up to 21 days [1].
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CHAPTER ONE: MONITORING SYSTEMS AND QUANTITATIVE
MEASUREMENT OF BIOMOLECULES FOR THE MANAGEMENT OF TRAUMA

1.1 Introduction
Hemorrhage is a primary complication of trauma as seen on battlefields, in
emergency departments, operating rooms, and intensive care units [13, 14]. Available
mortality data shows that, in 2006, unintentional injuries were the leading cause of death
in individuals of 1-44 years of age and the 5th over-all leading cause of death for all age
groups in the United States [15]. Also, in 2006, for every trauma induced death, there
were eleven times as many hospitalizations and 179 times as many emergency
department visits [15]. Trauma diagnosis describes the nature of an injury as well as the
body region affected by said injury. Injury severity score (ISS) based on both
mechanisms and locations of injury is typically used to gauge the threat to life that
trauma exhibits [16]. An ISS of ≥16 is considered severe trauma [16].
Discussion of hemorrhage is often difficult because the events of trauma are not
fully understood or immediately observable. Overlap of cardiovascular, metabolic,
neural, and endocrinal events blur the lines of trauma and hemorrhage related
phenomena. Factors of age, fitness, lifestyle, diet, type of trauma, total blood volume
(TBV) loss, rate of blood loss, and pre-existing physiologic condition have a cumulative
influence on the metabolic and physiologic responses for a trauma patient [17-22].
Severe trauma induced hemorrhage, or blood loss >30-40% total blood volume, is
capable of sending an individual into a state of hemorrhagic shock [23]. Shock is defined

as a physiological state of hypoperfusion in which oxygen is inadequately used or
delivered at the cellular level [24, 25].
Trauma management involves diagnostics and prognostics that begin in the prehospital setting at the site of patient injury and continues throughout the time course of
patient care. The goals of trauma management are to predict, prevent, and treat the state
of shock and its morbidities in order to improve survival. In the case of trauma, many
problems are centered on uncontrolled bleeding, patient instability, and hemorrhagic
shock. Major classifications of patient diagnostics can be considered as physical or
metabolic.
Physical or global vital signs are at the organismal (whole body) level and include
variables such as blood volume, hematocrit, blood pressure, heart rate, body temperature,
fluid output (urine), and other physically relevant observations, e.g. pupil dilation [26].
Physical variables can typically be measured directly with simple instruments or medical
devices and visual inspection [13, 27]. Physical vital signs are thus the first to be
measured by emergency medical technicians, paramedics, and battlefield medics. Early
decisions on trauma management, triage and resuscitation are often based on these
physical vital signs [28, 29].
More complex metabolic diagnostics involve monitoring of homeostatic
mechanisms by either direct or indirect measurement of metabolic products using
laboratory analysis or point of care (POC) testing devices. Metabolic markers are
monitored to supplement physical vital signs in order to assess body function, predict
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mortality and complications, and determine success of surgical interventions and
resuscitation.
The following chapter is a critical review of the methods for determining
physiologically-relevant biochemical markers that may serve as indicators of occult
bleeding and traumatic injury. Attention is given to advances in biomedical devices and
microdevice technology that are relevant to trauma, hemorrhage and hemorrhagic shock
diagnosis. Because of the inherent subjectivity in interpreting patient vital signs, there is
need for 'smart' sensors and information systems for assessing evolving trauma-related
shock on a patient-by-patient basis.
This review identifies the opportunity to develop different varieties of biosensors
to collect multivariate physiological data and the information systems to fuse and present
that data as useful information in the form of a rapidly-interpretable index of present
patient condition that could serve to change patient outcomes. Physiologic status markers
and monitoring technologies are important for building confidence in novel diagnostic
and prognostic platforms and will be considered simultaneously for effectiveness in their
use for the management of trauma. A summary of the diagnostic value and limitations of
these physiologic status markers are given in Table 1.1.
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Table 1.1 Summary of the diagnostic utility and limitations of physiologic status markers.
Diagnostic marker
Blood pressure

Diagnostic utility
•
•

Limitations

Hypotension defined at
SBP <90 mmHg
Predictive of mortality
beginning as high as 110
mmHg

•
•

Circulatory compensation skews
blood pressure measurements
Cannot be used to detect occult
hypoxia (tissue hypoxia without
hypotension)

Heart rate

•

Tachycardia (rate >100
BPM) indicative of need
for fluid resuscitation

•

Tachycardia may be absent even
after major blood loss in as high
as 35% of cases

Hematocrit

•

Low admittance
hematocrit at arrival to an
emergency department
implicates the presence of
a severe injury

•

Surrogate for detection of
hypoxia
Prognostic factor of
morbidity and mortality
for trauma patients with
shock

•

Usefulness limited to late-stage
determination of injury severity
Auto-resuscitation and prehospital fluid resuscitation will
cause continual variation in
hematocrit
Currently only considered useful
for treatment of patients in
intensive care units
Limited to discrete measurement
by laboratory and point of care
analysis

Correlates to systolic
blood pressure and
hypoperfusion
Differentiates reversible
from irreversible
hemorrhagic shock at late
stages of trauma

•

Has not been formally or
rigorously evaluated for the
management of trauma

Lactate (blood or
tissue)

•
•

Tissue oxygenation

•
•

•

•

Redox status

•

Trauma patient
improvement correlates
with electrochemical
response due to reactive
oxidative species

•

Has not been formally or
rigorously evaluated for the
management of trauma

Glucose

•

Hyperglycemic response
is indicative of injury
severity
Hypoglycemia is
indicative of shock

•

Limited to discrete measurement
by laboratory and point of care
analysis

Predictive of hemorrhagic
hypotension (in pigs)

•

Very few clinical studies
reporting on hyperkalemia in
shock
It is not well known if
hyperkalemia occurs in humans
following shock

•
Potassium

•

•

Base deficit

•

Measure of acidosis in a
trauma patient
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•

Poor independent marker for
distinguishing survivors from
non-survivors of hemorrhagic
shock

1.2 Physical vital signs
1.2.1 Blood Pressure
Systolic blood pressure is one of the Advanced Trauma and Life Support (ATLS)
standard vital signs for determining hypotension and hemorrhagic shock [30]. In the case
of severe blood loss, trauma patients are immediately taken to the intensive care unit
(ICU) by first-responders if found having a systolic blood pressure (SBP) of <90 mmHg
[31]. The time exposure to shock is a significant danger to any trauma patient, and
successful outcome is heavily dependent upon the depth and total duration of
hypoperfusion [21, 32]. However, not all trauma victims, even those in the state of shock,
will reach a SBP as low as 90 mmHg [31, 33]. Hypotension and hypoperfusion have
been observed to begin at SBP as high as 110 mmHg [34-36].
Monitoring blood pressure is relatively simple and can be done in an automated
fashion in the hospital setting using catheters in major blood vessels or the heart. Blood
pressure monitoring of trauma victims in the field by auscultation is standard for
diagnosing vascular injuries, extent of hemorrhage and shock [27]. There are difficulties
when continually measuring blood pressure in moving vehicles such as ambulances and
helicopters which may render some measurements unreliable [27, 37, 38]. This is of
special concern when in austere environments such as on battlefields and resource poor
rural and urban areas that do not allow for much sophisticated and automated equipment
[27].
Considering the potential of occult hypoxia combined with circulatory
compensation, blood pressure measurement with conventional means is less than ideal for
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continual monitoring of trauma victims for hemorrhagic shock. Advanced blood pressure
cuffs using programmable systems on a chip (PSOC) have been designed to better
automate SBP measurement [39]. Integration of all major components and subsystems
onto a single chip is an important step toward advancing wireless and mobile
oscillometric diagnostics. A small device footprint is attractive to combat medics who are
limited in the total weight each can carry. Having more advanced and accurate blood
pressure measurements may make field diagnostics and triage more reliable.
A

B

Figure 1.1. (A) Inductively powered blood flow microsensor, with an ASIC and two coils. (B) MEMS
pressure sensing element used in the microsensor based on silicon nitride and silicon oxide layers with a
piezoresistive silicon nanowire field effect transistor [40].

Invasive blood pressure monitoring with implantable biosensors is currently
nascent in its stages of development. Inductively powered blood flow sensor
microsystems have been shown to be effective at monitoring blood flow and degradation
in prosthetic vascular grafts, Figure 1.1 [40]. There is additional need for such sensors in
determining vascular graft infection and failure [41]. Biosensor technology based on
smart hydrogels combined with piezoresistive pressure transducers can produce
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chemomechanical sensors for determining blood pressure in vivo [42]. Advances in
CMOS implementation of a linear voltage regulator will enable powering of an implanted
wireless blood pressure biosensor [43]. Grand challenges of biocompatibility and
hermeticity have been identified as paramount for long-term implantation of such
pressure transducers.
1.2.2 Heart Rate
Heart rate has been a standard physical vital sign for hypovolemic shock for
several decades [44]. By the ATLS standards for in-hospital patient care, tachycardia
(heart rate > 100 BPM) suggests the need for fluids intervention and bradycardia (heart
rate ≈ 60 BPM) suggests patient stability [44]. Heart rate is an easy-to-monitor vital sign
using auscultation [45]. Absence of tachycardia in a trauma patient may lead to a false
sense of hemodynamic stability which may result in delays of emergent interventions
[44]. This is an important consideration when numerous animal studies have shown that
tachycardia may be absent even after major blood loss [46-53]. Of 489 hypotensive
patients of trauma studied, 35% showed no signs of tachycardia [54]. Thus, using heart
rate alone to determine the need for resuscitation is a danger to the trauma patient. Heart
rate is better utilized in trauma management when considered concomitantly with other
vital signs.
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A

B

Figure 1.2. (A) Edible microsensor by Proteus Biomedical directly attached to a tablet for ingestion. (B)
Wearable health monitor that wirelessly communicates with the edible microsensor to collect physiologic
data such as temperature and heart rate [55-57].

Although monitoring of hemorrhagic shock by means of heart rate as an
independent variable would not be reasonable, it remains a necessary and useful
measurement to all caregivers. Decreases in heart rate will follow circulatory
decompensation in the case of severe trauma and ushers in the state of irreversible shock.
Ingestible integrated circuit microchip sensors along with wearable wireless health
monitors are currently under development for the measurement of heart rate within the
body, Figure 1.2 [55-57]. Non-contact miniaturized biosensors have been able to reach
accuracy with mean errors in detection of respiration of 0.5 beat/min and heart rate of 1
beat/min [58]. Continuous heart rate monitors such as these would lessen the need to use
auscultation in the field and enable convenient heart rate measurements during patient
transit.
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1.3. Metabolic markers of stress
1.3.1 Hematocrit
Hematocrit is a measure of percentage of red blood cell volume to whole blood
volume [59]. Normal ranges of hematocrit are about ≥35% for women and ≥39% for men
[59]. Patients with penetrating trauma, although not receiving fluid resuscitation en route
to the hospital, have been observed to present lower hematocrit levels upon arrival to the
ED compared patients without significant injury (no surgery needed) [59]. Decreased
hematocrit due to trauma is due to self-compensation of interstitial fluid entering the
vascular space and due to any pre-hospital fluid resuscitation [60]. Lower admittance
hematocrit or greater rates of decrease in hematocrit after emergency department arrival
implicate the presence of a severe injury [59].

Figure 1.3. Capacitive hematocrit sensor working at 400 kHz. Temperature drift has a large effect on the
effectiveness of the sensor and requires compensatory feedback to account for it.
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Hematocrit is a good late-stage determinant of injury severity, but may not be
good for immediate risk assessment by first responders. Auto-resuscitation will occur
within 15 minutes after trauma and hemorrhage [61]. It will not be possible for EMS
personnel to know the trauma victim’s initial hematocrit, and much would still be left to
qualitative observation to estimate blood loss. Dielectric spectroscopy, through
permittivity measurements of blood samples, has been shown to be accurate for
measuring hematocrit in a continuous fashion in the clinical setting with high accuracy
and low error (5%) [62]. Other sensor designs utilize capacitive measurements to
determine hematocrit, wherein capacitance of a sample changes due to changing blood
cell count to total blood volume, Figure 1.3 [63]. These methods are useful for continual
monitoring of hematocrit and patient vital signs, but are very limited to their use inhospital. Changing hematocrit is also a variable that more often than not confounds
readings of glucose and lactate from in-dwelling implantable amperometric biosensors
and must be accounted for during design [64].
1.3.2 Lactate
Lactate (lactic acid; pKa = 3.86), is a clinically significant biomarker/metabolite
to medical professionals because of its importance in several conditions including; lactic
acidosis, severe dehydration, respiratory failure, heart failure, severe infections, alcohol
abuse, liver disease, ketoacidosis, hemorrhage and shock. Normal serum lactate is
defined by blood values from 0.5 to 2.2 mM for venous blood and 0.5 to 1.6 mM for
arterial blood. Hyperlactatemia is considered arterial blood lactate in excess of 2.2 mM,
and severely elevated blood lactate levels can be considered greater than or equal to 4
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mM [65, 66]. Blood lactate is most often measured via in-hospital laboratory analysis in
the lab. Lactic acidosis or hyperlactatemia occurs pursuant to anaerobic metabolism of
glucose during tissue hypoxia [67] and is linked to glycogen stores via the Cory cycle.
Arterial lactate has been well documented as a predictor of injury severity and a
prognostic factor of morbidity for trauma patients with hypovolemic shock [7, 8] and is
implicated in patient’s response to vasopressin therapy [68].
Having importance in both the sports and health care applications, continuous
lactate monitoring biosensors are under heavy research, design and development, Figure
1.4. Some recent novel continuous lactate monitoring transducer designs include
implantable needle type [69], implantable multidisc array [70], wearable and flexible
graphene-based nano-structured sheets [71], implantable Prussian Blue modified carbon
fibers [72], and transdermal microspike arrays [73]. These biosensor systems all have
excellent concentration detection ranges of approximately 0.4-7 mM [3], rapid response
times of 2-60 s in vitro [3, 71] and response times of <10 min in vivo [69]. Design of
long-term implantable devices requires use of permselective and anti-fouling membranes
which can lead to a significant decreases in overall sensitivity; as high as 60-75% [1, 72].
The small footprint of these systems will enable analyte measurement in tissues and
environments previously unexplored.

11

Figure 1.4. Lactate concentration in tissue and blood of a Sprague-Dawley rat. Tissue lactate was
continuously monitored with an implantable needle type biosensor and blood lactate was measured using
Lactate Pro test strips with venous blood from the tail vein. The implanted biosensor was interrogated by
infusing sodium lactate into the blood and the surrounding tissue.

Continual monitoring of lactate may give insight into the dynamic nature of
hemorrhagic shock. The temporal behavior and tissue-specific spatial distribution of
lactate has not yet been rigorously studied during hemorrhage through the initial onset of
hemorrhagic shock. There is clear indication that muscles, being the largest consumer of
oxygen, are likewise the dominant source of lactate during hemorrhage. Intramuscular
lactate must diffuse into the vasculature in order to establish the familiar venous and
arterial lactate values. Interstitial values of intramuscular lactate may therefore be a more
appropriate indicator than serum lactate in establishing temporal behavior. Such data may
be more useful in determining triage, assessing risk of mortality and co-morbidities, and
guiding patient-specific resuscitation strategies. These findings suggest a need to
continually monitor the total extent of elevated lactate for determination of total extent of
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hypoperfusion and hypoxia rather than taking discrete lactate measurements during
trauma management as is currently the standard of practice in hospitals.
1.3.3 Tissue oxygenation
Tissue oxygen saturation (StO2) is a medical parameter that quantifies the ratio of
oxygenated hemoglobin concentration to total hemoglobin concentration in the
microcirculation of tissues and is given as an absolute number or percentage.
Hemoglobin oxygen saturation (SpO2) and partial pressure of oxygen (pO2) are other
measures of oxygenation and pertain primarily to blood. Therefore, StO2 is primarily a
measurement of oxygen supply and consumption at the local tissue level and not a
measure of systemic oxygenation. Under standard conditions (T = 37 °C, pH = 7.4 and
PCO2 = 40 mm Hg) the partial oxygen pressure at half-saturation of hemoglobin (p50) was
25.7 ± 0.35 mmHg for humans [74, 75], 30.0 (±1.3) mmHg for dogs and 34.1 (±1.8)
mmHg for cats [76]. Healthy, ambulatory humans average tissue oxygen saturation of
87% ± 6% measured in the thenar muscle [18]. A cutoff value of <75% StO2 has been
used to discriminate mortality and severe hemorrhagic shock in major blood loss patients
[18].
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Figure 1.5. NIRS sensor placed on thenar eminence of hand (left). Using the fundamentals of Beer’s law, a
spectrum of reflected near-infrared light (700-1000 nm) is used to measure the percentage of hemoglobin
saturation (right) [77].

Near-infrared spectroscopy (NIRS) is a technology that has been developed to
estimate local tissue oxygen saturation [78]. The technology continually monitors light
transmission of cytochrome aa3, myoglobin, and hemoglobin based on Beer’s law [78].
Absorption spectra of oxygenated and deoxygenated hemoglobin differ, which allows
their relative concentrations to be measured within tissue [78]. The measurements of
NIRS are indicative of local venous and arterial oxyhemoglobin concentrations, as well
as oxygen delivery and consumption of the sampled tissue bed [78-80]. Cytochrome aa3
relates to oxygen consumption by mitochondria [81]. Being a completely non-invasive
platform is a major advantage for NIRS. Measurements are typically taken from the
thenar eminence of the hand, Figure 1.5 [77].
It has been surmised that tissue oxygen saturation (StO2) is a marker of
hypoperfusion that can be used for continual monitoring from the onset of a traumatic
injury in order to better identify patients of shock [18]. StO2 of rat skeletal muscle
measured by NIRS has been shown to differ between reversible and non-reversible shock
arising from severe hemorrhage (ca. 40% TBV) [82]. The NIRS system has been non-

14

rigorously tested in a battlefield Combat Support Hospital in Tikrit, Iraq in 2005 [77].
Among the cases where it was used, StO2 measurements were reasonably correlated to
patient status and were shown to be able to serve as a non-invasive tool for monitoring
hypoperfusion and resuscitation in severely injured trauma patients, Figure 1.6 [77].

Figure 1.6. Tissue oxygenation monitored with NIRS immediately prior to and following fluid
resuscitation of a warfighter. StO2 closely follows systolic blood pressure in real time (n = 1) [77].

Voltammetry using carbon paste electrodes (CPEs) has also been shown to be an
effective electrochemical technique for monitoring tissue oxygenation (oxygen
concentration) both in vitro and in vivo by studying oxygen reduction at the surface of the
electrodes [83]. At a potential of -650 mV vs SCE, Sensitivity of -1.49 (±0.01) nA/µM
with low limits of detection approaching 0.1 µM have been reported with additional
advantages of having no dependence upon pH, temperature, ion concentrations and fluid
convection [83]. Needle type oxygen microsensors with wireless telemetry have likewise
been shown to be highly stable during short-term implantation (ca. 24 hr) in conscious
rats; achieving a sensitivity of 213 (±2) pA/ µM [84].
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The number of times that tissue oxygenation has been evaluated for management
of trauma is too few to make formal recommendations. Further testing is still required to
determine if any muscle body is sensitive enough to detect minor changes in perfusion
hemostasis. The hurdles to overcome will be tissue site specific probe design, algorithm
development and optical modeling [85]. Concerning decision making algorithms for
patient resuscitation, the use of NIRS has not shown a significant influence in guiding
fluid management, for example, in colorectal surgery patients [86]. There are currently
very few recently published prospective studies examining the use of NIRS or tissue
oxygenation in trauma victim triage and fluid resuscitation. Further testing to establish
the usefulness of this vital sign in early shock management is necessary [32].
1.3.4 Redox status
The redox status of a trauma victim is determined by the milieu of reactive
oxidative species that result from trauma [87]. Hemorrhagic shock leads to increases in
extracellular hydrogen peroxide, superoxides, and peroxynitrite [87]. Monitoring of the
tissue-specific

redox

status

has

remained

largely unexplored

until

recently.

Electrochemical methods such as cyclic voltammetry have been employed in-vivo to
monitor serum redox status after hemorrhagic shock [87]. Preliminary results show that
real time improvements can be observed in a recovering trauma patient by monitoring the
changes and decreases in peak potentials of cyclic voltammograms [87]. These results
demonstrate the versatility of electrochemical techniques in assisting with patient
monitoring. Electrochemical methods are generally easy to implement and micron-sized
electrodes and electrochemical cells have been developed [70] along with miniaturized
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potentiostats. While generally non-specific, there is still much opportunity to explore
redox status in relation to trauma states.
1.3.5 Glucose
Glucose is another important metabolite measured in the hospital by blood
analysis. Hyperglycemia (arterial glucose ≥110 mg/dL) after injury has been observed in
both diabetic and non-diabetic patients [88, 89]. Early investigations have found that i)
initial hyperglycemia typically occurs rapidly after injury and ii) severity of shock, based
on blood pressure, can correlate to the magnitude of the hyperglycemic response [6].
Acute blood withdrawal has also been shown to induce the hyperglycemic response
followed by significant hypoglycemia in rats [90].
It is clear that trauma and hemorrhage have an effect on blood glucose
concentrations, making it an excellent biomarker for continuous monitoring during
trauma patient care. Glucose, because of its close biochemical link to lactate via
glycolysis, its relation to insulin resistance [91-93], and its physiologic link to lactate via
the Cory Cycle, may be a suitable metabolite whose real time and temporal levels may be
crucial for the prediction and management of hemorrhagic shock [94]. With early and
continuous monitoring of glucose, a patient beginning to present the hyperglycemic
response may quickly be resuscitated or triaged before further complications can arise.
This sort of treatment entails fast, efficient, and accurate glucose monitoring. Research
into diabetes has generated much knowledge on the metabolism of glucose and the means
by which it is monitored.
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Many different glucose biosensors have been developed, including transcutaneous
continual monitoring systems [95], capillary blood glucose test strips [96] and handheld
cartridge-based blood gas analyzers [97]. Many of these techniques are still considered
inaccurate for critically ill patients according to the Clinical and Laboratory Standards
Institute standards [96]. Cartridge based blood gas analyzers are becoming widely
adopted for fast turn around and critical care decisions [97]. Pilot studies have shown that
subcutaneous glucose monitors have been considered “good” when compared against
laboratory measurements using Bland-Altman and Clarke error grid analysis in critically
injured patients [98, 99].
Implantable biosensors based on osmotic swelling and electroconductive
hydrogels (ECH) are attractive new platforms for simple, rapid, sensitive and continuous
monitoring of glucose [1, 11, 12, 100, 101]. Oxygen independence is a major advantage
of swelling-based glucose sensitive hydrogels (GSHs) because enzymes are not present
within the system. Large magnitudes of swelling pressure have been reported for GSHs
with sensitivities of approximately 1750 Pa/mM in buffer [101]. Electroconductive
hydrogels

have

significantly

better

in

vitro

performance

with

respect

to

pheochromocytoma (PC12) cell and human muscle fibroblasts (RMS13) viability and
proliferation compared to gold electrodes and base (non-conductive) hydrogels [102].
Novel biotransducers have been fabricated by coating fully integrated
electrochemical

cell

microdisc

electrode

array

(MDEA)

transducers

with

electroconductive hydrogels containing glucose oxidase [12]. Such biotransducers
exhibited good in vitro performance with respect to low limits of detection of 0.02 mM
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and response times of 2-8 seconds. These ECH-modified transducers have the drawback
of lower sensitivity compared to non-ECH modified transducers [11, 12]. Additional in
vivo experiments on such electroconductive hydrogels are lacking and should be the next
point of interest for these biosensor systems. Glucose has not been well studied under
conditions of controlled hemorrhage or studied during the onset of hemorrhagic shock.
Therefore, these novel continuous glucose monitoring devices will need to be tested
under such pathophysiologic conditions in order to prove their usefulness in emergency
care.
1.3.6 Potassium
Potassium is an electrolyte measured from blood samples during trauma care.
There is evidence that fluid resuscitation, especially with packed red blood cells and
plasma products, renders hemorrhagic shock patients predisposed to hyperkalemia [103,
104]. Hyperkalemia is characterized by elevated plasma potassium levels (≥5.5 mmol/L)
and elevates the risks of cardiac arrhythmia and stand-still in trauma victims [103, 105].
Within 60 minutes of hemorrhagic hypotension at MAP <40 mmHg, rats surviving
hemorrhagic hypotension have shown to have significantly lower concentrations of
arterial and venous potassium, 5-6 mmol/L, than non-survivors, 6-9 mmol/L [90]. A rise
in serum potassium concentration will accompany the onset of hemorrhagic shock in pigs
[103]. Correlations of serum potassium to changes in arterial pH, PCO2, and SvO2
support its use as an acute ischemic insult marker in hemorrhagic shock, Figure 1.7
[103].
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Figure 1.7. Relationship of the changes in arterial partial pressure of CO2 and mixed venous oxygen
saturation (SvO2) to arterial potassium levels during hemorrhage in swine. Arterial potassium has potential
of being a marker of acute ischemia [103].

Ions are relatively easy to monitor via potentiometric and impedimetric analysis.
Impedance-based, contactless electrophoresis microchips offer detection of potassium
ions over a linear range of 0.02-7 mM with detection limits of 2.8 µM [106]. Contactless
conductivity measurement of potassium is most advantageous in that working electrodes
are insulated from the electrolyte thereby enabling simple construction, preventing
electrode degradation and mitigating undesirable crosstalk [107]. The power and scope of
microfluidic analytical devices in trauma diagnostics will be largely dependent upon their
cost, especially considering the need for continual or rapid monitoring of potassium. Low
cost materials such as aluminum and poly(methyl methacrylate) (PMMA) have been
employed to great success [106].
However, there are very few additional prospective clinical studies that report on
hyperkalemia in shock or trauma, and it is not well known whether hyperkalemia occurs
in humans following hemorrhagic shock [103]. Initial large animal studies have shown
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promising results with significant differences in both arterial and venous potassium
concentrations

when

comparing

survivors

and

non-survivors

of

hemorrhagic

hypotension. However, additional prospective work will be necessary in the clinical
setting to evaluate the usefulness of blood potassium as a surrogate for quantizing states
of hemorrhage. Some major challenges facing implantable potassium biosensors will
include ensuring selectivity and miniaturization of impedimetric microchip architectures.
Traditional amperometric detection, which most enzyme-based biosensors utilize, is not
likely to be useful in detection of potassium.
1.3.7 Base deficit
Base deficit (BD) is the measure of additional base that must be added to a liter of
blood in order to normalize the pH to a standard physiologic value [108]. However, base
deficit is often calculated and reported in terms of base excess [109]. Thus, the more
negative value of calculated base excess indicates a higher base deficit and acidosis.
Metabolic acidosis can be assessed with base deficit and other known parameters [110].
Normal levels of base deficit range from 2 to -2.0 mmol/L [111, 112]. A blood gas
analyzer may be used to measure partial pressure of CO2, pH, and HCO3- and base deficit
can be subsequently calculated in mEq/L [108, 109]. There have been several studies
showing the correlation of BD to injury severity and degree of hemorrhage [113, 114].
Base deficit has been shown to be a poor marker for distinguishing survivors from
non-survivors of hemorrhagic shock and trauma [90, 115]. In a prospective hemorrhagic
shock model, no statistical difference was observed in the BD values of rats surviving
hemorrhagic shock compared to non-survivors [90]. However, there was a significant
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increase in base deficit (more negative values) for rats undergoing shock when compared
to un-hemorrhaged rats [90]. Measurements of base deficit combined with other markers
of acidosis yield better estimates of survival probability [116]. Continually monitoring
base deficit would require monitoring of several different blood analytes simultaneously
[110]. Hemoglobin, blood PCO2, and pH all need to be taken into account in order to
determine a value for base deficit [110].
1.4. Advances in technology for monitoring trauma
1.4.1 Laboratory standards in trauma diagnostics
Standard means of blood analyte and biomarker measurement in-hospital is
typically made via laboratory analysis [117] performed under the Clinical Laboratory
Improvement Amendments (CLIA) program (in the USA). Plasma-based assays can be
performed on machines such as the Roche Cobas Integra 400 analyzer (Roche
Diagnostics, Indianapolis, IN) and the Vitros 250 analyzer (Ortho Clinical Diagnostics,
Rochester, NY) [118]. During critical care of patients, blood samples are periodically
taken and placed into special tubes which must be kept in ice [119]. Samples are then
transported to a laboratory to be prepared, centrifuged, and pipetted to definite volumes
for analysis [119]. Data acquired from analysis is transported to responsible physicians
for critical decision making [119]. Temperature, timing, and sample preparation all have
potential for introducing errors [119, 120]. In-hospital laboratory blood tests usually take
anywhere from forty minutes to four hours starting from when a patient is received at a
triage station [117, 119, 120].
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1.4.2 Point of care devices
Point of care testing has been gaining popularity due to the desire for rapid
monitoring of the numerous metabolic markers of stress [3, 117, 118, 121]. For trauma,
this involves sampling and analysis of whole blood using hand-held or bench top devices
[120, 121] approved by the FDA and that may be CLIA waived. Point of care devices
allow for rapid results, easy sample preparation and processing, small sample volumes,
small footprint, multifunctional analysis, and low cost [121]. Much emphasis and work is
going toward validating these devices in clinical use as either supplements to or as
potential replacements for laboratory testing [98, 99, 117, 121-123].
Whole blood analyzers typically work based on electrochemical or optical
methods [120]. Ion selective, potentiometric electrodes are used for detection of metal
ions such as calcium, magnesium and potassium [120]. Ion selective electrodes measure
the potential generated across a selectively permeable membrane reflecting the activity or
chemical potential of the analyte of interest in a test solution with respect to a reference
solution with known analyte activity. Substrate selective, amperometric electrodes are
used for detection of analytes such as pO2, creatinine, glucose, and lactate [118-120].
Accurate bench-top point of care blood analyzers such as the Vitros 9500 (Ortho-Clinical
Diagnostics, Rochester, NY) can yield results in approximately twelve minutes [117].
Hand-held point of care blood analyzers such as the i-STAT (Abbott Diagnostics, Abbott
Park, IL) and Lactate Pro LT-1710 (Arkray Inc., Kyoto, Japan) can give results in about a
minute [117, 120].
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1.4.3 Reliability of point of care monitoring
More recent comparisons of POC monitoring versus laboratory monitoring of
analytes such as glucose and lactate have been evaluated [117, 118, 122, 123]. The POC
monitoring of finger-tip lactate using a handheld lactate sensor (LT-1710) at the point of
emergency department triage has shown to be useful in early detection of lactate levels in
septic patients, and time of results acquisition from triage was significantly faster by 151
minutes when compared to whole blood analysis in a central emergency department
laboratory [117]. A mean difference of +0.26 mmol/L was observed in comparing the
readings from POC-capillary to laboratory-arterial lactate analysis [117]. All capillary
lactate readings >3 mmol/L using the POC device were successfully triaged [117]. In the
low (≤2.2 mmol/L) to mid (2.3-5 mmol/L) ranges of blood lactate, point of care devices
showed reasonable concordance (90-99%) with laboratory measurements of blood
lactate, Figure 1.8 [118]. The hand-held Lactate Plus (Nova Biomedical, Waltham, MA)
blood lactate sensor estimated higher values than those determined by laboratory
measurements [118].
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Figure 1.8. Bland-Altman plot: White) Concordance of the handheld point of care device, i-STAT
(Abbott), compared to laboratory standard measurements with the Vitros system (Ortho Clinical
Diagnostics) when monitoring lactate levels of trauma patients. Black) The Integra system (Roche) is
another lab analytical standard used as a control [118].

Blood glucose measurements with POC devices have not been observed to
significantly differ from laboratory measurements [122, 123]. Arterial and capillary
glucose measurements with the SureStep Pro Hospital Meter (Johnson & Johnson,
Milpitas, California) in randomized critically ill patients, including those with diabetes,
showed a mean difference of 10 mg/dL when compared to standard laboratory methods
of blood glucose measurement [123]. Hematocrit levels ranging from 25-55% are
required for accurate POC glucose measurements [123]. Abnormal hematocrit levels
affect rheological properties and are believed to prevent sufficient blood plasma from
reaching the reaction surface of test strips and cartridges in POC devices [123]. Other
interferents known to POC glucose monitors include elevated creatinine and bilirubin
levels, high arterial oxygen levels, shock-like states, and pH below physiological levels
(acidosis) [123].
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Clinicians are cautioned as current point of care technology is not yet perfected to
be a total replacement for laboratory measurement of blood analytes. Lab measurements
are done as plasma-based assays whereas points of care tests are done with whole blood.
Time of blood sample preparation in POC devices is short for convenience sake, but this
renders results more susceptible to error from sample differences. Test cartridges and
strips used in hand-held monitors will also have variability in their performance due to
manufacturing. When comparing POC results to delayed laboratory analysis, the current
underestimation of blood lactate levels seen in devices such as the i-STAT can lead to a
failure to recognize high risk trauma patients or a false perception of hemodynamic
instability.
1.4.4 Wireless vital signs monitoring systems
Wireless vital signs monitoring systems, WVSM (Athena GTX, Inc, Des Moines,
IA) are advanced physiologic status monitoring systems intended for use in the theatre of
war [124]. The WVSM technology automatically monitors vital signs of blood pressure,
pulse rate, blood oxygenation, and heart signals via a 3-lead electrocardiograph [124].
Computer decision support systems integrated with WVSMs provide end-users with
expertise and recommendations concerning treatment or diagnosis of injuries and disease
[124]. On its own, the device is capable of continual patient monitoring, producing up to
4.5 hours of collected data, wirelessly uploading data onto personal computers, and has a
battery life of up to 7 hours [124].
Current patient vital signs and previous trends can be automatically integrated
with a primary care facility’s computer networks when patients equipped with the
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WVSM are brought into close proximity to a Wi-Fi network. Additional software support
enables multiple patient monitoring [124]. The WVSM system incorporates easy to
understand color-coded and audible alarm systems to assist caregivers with triage
decisions at a glance [124]. The mini-Medic (Athena GTX, Des Moines, IA) is a similar
type of device that attaches to the forehead of a patient and measures similar vital signs as
the WVSM.
The WVSM and the mini-Medic systems are versatile in their ability to monitor
multiple vital signs while simultaneously providing decision support to caregivers based
on those vital signs. As a package for use in the field, the WVSM weighs approximately
16 ounces [124]. This light weight design is necessary for use in far-forward areas of
operation. Drawbacks of the system include the use of blood pressure cuffs, forehead
mounts, and ECG leads which require considerable time to put into place and may be
problematic dependent upon the nature and type of injury and its location. Use in the
battlefield while under hostile fire will also make WVSM deployment more challenging.
The vital signs measured using the WVSM will certainly be able to detect the
presence of hemorrhagic shock within decompensated trauma victims but may have more
difficulty with compensated trauma patients in assessing their need for resuscitation or
lifesaving interventions (LSI). These devices do not yet incorporate direct monitoring of
metabolic analytes. Such non-invasive systems must depend upon the fusion of diverse
sources of data, and its efficacy is vested in the sophistication of computer decision
support systems to aid in the diagnosis and treatment of injuries. Ideally, the WVSM
systems will consider more direct variables such as the fundamental metabolic
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biomarkers of physiological stress. Biosensors are capable of monitoring metabolic
variables in a minimally invasive manner [4] and have great potential to augment current
WVSM technology in order to make a more robust physiologic status monitoring
platform [3].
1.4.5 In-vivo biosensors for monitoring of trauma
In-vivo biosensors are special point of care testing platforms upon which
biological phenomena may be observed and measured in the most direct and continuous
manner possible. The means of sensing and detecting biological phenomena are no
different from that which can be accomplished on the lab bench or via the hand-held
point of care device. Biosensors can provide convenient and timely data with reasonably
sized equipment. A successful biosensor system requires a high degree of selectivity,
rapid response, repeatability, stability, limited drift, long shelf-life, limited sample
preparation, and reasonable cost per test.
Aside from preliminary and pilot studies, no implantable in vivo sensors have
been approved for clinical use in trauma management. Animal trauma models and
clinical trials are ongoing. Subcutaneous and intramuscular lactate electrodes have been
used to examine interstitial lactate during hemorrhagic shock in rats [3, 9]. Reasonable
concordance of interstitial lactate to systemic blood lactate has been observed during the
non-shock state; which is consistent with previous literature [125, 126]. During the
various stages of hemorrhage, from onset to diagnosis of shock, significant differences in
both rate of production and final concentration of lactate have been observed when
comparing interstitial to blood lactate [3, 9]. Intramuscular lactate levels have been

28

shown to increase more rapidly than serum lactate during the onset of hemorrhagic shock,
but no intramuscular lactate concentrations were reported due to lack of in vivo
calibration, Fig. 1.9 [3].

Figure 1.9. In vivo amperometric response of intramuscularly implanted lactate biosensors (n = 5) and
systemic blood lactate levels (n = 5) measured using a YSI Biostat Bioanalyzer during onset of
hemorrhagic shock (MAP = 40 mmHg). Intramuscular lactate levels are unknown but shown to increase
more rapidly than in blood (Error bars show SE) [3].

Disparities between interstitial and blood lactate levels can be attributed to
individual or combined effects of a number of possible events such as changes in
diffusion coefficients of analytes due to loss of skeletal muscle contractions, loss of
interstitial fluid between muscle cells due to auto-resuscitation, muscle cell swelling due
to changes in ion and substrate transport systems in the plasma membrane, and decreased
peripheral perfusion due to vasoconstriction [61, 127-130]. Using transcutaneous needletype lactate biosensors, subcutaneously monitored lactate levels have been shown to be
lower compared to lactate levels in the blood in a deep state of hemorrhagic shock [9].
This is consistent with previous studies in rats where lower lactate levels were observed
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in skeletal muscle compared to blood during states of hypoxia [125, 126]. Fully
implanted needle type lactate sensors have shown to maintain stable short-term
performance with high sensitivity in interstitial tissue of anesthetized rats, and it was
shown that no changes in tissue lactate levels occur during sodium lactate infusions
directly into blood [69].
These preliminary results are promising and reinforce the movement toward
minimally invasive physiologic status monitoring of trauma through biosensor and
biochip technology. More research to observe the temporal aspects of the metabolic
events of trauma within various compartments of the body are necessary to acquire
statistical power. One of the major limitations to these implantable devices is the
difficulty of in vivo calibration. Calibrations made prior to implantation will not be
completely accurate due to background signal and interference from electroactive
molecules in the tissue environment. Calibrations performed post-implantation often
require infusions of the target analyte into the surrounding tissue which can be a
cumbersome and time consuming process. Simplicity and accuracy of in vivo calibration
is paramount to producing clinically successful implantable biosensors.
1.5. Applications of biomarkers and technology to trauma management
1.5.1 Application of in vivo biosensors to the standard of care
An in vivo biosensor can be small, minimally invasive, wireless, and be powered
inductively, by battery, or in the future, by an implantable biofuel cell. Once implanted,
the biosensor can be used for continual monitoring of physiologic stress biomarkers. This
will allow for practical dynamic monitoring of biological markers for use in better
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quantifying the beginnings, complicating events, and endpoints of trauma. The current
standard of care for trauma patients in both the military and civilian context is often
qualitative. Trauma standards for treatment of all trauma victims still call for physical
vital signs in the face of much literature revealing their shortcomings. This is mostly due
to lack of proven alternatives. Emergency medical technicians and battlefield medics
need to rely on what they know will work for the time being. New technology and
innovation in the field of biomedical microdevices are needed, but, more importantly,
existing microchip technology must approach translational research to go beyond what is
currently known about trauma physiology. The stigma of invasive monitoring techniques
needs to be overcome to make way for in-vivo biosensor technology and advance trauma
diagnostic technology further than ever before.
1.5.2 Perspectives on the next generation of diagnostics
The use of an in vivo biosensor system for the continual monitoring of analytes
relating to hypoperfusion may better indicate severity, onset, and survivability of trauma
induced shock. Two important perceptions undergird the current advances in trauma
diagnostic biosensors. First, the physiologic status of a traumatized individual can be
elucidated through the use of an easily deployable, minimally-invasive biosensor system
that has specificity toward the metabolic markers of hypoperfusion that have been
discussed. Second, glucose and lactate have proven to be among the foremost clinically
relevant analytes to trauma, hemorrhage, shock, resuscitation, mortality, and infection.
These perceptions have successfully led biomedical microdevice research to design and
develop enzyme-based, substrate-selective electrode biosensors that detect both glucose
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and lactate simultaneously [3, 70, 131-133]. Figure 1.10 shows the schematic for an
inductively powered minimally invasive physiological monitoring biochip for the
measurement and monitoring of a suite of analytes that include; glucose, lactate, K+,
VO2, pH and T (°C). The system seeks to combine the IronIC Patch®, a wearable device
to power implanted sensors by means of an inductive link [134] with the PSMBioChip®,
a minimally invasive implantable biosensor for hemorrhage monitoring [3, 70, 135] to
yield a fully integrated system suitable for civilian and military use [136].
IronICPatch®

PSMBiochip®

OUTPUT
INFORMATION

KEY
ANALYTES
Glucose
Lactate
K+
VO2
pH
T ( C)

Figure 1.10. Schematic of a multi-analyte implantable in vivo amperometric biosensor (The
PSMBioChip®) that is powered inductively by the IronIC Patch® [134].

Implantation of biosensors can be done subcutaneously or intramuscularly to
access new avenues of monitoring interstitial metabolism during trauma. For example,
skeletal muscle is greatly influenced by trauma by virtue of having the greatest oxygen
consumption rate and lowest blood delivery rate compared to all other organs in the body
[3, 137]. The amount and duration of intramuscular glucose and lactate may be better

32

indicators of survivability during hemorrhage than typical vital measurements such as
blood pressure and heart rate.
The unknown relationships between interstitial and systemic analytes must still be
reliably established during the various phases of hemorrhage and hemorrhagic shock.
This knowledge may open new avenues of trauma diagnostics in the field as well as in
the hospital setting. Implantable biosensor design criteria will be more stringent than
those of in vitro devices due to the hostile environment of the body. Some important
performance parameters to consider include response time, enzyme stability,
biocompatibility, sensitivity, selectivity of analytes, and in vivo calibration [138]. The
evaluation of these biosensors in vivo will elucidate how these design parameters will
need to be improved.
Primary long-term goals include the development and deployment of a technology
that may, in a military context, be administered to combatants prior to a high risk mission
or be administered by a medic to an injured, fallen combatant prior to evacuation. In a
civilian context, such a device may be administered by emergency medical personnel to
an accident or trauma victim. This device will allow the continuous monitoring of
analytes such as tissue lactate and glucose to augment pre-clinical diagnosis of trauma
victims during hemorrhage. This may then enable patient specific resuscitation strategies,
stratification of trauma patients, and more efficient use of resources such as in the
battlefield or mass casualty setting.
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1.6. Conclusions: Current standards of care and microdevice diagnostics in
clinical practice
Current laboratory methods are cumbersome and require long periods of time
before results can be available to clinicians. Use of point of care devices is quick and
results are typically easy to interpret via handheld displays, but many critical vital sign
measurements such as glucose and lactate are still discrete and time point dependent. This
leaves much to be desired in understanding the dynamics of the analytes under test. Use
of in vivo biosensors for use in physiological status monitoring can and will offer unique
advantages to current ICU diagnostics and point of care devices. However, aside from the
current standards of laboratory blood testing and point of care testing, little to no reliance
has been given to the advanced implantable diagnostic microdevices and technologies.
These devices that measure the clinically relevant markers of physiologic stress still need
to be rigorously tested in vitro and in vivo to show significant usefulness in predicting
mortality, morbidity and need for resuscitative intervention before they will be
considered for use in the clinical setting.
While the need for continued research in novel diagnostic microdevices is
apparent, it is still uncertain what sort of information would currently be relevant or
useful to first responders and care givers. It is imperative to know and understand the
needs of these care givers to better implement new diagnostic platforms. Among the most
important considerations are; i) what patient data and information is currently useful in
triaging patients, ii) how patient information and status is currently handled and
documented, iii) how patient information translates into critical care decisions, and iv) the
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methods of information transfer between caregivers. Combining and consideration of
simultaneously acquired vital signs into meaningful and relevant information will be a
grand challenge. Stronger correlations between vital signs and trauma/hemorrhage are
currently needed; this will require more investigation of these vital signs using the
currently developing novel technologies and microdiagnostic devices.
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CHAPTER TWO: IMPLANTABLE AMPEROMETRIC BIOSENSORS AND DESIGN
OF AN IMPLANTABLE DUAL ANALYTE BIOSENSOR

2.1 Introduction
An implantable enzyme amperometric biosensor is a bioanalytical technology that
is intended to measure and often remotely transmit a record of specific molecular-level of
a biological analyte within the human body [139]. The basic function is to indwell a
tissue and to detect, measure and record the levels of a molecule of interest within those
tissues. Being amperometric, the biotransducer generally comprises two or three
electrodes: a working electrode rendered specific to the analyte of interest via
immobilization of the appropriate enzyme, a counter electrode to support the ensuing
current, and a reference electrode to provide a suitable voltage plane against which the
interrogating voltage may be referenced. Two electrode biotransducers functionally cojoin the counter and reference electrodes. Implantable amperometric biosensors generally
use enzymes as the biorecognition biomolecule to enable the detection of biochemicals of
interest within the body [140]. Enzymes catalyze chemical reactions of specific
substrates, the products of which may then be detected via electrochemical oxidation or
reduction that occurs at the surface of the working electrode while under a suitable
impressed potential. For amperometry, a potential is impressed at the working electrode
where the enzyme is immobilized. Bioimmobilization, a major technical challenge in its
own right, is often achieved using a number of different techniques [141], and the current
generated by the electrochemical oxidation or reduction of the enzymatic reactants or
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products generates a measurable current. The potential applied may be with respect to a
reference electrode with a known redox potential such as a silver/silver chloride
electrode, although silver presents rather unique challenges when used in vivo [142], or
with respect to a pseudo-reference electrode such as platinum, if the magnitude of current
generated is sufficiently small as to not induce polarization.
Amperometry is an electrochemical technique wherein a fixed voltage is
impressed upon the working electrode thereby generating an initial transient current, i(t),
related to the activity of redox species at the interface. The current decays to a steady
state value, iss, that is dependent upon the bulk chemical potential of electroactive
species. For a single analyte at a macro electrode (critical length scale >25 μm), the
resulting current is given by Cottrel’s equation [143]. At a microelectrode (critical length
scale <25 μm), the current profile, shown in Figure 2.1, is given by a modified form of
Cottrel’s equation (Equation 2.1). Table A.1 and Table A.2 (Appendix A) provides a
summary of available geometries of implantable amperometric electrodes, their
associated forms of the Cottrel’s equation and schematics of the diffusive mass transport
field associated with each type of electrode.

nFA Dapp1/2C * nFA DappC *
i(t ) 

2 1/2t1/2
2r0
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(2.1)
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Figure 2.1. Voltage applied to cell begins at E1 where no reaction occurs and is stepped up to E 2 causing
electrode processes to begin and a current transient ensues. Current, I, drops off with time according to the
Cottrell equation as substance, C*, must diffuse to the electrode surface in order to react.

The goal in the design of implantable amperometric biosensors is to make the
steady-state current, iss, directly proportional to the chemical potential of the in vivo
analyte that is recognized by the enzyme. The bioanalytical sensitivity [s = (iss – ibl)/log C
vs. log(C*/C°*)] (where iss is the steady state current, ibl is the base line current, and C°*
is a standard concentration), linear dynamic range (the range of concentrations over
which the response of the biotransducer is linear), and the limit of detection [3(SD/s)]
(where SD is the standard deviation of the blank or a measure of system noise) are
important figures of merit in assessing bioanalytical performance of the biosensor [144].
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2.1.1. Generation I biotransducers and unmediated amperometric response
Oxidoreductase enzymes, such as the FAD-dependent (flavin adenine
dinucleotide) glucose oxidase (GOx) (EC 1.1.3.4) and FMN-dependent (flavin
mononucleotide) lactate oxidase (LOx) (EC 1.1.3.2.) are suitable candidates for the
recognition of important physiologic biomarkers related to diabetes care and management
and to hemorrhage-associated trauma care and management, respectively. GOx is a
structurally rigid glycoprotein with a molecular weight of ca. 160 kDa [145] and consists
of two identical polypeptide sub-units, each containing a FAD redox center. In
Generation I biotransducers, these enzymes, in the presence of dissolved molecular
oxygen, produce equivalents of hydrogen peroxide that may be oxidized anodically at a
potential which is positive (typically ≥0.60 V vs. Ag/AgCl) [146] or cathodically reduced
at a potential which may be negative (typically 0.0 vs. Ag/AgCl) [147] relative to the
redox potential of hydrogen peroxide.

β-D-glucose + GOx/FAD →

D-glucono-δ-lactone

+ GOx/FADH2

(2.2)

GOx/FADH2 + O2 → GOx/FAD + H2O2

(2.3)

H2O2 → O2 + 2H+ + 2e−

(2.4)

2.1.2. Bioanalytical performance of amperometric biosensors
Enzyme kinetic parameters may be obtained from the steady state current of the
amperometric enzyme biotransducer. A Hill or Lineweaver-Burk analysis using Equation
(2.5) allows calculation of the apparent enzyme kinetic parameters.
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K 1
1
1
 M *
I SS I max CS I max

(2.5)

Here ISS is the steady-state current or response after substrate, S, addition, C*S is
the bulk concentration of substrate and Imax is the maximum current or response measured
under enzyme saturated substrate conditions. The maximum current, Imax, and the
Michaelis-Menten constant of the system, KM (mM), may thus be determined, allowing
evaluation of the contextual performance of the enzyme relative to some standard
condition, such as in solution. Commonly known implantable biosensor systems include
short-term indwelling continuous glucose monitoring systems such as Dexcom’s 2006
FDA-approved STS [148] and 2007 FDA-approved STS-7 Continuous Glucose
Monitoring System for diabetics [149]. Newer implantable biosensor systems are being
designed with intended use in trauma management [3].
2.1.3 Design of a dual analyte monitoring biotransducer
The Electrochemical Cell-on-a-Chip Microdisc Electrode Arrays (MDEA 5037) is
a dual analyte electrochemical transducer intended for amperometric and voltammetric
biosensor analysis when coated with bioactive hydrogel membranes. The MDEA 5037
was developed in conjunction with ABTECH Scientific, Inc. (Richmond, VA) to address
the need for simultaneous monitoring of interstitial glucose and lactate [150]. A prototype
dual responsive electrochemical biotransducer has been developed using bioactive
electroconductive hydrogels [11, 12, 70, 135, 151]. The MDEA 5037 is a single
transducer (chip) with two independently addressable electrochemical cells. The
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geometric

layout

and

microlithographic

fabrication

of

these

three-electrode

electrochemical biotransducers have been described in detail elsewhere [135] and the
details of the assembly and packaging of the chip or die for implantation into small
vertebrate animals has likewise been described in detail elsewhere [70]. Briefly,
electrochemical transducers (0.2 cm x 0.4 cm x 0.05 cm) were fabricated from e-gun
vapor deposited platinum (100 nm) on an adhesion promoting titanium/tungsten (Ti/W)
layer (10 nm) deposited onto an electronics grade borosilicate glass (0.5 mm thick Schott
D263). The electrodes were fashioned into two separate three-electrode electrochemical
cells and the electrodes were passivated with 0.5 micron thick silicon nitride (Si3N4). The
nitride layer was then resist patterned and fluoro-plasma etched to reveal the multiple
microdiscs of the working electrode (WEA), the large area counter electrode (CE, 7.3 x
10-3 cm2) and the shared reference electrode (RE, 7.3 x 10-5 cm2) that were connected to
the five bonding pads, Figure 2.2. Each electrochemical cell possesses 37 recessed
microdiscs arranged in a hexagonal packed array for each working electrode array. Each
disc has a diameter of φ=50 microns, with center-to-center separation of 100 microns, for
a total working electrode area, WEA = 7.3 x 10-4 cm2 [135]. In general, biospecificity is
conferred to each working electrode of the device by immobilizing a bioreceptor to each
working electrode.
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Figure 2.2. Microscopic photograph of the MDEA 5037 implantable transducer with two addressable
cells/channels (Ch1 & Ch2); each cell has a working electrode array (WEA), counter electrode (CE) and
reference electrode (RE).

Microdisc working electrodes promote hemispherical diffusion of analytes to their
surface having consequences on limits of detection, sensitivity, dynamic range, and
response rate [152]. The MDEA 5037 design was selected based on observed
bioanalytical performance of lactate biotransducers tested as a function of microdisc
feature size, Table 2.1 [2]. Electrode arrays with disc sizes of r = 25 µm were shown to
have excellent limits of detection while maintaining high sensitivity and linear range.
Activation, modification, and derivatization procedures have been developed for
hydrogel casting upon MDEA 5037 surfaces, Fig. 2.3 [2]. In this body of work the
MDEA 5037 system is characterized via chronoamperometry using a facile and
reversible electrochemical probe ferrocene carboxylic acid (FcCOOH), a surrogate redox
couple, for what would otherwise be a mediator in a mediated enzyme biosensor reaction.
Results were compared to the theoretical steady state current response given by the
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Cottrell relationship to evaluate performance of the transducer for use in amperometry.
The effects coating an MDEA 5037 with electroconductive hydrogel was examined using
electrochemical impedance spectroscopy.
Table 2.1: A comparison of the bioanalytical performance of lactate biotransducers formed from MDEAPt-Pt electrodes as a function of microdisc feature size. Membranes are electroconductive hydrogels of
poly(2-hydroxyethyl methacrylate) = p(HEMA), PEGLOx = PEGylated lactate oxidase and PPy =
poly(pyrrole-co-4(3-pyrrolyl)butyric acid) [2].

Figure 2.3. Optical micrograph of the MDEA 5037 transducer and schematic illustration of surface
activation, modification, and derivatization for preparation of electroconductive hydrogel casting [3].

2.1.4 Systems integration with a dual channel wireless potentiostat
Potentiostat technology of this age is facilitating novel research in the field of
biosensors [153-158] and translational research is dependent upon making efficient
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potentiostat systems for implantable biosensor devices [3, 158-161]. The potentiostat
continues to be a viable frontend instrument for biosensor technology as it allows several
electrochemical modes of biotransducer interrogation. Among these are amperometry
(constant voltage), voltammetry (a swept voltage) and coulometry (charge integration).
For Implantable amperometric biosensor systems to fulfill their desired functionality in
the most efficient way possible, developers must pay special consideration to size
(footprint), power management, telemetry capabilities, and signal processing [162]. The
implantable potentiostat may be discrete or an application specific integrated circuit
(ASIC) and may be fully implanted or of the type where the biotransducer is implanted
and the instrumentation is affixed externally to the subject/patient. Implantable systems
enable observation of biological phenomena in a more natural, physiologically relevant
state wherein subjects are able to move about freely while being monitored. A two
channel, two terminal wireless potentiostat system, the 8151 potentiostat by Pinnacle
Technology, has previously been considered for use in a minimally invasive biosensor
system for the management of hemorrhage associated trauma [2, 3]. In this body of work
model electrochemical cells are used to consider the merits and drawbacks of the 8151
potentiostat for use with a novel implantable biotransducer, the MDEA 5037 [70].
2.2 Materials and Methods
2.2.1 Components
The 8100-K1 fixed frequency wireless dual potentiostat system was purchased
from Pinnacle Technology (Lawrence, KS). The kit contained the Pinnacle 8151 wireless
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dual potentiostat, the voltage programmer, and a receiver base station (model 8106) with
USB cables. Software for data acquisition (PAL) was also included in the kit.
2.2.2 Accuracy testing of the Pinnacle 8151 potentiostat system
The accuracy of the 8151 potentiostat was tested using discrete combinations of two
models or “dummy” cells of known impedance. These model cells served as a virtual
device under test (VDUT) and were applied to the two available channels of the dual
potentiostat. The dummy cells consisted of i) a single resistor (R) of 10 MΩ (nominally)
as prescribed by the manufacturer, and ii) a parallel resistor-capacitor (RC) network of R
= 10 MΩ and capacitor of 1 µF (nominally). The single resistor VDUT models facile
electrochemical reactions having large heterogeneous electron transfer rate constants with
little or no capacitative contribution at the interrogation voltage. The complex RC cell
models real electrochemical cells wherein the double layer capacitance sits in parallel
with faradaic reactions [163]. Two identical resistor cells and two identical RC cells were
acquired from Pinnacle Technology. Bias potentials of 0.50 V were applied to channel 1
and channel 2 during experimentation. Thirteen discrete configurations of R and RC were
tested on the two channels of the 8151 potentiostat and the % error between the two
channels was calculated for the response to model R or RC cells in the following manner:

(2.6)
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Where ICh1 and ICh2 refer to the current response of channel 1 and channel 2
respectively. The telemetry distance of the 8151 potentiostat was determined in a
laboratory setting. A resistor of 10 MΩ was connected to channel 1 of the potentiostat
and a bias potential of 0.5 V was applied. The potentiostat was moved away from the
base station until a loss of signal was observed.
2.2.3 Chemicals and reagents
Dulbecco’s Phosphate Buffered Saline (PBS, pH = 7.2), Pyrrole monomer
(reagent grade 98+%), 4-(3-Pyrrolyl)butyric acid (PyBA), Ferrocenecarboxylic acid, 2hydroxyethyl methacrylate (HEMA), tetra(ethylene glycol) diacrylate (TEGDA, technical
grade), tert-Butyl acrylate (t-BA), poly(ethylene glycol) methyl ether methacrylate (Mn =
950, PEG(950)MEM), N-[Tris(hydroxymethyl)methyl]acrylamide (HMMA, 93%), 2(Dimethylamino) ethyl methacrylate (DMAEMA, 98%), the photo-initiator 2,2Dimethoxy-2-phenylacetophenone (DMPA, 99+%), Benzophenone, sodium dihydrogen
phosphate, disodium hydrogen phosphate, potassium chloride, sodium hydroxide, and
sulfuric acid

were purchased from Sigma Aldrich Co. (St. Louis, MO, USA). 2-

(Methacryloyloxy)ethyl 2-(Trimethylammonio) ethyl phosphate (MPC) was purchased
from Tokyo Chemical Industry CO., LTD. The HEMA, methacrylate and diacrylate
reagents were passed through an inhibitor removal column (Sigma-Aldrich) for removal
of the polymerization inhibitors hydroquinone and monomethyl ether hydroquinone
before using them in the preparation of the hydrogel cocktail. Pyrrole monomer was
purified by double passage through an alumina silicate column. Solutions were prepared
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in deionized water prepared by purifying distilled water through a Milli-Q plus (Millipore
Inc) ultrapure water system.
2.2.4 Cleaning of transducers
The MDEA 5037 transducers (ABTECH Scientific, Inc., Richmond, Virginia)
were first ultrasonicated in DI-water, IPA, and DI-water for 5 minutes each. Next the
transducer was placed in a UV-ozone cleaner (Boekel Industries) and irradiated for 10
minutes followed by 1 minute of ultrasonication in IPA. The transducer was then
immersed in PBS buffer, made the working electrode of a three electrode electrochemical
cell and was electrochemically cleaned by sweeping the potential between 0 to -1.2 V (vs.
Ag/AgCl, 3 M KCl) at 100 mV/s for 40 cycles. Transducers were finally thoroughly
rinsed in flowing DI-water before use.
2.2.5 Functionalization and derivatization procedures for hydrogel application
Plasma modification of the cleaned MDEA 5037 transducers to generate hydroxyl
groups onto the silicon nitride was performed under vacuum in the presence of water
vapor using a Harrick Plasma Cleaner (Harrick Plasma). Following plasma activation the
bare platinum microelectrode surface was silanized by incubation in a 0.1 wt% solution
of 3-aminopropyl-trimethoxysilane (APTMS) in ethanol for 45 minutes followed by
ultrasonication in IPA for 5 minutes. Curing was then performed at 20 minute intervals of
40 oC, 110 oC, and 40 oC. To remove the APTMS from the electrodes, the transducer was
immersed in PBS buffer (0.1 M, pH = 7.2), made the working electrode of a three
electrode electrochemical cell and was electrochemically cleaned by sweeping the
potential between 0 to -1.2 V (vs. Ag/AgCl, 3 M KCl) at 100 mV/s for 40 cycles.
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Polypyrrole was deposited potentiostatically at 750 mV vs. Ag/AgCl onto the working
electrodes of the MDEA 5037 using an electropolymerization solution consisting of 0.4
M Py with 0.1 M repeat units of polystyrene sulfonate as dopant prepared in DI-water
and pH-adjusted to pH=4.75 using 0.1 M NaOH. An electropolymerization charge
density of 10 mC/cm2 was applied to produce a seeding layer of polypyrrole for hydrogel
attachment. Transducers were then immersed in a 0.01 M benzophenone solution
prepared in ethanol, removed and allowed to air dry for several minutes followed by UV
irradiation (365 nm) for 5 minutes each on the front and back side of the transducer to
initiate hydrogen abstraction and termination of both the polypyrrole and primary amine
groups of the transducer with benzophenone.
2.2.6 Preparation of hydrogel monomer cocktails
A 1.5 mol % TEGDA cross-linked electroconductive hydrogel (ECH) monomer
cocktail was prepared according to a previously described protocol [131] by mixing
twelve monomer constituents in a mole % fashion as detailed in Table 2.2. A 1:1 (v/v)
solvent solution of ethylene glycol/water (pH ≈ 8) corresponding to 40 % of the volume
of the monomer cocktail was then added to the monomer cocktail and stirred overnight
under UV-free conditions. Bifunctional monomer of 2-methacryloyloxyethyl-4(3pyrrolyl)butanate

(MPB)

was

first

synthesized

using

1-ethyl-3-[3-

dimethylaminopropyl]carbodiimide (EDC), N-hydroxysulfosuccinimide (sulfo-NHS)
chemistry by: i) dissolving PyBA in the solvent solution and reacting this with an equimolar concentration of EDC for 30 minutes, ii) adding an equi-molar concentration of
sulfo-NHS and incubating for 5 minutes, and iii) adding an equi-molar concentration of
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AEMA and incubating for 2 hours at room temperature. Immediately following MPB
formulation all remaining liquid monomer constituents were mixed into the solution
followed by the remaining solid monomer constituents and stirred until thoroughly mixed
and clear. The resulting monomer cocktail was sparged with nitrogen and stored at 4 oC
until ready for use.
Table 2.2. Hydrogel constituents and composition expressed in mol% and mol% of repeat units where
noted, HEMA and n-BA were maintained at a constant 10:3 mol ratio and TEGDA was varied for the
hydrogel compositions under test.

Constituent

Mole fraction (%)

HEMA
t-BA
Pyrrole
MPB – Bi-functional pyrrole monomer
TEGDA
PEG(950)MEM (mol% of repeat units)
MPC
HMMA
DMAEMA
AEMA
DMPA
SPMA
Total:

59.75
5.00
7.50
1.50
1.50
5.00
5.00
5.00
5.00
1.50
1.00
2.25
100.00

2.2.7 Hydrogel application to MDEA 5037 transducers
Immediately after cleaning and surface functionalization, 50 µL of the ECH
cocktail (Table 2.2) was pipetted onto the surface of the MDEA 5037. Excess monomer
cocktail was removed by touching the edge of the transducer to a KimWipe®. The thin
film was then crosslinked with UV light for 5 minutes on the front and back of the
transducer using a UV cross-linker (CX-2000 Crosslinker, UVP, Upland, California)
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under an inert nitrogen atmosphere to yield a hydrogel membrane. Gel-transducers were
then placed into a convection oven at 60 oC to anneal for 60 minutes. Following
annealing, the transducers were immersed in an electropolymerization solution of 0.2 M
Py and 0.2 M PSSA (repeat units) for 1 hour and electropolymerization of pyrrole was
then performed at 0.8 V vs. Ag/AgCl for a charge density of 10 or 100 mC/cm2 to form
an electroconductive hydrogel (ECH). Overoxidation of polypyrrole was performed by
sweeping the potential from -0.2 to 1.3 V vs. Ag/AgCl at 100 mV/s for 40 cycles to yield
an overoxidized electroconductive hydrogel (OO-ECH).
2.2.8 Enzyme immobilization onto MDEA 5037 transducers
Amperometric enzyme biotransducers were prepared by placing electrodes, with
or without a hydrogel (non-electroconductive) coating, into a solution of 0.2 M Py and 1
mg/mL of GOx prepared in prepared in Milli-Q® water (pH=6.0). Potentiostatic
electropolymerization of pyrrole was initiated using an oxidative potential of 0.75 V
(without hydrogel) or 0.80 V (with hydrogel) vs. Ag/AgCl. Enzymes were
electrostatically and physically entrapped within the electrodeposited polypyrrole
network (PPy-GOx|PtMDEA and PPy-GOx-Gel|PtMDEA). The electropolymerized
polypyrrole and entrapped enzymes within the hydrogel formed the ECH. The
polypyrrole was subsequently overoxidized as previously described.
2.2.9 Impedance spectroscopy of MDEA 5037s and VDUTs
Electrochemical impedance spectroscopy was performed using a Princeton
Applied Research Potentiostat/Galvanostat model 283 (Princeton Applied Research)
coupled to a Solartron 1260 Frequency Response Analyzer (Solartron Analytical).
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Transducers were studied in 1.0 mM FcCOOH in PBS buffer at pH = 7.2 at room
temperature in three electrode mode (RE: Ag/AgCl, CE: Platinum mesh) and using a sine
wave with 10 mV amplitude. Electrical impedance spectroscopy was similarly performed
in two electrode mode to characterize the R and RC dummy cells. MATLAB 2011b
software was utilized with default Savitzky-Golay smoothing filters for collected
spectroscopy data.
2.2.10 Interrogation of MDEA 5037-Pinnacle 8151 wireless biosensor system
A Dell Latitude laptop with PAL software (Pinnacle Technology, Inc.) was used
for data acquisition. The bioactive MDEA 5037 was interfaced with the 8151 wireless
potentiostat via a custom connector. For the MDEA 5037, two electrode electrochemical
detection of glucose was utilized with the on-board working electrode array serving as
the working electrode and the on-board counter electrode serving as the shorted counter
and reference. Bias potentials were programmed into the 8151 anywhere from 0.4 to 0.65
V and applied to the working electrode array of the MDEA 5037 with respect to the
onboard counter electrode. Experiments were performed in PBS (pH = 7.2) at room
temperature under gentle stirring.
2.2.11 Electrochemical characterization
Electrochemical

experiments

were

performed

using

a

BAS-100B/W

Electrochemical Analyzer with a BAS PA-1 preamplifier module used to amplify the
current

and

to

filter

out

noise

(BAS,

West

Lafayette,

Indiana,

USA).

Chronoamperometric measurements were taken with both MDEA 5037 electrochemical
cells simultaneously in a two electrode configuration of on-board working electrode array
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vs. on-board counter electrode at a bias potential of 700 mV. Current was observed as a
function of FcCOOH concentration in PBS buffer at room temperature (25 oC).
Electrochemical impedance spectroscopy experiments were carried out in 1 mM
FcCOOH in PBS buffer a three-electrode setup with a working electrode array of the
MDEA 5037 as the working electrode, a Ag/AgCl (3 M KCl) reference electrode
(RE803; ABTECH Scientific, Inc., Richmond, Virginia, USA) and a platinum mesh
counter electrode. A sine wave with 10 mV amplitude was utilized and frequencies of 1 –
106 Hz were examined. MATLAB 2011b software was utilized with default SavitzkyGolay smoothing filters for collected spectroscopy data.
2.3 Results and Discussion
2.3.1 Foot print
The 8151 potentiostat can capture signals coming from biotransducers and
wirelessly transmit two digitized signals on a 916 Hz band to a central base station that is
interfaced to a computer via USB. Transmission may be maintained for up to 72 hours
straight using a 3 V lithium battery. The full system with battery weighs approximately
8.7 grams with a footprint of approximately 8.2 mm3. The device is sufficiently small
enough to allow continuous measurement with an implanted biotransducer while
maintaining a comfortable size and weight for small animals such rats [164, 165] and fish
[166, 167]. Having externalized electronics is the current modality for implantable
biosensor systems using this potentiostat; much like other commercially available,
subcutaneous glucose monitors [168].
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2.3.2 Telemetric performance
The 8151 and MDEA 5037 biosensor system, as seen in Figure 2.4, has
previously been shown to have the capability to measure and record two analytes
simultaneously at two applied potentials [2]. Preliminary studies on the performance of
unmodified MDEA 5037 transducers was performed in solutions of 1:1 mixture of 1.0
mM ferrocyanide and 1.0 mM ferricyanide (Eo = 0.76 V vs. Ag/AgCl). Current was
observed as a function of concentration at room temperature (25 oC). Electrochemical
measurements were taken with both MDEA 5037 electrochemical cells simultaneously in
a two electrode configuration of on-board working electrode array vs. on-board counter
electrode. Current was shown to monotonically increase as a function of
ferri/ferrocyanide concentration at oxidative bias potentials of 0.5 (channel 1) and 0.6 V
(channel 2), Figure 2.5. The equi-molar, aqueous ferri/ferrocyanide couple is an example
of a facile electron transfer reaction with large heterogeneous rate constant at platinum.
Calibration curves serve as sufficient evidence that current readings can be taken at
different concentrations of solution and at different impressed potentials.
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A

B

Ch 1
Ch 2

Antenna
Figure 2.4. Image of (A) the Pinnacle 8151 wireless potentiostat showing the two channels with which it
can interface with transducers such as (B) the MDEA 5037 implantable biochip with two independently
addressable electrochemical cells, each having a working, counter and reference electrodes.

Figure 2.5. An MDEA 5037 interfaced with the 8151 potentiostat demonstrating the simultaneous
measurement of Fe2+/3+ at two different bias potentials applied to the two working electrodes of the MDEA
5037.

In a laboratory setting, the 8151 potentiostat maintained a steady and unbroken
signal as far away as approximately 75 ft (23 m). If a line of sight to the base station was
maintained, this distance can be increased to up to 100 ft (30 m) or more. The response
time of the potentiostat was found to be between 2-8 seconds when performing
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amperometry. The overall performance makes this system advantageous for long-range
monitoring of conscious animals in terms of footprint and telemetry performance. For
future in vivo characterization, the biosensor system under development will have the
biotransducer implanted in the trapezius muscle of rats. Tunneling and exteriorization of
lead wires will be necessary in order to interface with the potentiostat. Once the device is
interfaced, interstitial glucose and lactate levels can be monitored remotely at an
acquisition rate of 1 Hz.
2.3.3 Accuracy of response of the 8151 potentiostat channels
The current response of channel 1 and channel 2 to resistor (VDUT) dummy cells
averaged 49.9 (±0.1) nA and 49.6 (±0.0) nA (n=4) respectively. The current response of
channel 1 and channel 2 to the complex RC cell averaged 51.1 (±0.1) nA and 54.4 (±0.1)
nA respectively (n=6). The % error between the two channels was determined to be 6.4
(±0.3) and 0.7 (±0.1) for RC and R model cells respectively, Figure 2.6. A two-tailed ttest indicated a significant difference in the mean % error when comparing the 8151
potentiostat response to R and RC circuits (p ≈ 10-8). These results indicate that the 8151
potentiostat system’s two channels are within a reasonable 1% error for electrochemical
redox reactions that are reversible and facile and can make reproducible results when
using both channels simultaneously. A high level of reproducibility for this biosensor
system has been observed during interrogation with ferrocene monocarboxylic acid
(FcCOOH), a well-known redox mediator, which supports these findings [12].
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Figure 2.6. The percent error between channels of the Pinnacle Technologies 8151 wireless potentiostat for
complex (RC) and simple (R) circuits, 95% confidence intervals are shown.

For complex circuits using the resistor and capacitor in parallel, the 8151 system
shows a large margin of error between the two channels. Ideally, the response from both
of the channels ought to be identical; much like was seen for the resistors tested. This
difference in measurement will be problematic for complex electrochemical reactions
such as during dual analyte sensing where both channels must be utilized simultaneously
to monitor the activity of analyte using two redox enzymes. We have established that the
bias potentials applied by the 8151 to either of the two channels utilize a common
reference, that is, the apparent four poles among the two channels are truly three poles.
This means that during operation both of the independent counter/reference electrodes of
each electrochemical cell share a single counter/reference electrode between the two
independent working electrodes.
For clean MDEA 5037 transducers, having a common reference/counter electrode
should not engender any significant changes to predicted chronoamperometric responses
based on Cottrel’s equation [143]. Current densities would be evenly distributed to both
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of the MDEA 5037 working electrodes during operation in simple electrochemical
systems. For fully modified MDEA 5037 biotransducers with hydrogels, polypyrrole, and
enzymes immobilized onto their microdisc array surfaces, current densities can be
expected to be relatively uneven compared to the bare transducer. The design for the
MDEA 5037 was with the intent to utilize each of its electrochemical cells (working,
counter, and reference electrodes) independently. Being unable to do this will lead to
unpredictable behavior between the two cells of the MDEA 5037. The full and
independent characterization of all biotransducers fabricated will be necessary during
future experimentation in vitro and in vivo when using the combined MDEA 5037 and
the 8151 biosensor system. Unfortunately, additional biotransducer variability will now
be introduced by the potentiostat system alone, which is less than ideal.
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Figure 2.7. Electrical impedance spectroscopy of virtual device under test dummy cells (n = 4, error bars
indicate standard deviation).

The R and RC dummy cells were tested using electrical impedance spectroscopy
at frequencies from 100 - 104 Hz. A total of four (n=4) spectroscopic analyses were
performed on each of the cells, Figure 2.7. Dummy cell resistive element values derived
from the 8151 potentiostat were determined by dividing the observed current by the
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applied voltage. As expected from the Solartron 1260, both of the resistor dummy cells
behaved as a pure resistor with an impedance magnitude of 107 Ω. A phase of
approximately 0 was observed for the resistors. The complex RC dummy cells showed
capacitive phase response (-90o). A classical Randles circuit with a capacitive element
was applied to all of the tested dummy cells, Figure 2.8. Resistor cells R1 and R2
showed a charge transfer resistances of 10.47 (±0.19) MΩ and 9.33 (±0.78) MΩ
respectively. Both of the RC cells showed very close concordance with one another.
Complex cells RC1 and RC2 showed capacitive elements of 1.341 (±0.010) µF and 1.220
(±0.065) µF respectively, which were slightly higher to the expected 1 µF values but fit
the model well.

C

CPE

Rs

Rs

RP

RP

Figure 2.8. (Left) Simple Randle’s equivalent circuit model with series resistance (Rs), capacitance (C),
and polarization resistance (RP) applied to dummy cell VDUTs. (Right) Randle’s equivalent circuit model
with a constant phase element in the place of double layer capacitance.

A slightly higher error was observed for the parallel resistive element for RC
dummy cells when applying the Randles circuit model. It is known that real electrified
interfaces are most aptly modeled by a resistor in series with a capacitor-resistor in
parallel [169]. In the case of the RC circuits tested here, the 1 µF capacitor’s resistive
contribution is in parallel to the 10 MΩ resistor which negates its contribution at high
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frequencies making it appear as though the RC dummy cell is simply a capacitor. Only at
low frequencies of < 10-2 Hz (approaching DC) do we observe the effects of the 10 MΩ
resistor which can clearly be observed with the 8151 potentiostat as seen in Table 2.3. A
two-tailed t-test showed that only one of the resistor circuits, R1, as measured by the
8151, was statistically different from the resistance determined by the Solartron. All other
resistive element values were not statistically different. These results indicate that the
8151 is a precise instrument but not completely accurate in both channels. High accuracy
electrochemistry goes beyond the scope of this wireless potentiostat system. The 8151 is
sufficient for performing simple amperometric measurements wherein the current
response can be associated with and calibrated to a biomolecular response.
Table 2.3. Statistical comparison of the values of the dummy cells returned by the FRA 1260 compared to
the Pinnacle 8151.
Dummy Cell
(nominal values)

Solatron 1260 (n=4)
Equivalent Circuit
Values

Model
Error

Pinnacle 8151
(n=4)

Statistical
significance

R1 (10 MΩ)

10.47 (±0.19) MΩ

3.2 %

9.96 (±0.03) MΩ

p = 0.03

R2 (10 MΩ)

9.33 (±0.78) MΩ

3.2 %

9.99 (±0.03) MΩ

p = 0.29

RC1
(10 MΩ, 1.0 µF)

9.58 (±1.16) MΩ
1.341 (±0.010) µF

7.0 %
2.5 %

9.48 (±0.33) MΩ
n/a

p = 0.85

RC2
(10 MΩ, 1.0 µF)

11.13 (±3.67) MΩ
1.220 (±0.065) µF

7.6 %
2.6 %

9.48 (±0.31) MΩ
n/a

p = 0.32

2.3.4 Amperometric performance of MDEA 5037 transducers
Ferrocene monocarboxylic acid, a well-known reversible redox probe molecule,
was used to interrogate cleaned MDEA 5037s using chronoamperometry. The pKa value
for FcCOOH is 4.2, the same as that of ascorbic acid which is a well-known in vivo
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biosensor interferent [170-172]. Interrogation was performed in PBS at pH = 7.2 with a
concentration range of 0.0–0.2 mM FcCOOH. Each electrochemical cell of the MDEA
5037 was interrogated independently and was analyzed (n = 10). A potential of 700 mV
was applied to the working electrode with respect to the on-board counter electrode. The
dose response curves of the cleaned, bare transducers were observed and compared to
theoretical responses based on steady state diffusion limited current, Figure 2.9.

Figure 2.9. The theoretical dose response curves of multidisc array (MDEA) and ultra-microdisc (UME)
electrodes for comparison with experimental dose response of cleaned/bare MDEA 5037 electrochemical
cells (Experimental MDEA 5037, n = 10) interrogated in two electrode mode using a 700 mV bias potential
of working versus counter electrodes; Error bars portray 95% confidence intervals.

The dose response curve of freshly cleaned, bare platinum transducers to
FcCOOH showed an expected linear response. The sensitivity of bare transducers
averaged approximately 391 ±68 nA/mM and R2 = 0.9991. The performance of Cell A
(top cell – Ch1, n =5, average sensitivity = 386 ±54 nA/mM) and Cell B (bottom cell –
Ch2, n = 5, sensitivity = 396 ±86 nA/mM) were not significantly different based on a
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two-tailed t-test (p = 0.82). We have concluded that for very facile electrochemical
reactions (large heterogeneous rate constants), where the device under test behaves as a
resistor, the transducer appears quite capable of delivering desired reproducibility. The
theoretical steady state response of a microdisc electrode array (MDEA) and single ultramicrodisc electrode (UME) with equal area to the MDEA 5037 had sensitivities of 205
nA/mM and 34 nA/mM respectively. The MDEA 5037 transducer’s had approximately
twice the expected theoretical sensitivity for MDEAs and ten times the expected
theoretical sensitivity for single UMEs given by the steady state diffusion limited Cottrell
equation.
2.3.5 Electrochemical impedance spectroscopy of MDEA 5037s
Electrochemical impedance spectroscopy (EIS) was performed on cleaned, ECH,
and OO-ECH modified MDEA 5037 transducers, Figure 2.10. Bare MDEA 5037
transducers showed Bode plots with trends that were identical to previously reported EIS
measurements [173]. The magnitude of impedance was lower compared to these previous
findings but this is likely due to the higher conductivity of the buffer (Dulbecco’s PBS)
that was used for interrogation. Transducers modified with freshly prepared ECH had an
overall higher impedance for high (>104 Hz) frequencies and an overall lower impedance
for low (<101) frequencies consistent with increased solution and reduced charge transfer
resistance respectively. These results show that the ECH modified electrodes influenced
ion incorporation as well as charge transfer. Charge transfer in polypyrrole occurs by
transport of polarons and bipolarons along the backbones of the 1-D polymer chains with
hopping between chains [174], the density of which are highly dependent upon the nature
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of the dopant counter anions used during the polymerization process [175]. At
physiologically relevant temperatures (300 K), hopping conduction modeled by Mott’s
variable range hopping is the dominant mechanism of charge transport for polypyrrole
[176, 177]. Previous findings have shown that bipolaronic (electronic) conduction of
polypyrrole within similar hydrogel systems leads to a decrease in impedance,
indiscriminate conducting/insulating impressed potential, ca. three orders in magnitude
less compared to ionic conductivity in buffer [178].

Figure 2.10. Electrochemical impedance spectroscopy of MDEA 5037 working electrode arrays in 1 mM
FcCOOH, PBS buffer with varying surface modifications.

The Randle’s circuit model was also applied to the ECH-MDEA 5037 transducers
but with a conducting phase element (CPE) taking the place of the double layer
capacitance in order to account for non-ideal capacitance distribution due to surface
heterogeneity. The impedance of the CPE is given by (2.7).
(2.7)

Where T is the capacitance parameter and P is the ideality factor ranging from 0.5 to 1
that accounts for surface roughness and for which P = 1 equates to a completely flat
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surface [179]. Circuit model elements are summarized in Table 2.4. Transducers were
tested from frequencies of 1 to 106 Hz. Fresh application of an electroconductive
hydrogel to MDEA 5037 transducers increased the total capacitive response of the system
but this difference was not statistically significant (p = 0.2) when compared to either
cleaned or overoxidized ECH transducers. Overoxidized ECH modified transducers had a
higher solution resistance but this was not significantly greater (p = 0.08) when compared
to Cleaned and freshly applied ECH modified transducers. The polarization resistance or
charge transfer resistance decreased by a factor of five but this difference was also
insignificant (p = 0.18). This effect was negated as shown by the drastic increase in
polarization resistance once the polypyrrole was subsequently electrochemically
overoxidized indicating formation of a redox inactive membrane. Both Cleaned and ECH
transducers fit the Randle’s model well but the OO-ECH transducer did not as can be
seen by the higher degree of error in the polarization resistance. This degree of error
indicates that OO-ECH transducers cannot be accurately characterized using simplified
models.
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Table 2.4. Randle’s equivalent circuit model elements for the MDEA 5037 transducers; standard deviation
given in parentheses and %error given for model values compared to actual data. PPy-ECH = Polypyrrole
Electroconductive Hydrogel; OOPPy-ECH = over oxidized polypyrrole electroconductive hydrogel.

The overall increase in impedance for ECH modified transducers can be attributed
to both diffusional limitations imparted by the hydrogel [180, 181] as well as the anion
screening capability of polypyrrole that has been previously reported [12]. The faradaic
component of the FcCOOH reaction with the MDEA transducer is made more facile with
the freshly prepared ECH as can be seen in the low frequency domain. The negative
phase angle for all transducers indicates a capacitive response. Overoxidizing the
polypyrrole removed this effect while limiting ion intercalation showing that it is indeed
the conducting electroactive polymer that is responsible for the reduction in impedance
magnitude for the low frequency domain. Conducting gels and overoxidized conducting
gels were not purely resistive nor purely capacitive; as shown by the phase ranging from 30 to -80 degrees. The significant (p = 0.006) decrease in the ideality factor from 0.88 to
0.61 shows that adding an electroconductive hydrogel with polypyrrole increases the
heterogeneity of the transducer surface.
2.3.6 In-vitro biosensor performance
Polypyrrole doped with GOx was polymerized onto working electrode array
(connected to channel 1) of the MDEA 5037 at a charge density of 100 mC/cm2. Working
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electrode array B (connected to channel 2) was left unmodified to compare response of
enzymes that may have non-specifically adsorbed during the fabrication process. The
biosensor system was first tested with both channels of the 8151 enabled at a bias
potential of 0.65 V. Infusion of glucose lead to an increase in amperometric current for
the PPy-GOx modified array whereas no current response was noted for the unmodified
array, Figure 2.11. The biosensor had a good response time of approximately 20 s and
the biosensor performance parameters are summarized in Table 2.5.
The mechanism of transduction for the biosensor is oxidation of hydrogen
peroxide generated from the glucose in the presence of oxygen in the reaction catalyzed
by glucose oxidase [1]. These results indicate that no discernable electrochemical
crosstalk is occurring between the two working electrode arrays of the MDEA 5037
during glucose detection. No measurable current response was generated at channel 2 as
was expected for the unmodified electrode array. Therefore, no appreciable contribution
to amperometric response of the biosensor system is occurring from non-specifically
adsorbed enzymes.

65

45

PPy-GOx at 0.65 V bias
Unmodified at 0.65 V bias

35
30
25

30
Current (nA)

Current Density (µA/cm2)

40

20
15

Ch 1
Ch 2

20
10
0

10

0

500

1000 1500
Time (s)

2000

5
0
0

10

20
Glucose (mM)

30

40

Figure 2.11. Dose response of the biosensor system to glucose with both channels enabled where Ch1
measures from the bioactive working electrode array and Ch2 measures from the unmodified working
electrode array of the MDEA 5037; inset shows amperometric response and error bars show the standard
deviation of the steady state response.

Table 2.5. Summary of performance parameters for the 8151 and MDEA 5037 wireless biosensor system.
Bias potential (V):

0.65

0.65

0.5

0.4

1&2

1

1

1

2.2

1.6

1.3

0.7

Maximum current (µA cm )

45.9

32.8

27.1

14.4

LOD (mM)

0.01

0.01

0.01

0.04

KMapp (mM)

9.4

10.3

7.0

6.5

Linear dynamic range maximum (mM)

11.6

12.6

7.6

7.1

Channels enabled
-2

-1

Sensitivity (µA cm mM )
-2

This wireless biosensor system is intended for use as a dual analyte monitoring
system to measure clinically relevant interstitial glucose and lactate simultaneously [70].
Independence between the two channels is paramount to accurate detection of vital signs.
Channel 1 was tested independently at bias potentials of 0.4, 0.5 and 0.65 V by
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disconnecting the unmodified MDEA 5037’s working region B from channel 2 of the
8151 potentiostat. The dose response curves for bioactive channel 1 are shown in Figure
2.12. Disabling channel 2 lead to a decrease in sensitivity from 2.2 µA cm-2 mM-1 to 1.6
µA cm-2 mM-1 at a bias potential of 0.65V. Enabling amperometric measurement from
channel 2 during glucose detection using channel 1 was shown to lead to a percent error
of 9.2%, 22.7% and 43.9% in channel 1 at bias potentials of 0.65, 0.5 and 0.4 V
respectively, Figure 2.13. No change in the magnitude of amperometric response should
occur when connecting/disconnecting the MDEA 5037 to the two channels of the 8151 if
the two channels are truly independent of each other. This crosstalk between channels is
likely due to the internal potentiostat instrumentation architecture as no detectable
enzymatic current response from channel 2 exists.
35

Ch 1 at 0.65 V bias
Ch 1 at 0.5 V bias
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Figure 2.12. Bias potential dependence of biosensor performance where only Ch1 is enabled during
interrogation; error bars show the standard deviation of the steady state response.
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Figure 2.13. The influence on current response due to measuring amperometric response from both
channels simultaneously at a fixed glucose concentration (30 mM); inset shows the % error of Ch1 when
Ch2 is enabled.

2.4 Conclusions
The pinnacle 8151 wireless potentiostat was shown to have excellent response
time and telemetric distance for small animal testing. The potentiostat can communicate
with a base station in a laboratory setting at a distance of up to 100 feet. The battery life
is sufficient for continuous monitoring of up to three days and the size/weight of the
device makes it an excellent choice for biosensor animal models. The major drawback for
the 8151 is its significant percentage of error between its two channels when measuring
“real” biosensors. A 6% error was observed between channels 1 and 2 for complex
circuits. This inherent error may lead to problems of inaccuracies during enzyme-based
amperometric detection of analytes while using the two channels of the 8151
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simultaneously. The MDEA 5037 transducer is a chip with two independently
addressable electrochemical cells, and could potentially be used with the 8151
potentiostat for performing dual analyte measurements.
Electrochemical impedance spectroscopy of modified MDEA 5037 transducers
and VDUT R/RC dummy cells reveal a close approximation to a simple Randle’s circuit
model. The two channels of the 8151 share a common reference/counter electrode and
therefore require the independent working electrodes of the MDEA 5037 to utilize a
common reference/counter electrode, contrary to its design. The 8151 and MDEA 5037
biosensor was shown to be capable of wireless detection of glucose with the potential for
dual analyte measurement as no electrochemical crosstalk occurred during interrogation
of the biosensor system. However, there was a discernable change in current response
when measuring independently from only one channel of the 8151 potentiostat. This
raises a concern for the accuracy of the detection of multiple analytes as the two channels
are not independent with respect to commercially available potentiostat instrumentation.
This issue can be circumvented by careful calibration of devices prior to use. The 8151
dual potentiostat has excellent performance aside from its lack of customizability. The
design of the 8151 potentiostat would benefit greatly by including options to allow the
use of two independent reference/counter electrodes for the two channels of the
potentiostat as well as sample and hold programming.
The MDEA 5037 biotransducer was shown to be highly reproducible with
analyzing ferrocene monocarboxylic acid, (FcCOOH), a facile redox probe. The steady
state, diffusion limited current produced at the surface of MDEA 5037 showed excellent
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sensitivity to FcCOOH. Experimental dose response curves showed higher sensitivity
compared to theoretical dose response curves. No differences were shown in performance
between the two electrochemical cells of the MDEA 5037. Casting of hydrogels onto a
MDEA 5037 transducer surface utilizing APTMS, polypyrrole seeding and hydrogen
abstraction with benzophenone was successful. Electrochemical impedance spectroscopy
of modified MDEA 5037 transducers reveals a close approximation to a simple Randle’s
circuit model.
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CHAPTER THREE: FABRICATION AND CHARACTERIZATION OF
BIOTRANSDUCERS BASED ON ELECTROPOLYMERIZED POLYPYRROLE AND
ELECTROCONDUCTIVE HYDROGELS

3.1 Introduction
3.1.1 Enzyme immobilization techniques for amperometric biosensors
Stability of enzymes is highly dependent on their mode of immobilization. The
immobilization technique to localize different enzymes at the surface of multi-analyte
electrodes is an engineering challenge in the fabrication of glucose and lactate
biotransducers. This challenge is particularly relevant in the fabrication of fully
implantable multi-analyte biosensors when the electrode sites are micron dimensions and
are adjacent to each other such as in a CMOS device [70]. Various immobilization
procedures have been developed for macro-electrodes or single microelectrodes. Among
these are physical adsorption [182], enzyme entrapment and encapsulation within
polymer membranes with or without covalent tethering that may be spun applied, dippedcoated, sprayed, covalently immobilized using homo- or hetero-bifunctional conjugation
agents [2, 183-185], or adsorbed via cross-linking with bifunctional cross-linkers such as
glutaraldehyde [186]. None of these additive techniques are however appropriate for
closely spaced microelectrodes on a CMOS device.
3.1.2 Polypyrrole for use in fabricating enzyme-based biosensors
The additive placement and entrapment of enzymes on such devices may be
achieved by electropolymerization. Electropolymerization produces controllable thin

71

films of inherently conductive electroactive polymers (CEP) deposited at electrode sites
[187]. During formation such polymers entrap counter anions that serve as “dopants”. In
the presence of enzymes, which are often negatively charged, electropolymerization leads
to formation of an enzyme enriched membrane layer deposited directly on the electrode
[188]. Advantageous properties of conductive polymers such as polypyrrole (PPy)
include good environmental and thermal stability [189, 190], corrosion protection of
metallic

electrodes

[191],

ease

of

preparation

either

chemically

[192]

or

electrochemically [193] as a homo-polymer or co-polymer, nano-structuring [194-197]
and precise tuning of its electrical conductivity [198]. The amount of PPy
electrodeposited onto a metallic or semiconductor electrode can be carefully controlled
based on charge density from which the thickness of the CEP can be calculated [199].
Polypyrrole is also known to impart interference suppression for amperometric
biosensors [200] and enables control of the hybrid polymer membrane properties. In this
work the effectiveness of polypyrrole to act as a screen for interferents is tested with a
novel transducer intended for use as a trauma management platform, the ElectrochemicalCell-on-a-Chip Multidisc Electrode Array (MDEA 5037) [70].
3.1.3 Electroconductive hydrogels for engineering the abio-bio interface
Research on soft electrode materials for engineering the abio-bio interface is a
growing field of interest for implantable biosensors, bioelectronic devices and next
generation bionics [1, 4, 201, 202]. We have previously introduced a class of hybrid
biomaterial, the electroconductive hydrogel (ECH) with the potential to address this need
[201]. An ECH is a polymeric blend or interpenetrating network that combines the
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electrical, redox and optical properties of conducting electroactive polymers with the
environmentally responsive properties and biocompatibility of highly hydrated hydrogels.
These hybrid biomaterials are capable of merging several attractive physical, chemical
and electrochemical properties [102]. The physical and chemical properties of hydrogels
can likewise be modified through varying crosslink density [180], inclusion of voids
using porogens [203], the incorporation of highly hydrophilic and/or hydrophobic
moieties [204] and the inclusion of bioactive components such as hyaluronic acid (HA),
phosphorylcholine (PC) and peptides. Both components lend themselves to molecular
engineering (tuning) of properties in diverse applications including; artificial muscles,
cell-culture and regenerative medicine, electro-stimulated drug release, and biosensors
[201, 205]. Importantly, the combination of these two materials and the process of
electropolymerization provide a convenient route for the biofabrication of immobilized
biomolecules within hydrogels on microfabricated electrodes surfaces [1, 4].
3.1.4 Research aims
3.1.4.1 Polypyrrole charge density dependence of biosensor performance and
storage stability
The simultaneous guiding and immobilization of biomolecules via the process of
electropolymerization of pyrrole into an electropolymerized polymer membrane as well
as within an existing electrode-supported, swollen hydrogel membrane layer is an
attractive method for the electrode specific immobilization of glucose oxidase and other
enzymes [11, 206, 207]. Polymer thickness and quantity of immobilized enzyme can be
controlled via the electropolymerization charge density (mC/cm2) used to create the
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PPy/Hydrogel/enzyme composite film. However, such immobilized enzymes rapidly lose
their activity due to denaturation and/or leaching [208]. Over time, significant changes to
biosensor performance in terms of sensitivity, dynamic range, response time and limits of
detection can be expected. The biotransducer performance as a function of
electropolymerized polypyrrole charge density (0.1–100 mC/cm2) within hydrogel
modified transducers was examined.
Biosensors can be optimized as a function of incorporated hydrogel and
polypyrrole content to maximize these performance criteria. The long-term effects of
polypyrrole incorporation on biosensor performance is explored. In addition to the
materials selection, longevity of biosensor systems is also a function of their
manufacturing, packaging, and storage. During storage, a stable environment for
maintaining enzyme activity and hydrogel conditioning requires optimization of buffer
type, pH, ionic strength and temperature. The effects of storage on the apparent enzyme
kinetic parameters of a biosensor systems utilizing hydrogels designed for intramuscular
implantation are outlined. The screening capability of the biosensors to the endogenous
interferent, ascorbic acid, was examined. Deleterious influence of PPy on an
amperometric electrochemical reaction of ferrocene (Fc-Fc+), a surrogate redox couple,
for what would otherwise be a mediator in a mediated enzyme biosensor reaction was
also investigated. Furthermore, the effect of seeding electrodes with polypyrrole doped
with polystyrene sulfonic acid (PSSA) on biosensor fabrication and performance was
determined.
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3.1.4.2 Pysico-chemical properties of ECHs as a function of charge density
Bioactive

electroconductive

hydrogels

combining

poly(hydroxyethyl

methacrylate) (pHEMA) based chemistry with PPy are currently being developed for use
in implantable amperometric biosensor systems intended for use as a trauma diagnostic
platform [1, 3, 5], in advanced bionic devices [209, 210], and in neural device
engineering [211]. The hydrogel component is rendered bioactive by the inclusion of
poly(ethylene

glycol)(950)methylethermethacrylate

(PEGMEM)

and

2-

(methacryloyloxy)ethyl 2-(trimethylammonio) ethyl phosphate (MPC). Controlling the
electrical impedance properties of the bioactive ECHs can be accomplished through
modification of the applied electropolymerization charge density of electrochemically
polymerized PPy. It has been previously shown that PPy charge density within an ECH
has a significant impact on murine pheochromocytoma (PC12) and human muscle
fibroblasts (RMS13) cell growth and proliferation [102]. The RMS13 cell line is of
particular interest because of its relevance to intramuscular implantation of biosensors
used in trauma management. The PC12 cell line is of particular interest because of its
relevance to neural implants. Since these attachment dependent cells are capable of
sensing and responding to changes in the physicochemical, and possibly electrical,
properties of their environment [212, 213], one possible explanation for the ECH induced
impact on their growth is that a change in the mechanical properties of the
electroconductive hydrogel occurs as a result of increasing the applied charge density of
PPy. Furthermore, the elastic modulus is an especially important property of
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bioengineered scaffold materials such as hydrogels and can influence the differentiation
of cells [214].
In this body of work the correlations among the different materials properties
were elaborated; physicochemical, electrical and mechanical, with their influence on the
growth and proliferation behavior of attachment dependent cells. The cells;
Rhabdomyosarcoma (RMS 13) and pheochromocytoma (PC 12), were grown on
electroconductive hydrogels of increasing electropolymerization charge density. The
effects of electropolymerization charge density on the UV-Vis characteristics, hydration
characteristics, the elastic modulus and the electrical impedance properties of
electroconductive hydrogels based on pHEMA and PPy were explored and related to
previously reported cell growth and proliferation studies. The goal is to develop usercontrolled hybrid biomaterials, such as these biosmart polymers, for engineering the abiobio interface of next generation implantable biosensors, bioelectronics devices, and for
applications in bionics.
3.1.4.3 Enzyme engineering for improved biosensor performance
Enzymes such as glucose oxidase have a number amino acids in their primary
structure to which covalent coupling of other functional moieties can be performed. For
instance GOx from Aspergillus niger (EC 1.1.3.4, PDB ID 1CF3) has 15 lysine groups
per subunit (2 subunits per molecule of GOx) with primary amines available for
modification. Modifying enzymes in such a manner will affect the way they are
incorporated into and interact with polypyrrole. As a direct means of improving biosensor
performance, i.e. increasing biosensor sensitivity and maximum current, lysine groups of
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enzymes were functionalized with i) a pyrrole moiety (monomerization) thereby directly
incorporating enzymes into the growing polypyrrole, or ii) a sulfonic acid moiety
(sulfonization) to make enzymes more effective dopants. Non-covalent and covalent
enzyme modifications of monomerization and sulfonization were performed and the
effects on biosensor performance were observed.
3.2 Materials and Methods
3.2.1 Chemicals and reagents
Poly(styrene sulfonic acid) was purchased from Polysciences, Inc. Ferric Chloride
was purchased from M.G. Chemicals. Dulbecco’s phosphate buffer saline, Benzophenone
(reagent grade 99%), Pyrrole monomer (reagent grade 98+%), 4-(3-Pyrrolyl)butyric acid
(PyBA),

Ferrocenecarboxylic

acid

(FcCOOH),

3-aminopropyl-trimethoxysilane

(APTMS), Glucose oxidase (GOx, E.C. 1.1.3.4 from Aspergillus niger), 2-hydroxyethyl
methacrylate (HEMA), tetra(ethylene glycol) diacrylate (TEGDA, technical grade),
poly(ethylene

glycol)(950)methylethermethacrylate

(PEGMEM),

N-

[Tris(hydroxymethyl)methyl]acrylamide (HMMA, 93%), 2-(Dimethylamino) ethyl
methacrylate (DMAEMA, 98%), 2-aminoethyl methacrylate (AEMA, 97%), the photoinitiator 2,2-Dimethoxy-2-phenylacetophenone (DMPA, 99+%), β-D(+)-glucose, 1-Ethyl3-[3-dimethylaminopropyl] carbodiimide (EDC), N-hydroxysulfosuccinimide (SulfoNHS), N-hydroxysuccinimide (NHS), sulfobenzoic acid (SBA) and all other common
solvents were purchased from Sigma Aldrich Co. (St. Louis, MO, USA). 2(Methacryloyloxy)ethyl 2-(trimethylammonio) ethyl phosphate (MPC) was purchased
from Tokyo Chemical Industry CO., LTD. Hetero-bifunctional monomer, 2-
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methacryloyloxyethyl-4(3-pyrrolyl)butanate (MPB), was synthesized in house from the
conjugation of PyBA (acid) and AEMA (amine).

The HEMA, methacrylate and

diacrylate reagents were passed through an inhibitor removal column (Sigma-Aldrich) for
removal of the polymerization inhibitors hydroquinone and monomethyl ether
hydroquinone before using them in the preparation of the hydrogel cocktail. Pyrrole
monomer was purified by double passage through an alumina silicate column. Solutions
were prepared in deionized water prepared by purifying distilled water through a MilliQ® plus (Millipore Inc.) ultrapure water system. The glucose stock solution of 1.0 M was
prepared and allowed to mutarotate overnight.
3.2.2 Characterization of electrodes and enzyme electrodes
Electrochemical

experiments

were

performed

using

a

BAS-100B/W

Electrochemical Analyzer with a BAS PA-1 preamplifier module used to amplify the
current and to filter out noise (BAS, West Lafayette, Indiana, USA). All experiments
were carried out in a three-electrode setup with platinum microelectrodes ( = 25µm or
100µm; BAS) as the working electrode, a Ag/AgCl (3 M KCl) reference electrode
(RE803; ABTECH Scientific, Inc., Richmond, Virginia, USA) and a platinum mesh
counter electrode (CE).
Microelectroes were characterized at various stages of fabrication, including
cleaned and APTMS surface modified, using the probe 50 mM Fe(CN)63-/4- and in
ferrocene

monocarboxylic

acid

(FcCOOH).

Before

use,

enzyme-modified

microelectrodes were over-oxidized (OO-PPy) by repeatedly cycling the electrode in PBS
(100 mM, pH 7.0) between 0 to 1.2 V vs. Ag/AgCl, 3M KCl for 40 cycles at 100 mV/s.
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For immobilized enzyme kinetics, biosensor sensitivity, response time and
biosensor stability studies, amperometric measurements were performed at potentials of
0.4 – 0.65 V vs. Ag/AgCl, 3 M KCl and by sequential injection of appropriate aliquots of
glucose solution into 100 mM PBS (pH 7.2) under continuous stirring to provide for
convective transport. Enzyme electrodes were stored in PBS solution at 4 oC over a
period up to 18 days. The kinetic parameters were determined using Lineweaver-Burk
analysis of biosensor amperometric response every few days during storage periods.
3.2.3 Enzyme monomerization and sulfonization
Pyrrole butyric acid and sulfobenzoic acid were covalently conjugated to lysine
groups of glucose oxidase. For monomerizing enzymes a 0.175 M Py, 0.025 M PyBA
solution was prepared in DI-Water with pH adjustment to 4.5-5.5 using 1 M NaOH. For
sulfonizing enzymes a 0.2 M Py, 0.625 mM SBA solution was prepared in DI-Water (pH
≈ 4-4.5 without needing adjustment). Then 0.625 mM of EDC, the necessary
concentration to achieve 10:1 ratio of PyBA:GOx or SBA:GOx conjugation, was
incorporated and allowed to incubate for 1 hour at 25 oC to activate the acid groups of
PyBA or SBA. Next 0.625 mM of NHS was incorporated and allowed to incubate for 5
min at 25 oC. Lastly 1 mg/mL of GOx was incorporated and allowed to incubate for 24
hours at 4 oC. Enzyme solutions were immediately utilized for electropolymerization
after conjugation was completed to form the covalently conjugated polypyrrole systems
of PPy(SBA-con-GOx) and P(Py-co-PyBA-con-GOx). Non-covalently conjugated
systems did not incorporate EDC or NHS in the electropolymerization solutions to make
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the systems of PPy(SBA)-GOx, P(Py-co-PyBA)-GOx. Control systems (PPy-GOx) were
prepared with 0.2 M Py and 1 mg/mL GOx in DI-Water.
3.2.4 Preparation of the enzyme electrodes
A 3 mol % TEGDA cross-linked standard hydrogel cocktail was prepared
according to a previously described recipe and protocol [131] by mixing HEMA,
TEGDA, PEG(400)MA, MPC, HMMA, p(NVP), DMAEMA, and DMPA in typical ratio
78:3:5:1:5:2:5:1 mol%. A 1:1 (v/v) solution of ethylene glycol/water corresponding to 20
% of the volume of the monomer cocktail was then added and the mixture stirred
overnight under UV-free conditions. Initially, the working platinum microelectrode
(BASi,  = 100µm) was mechanically polished with 0.05 μm alumina for 10 min and
then washed with nanopore water and acetone, respectively, in order to expose a fresh
platinum surface. The electrode was then immersed in 0.5 M sulfuric acid, made the
working electrode of a three electrode electrochemical cell and was electrochemically
cleaned by sweeping the potential between -0.20 to 1.40 V (vs. Ag/AgCl, 3 M KCl) at
100 mV/s until a steady state cyclic voltammogram was obtained. This electrochemical
pretreatment was followed by rinsing with nanopore water several times to ensure good
repeatability of electrode surfaces. Following cleaning the bare platinum microelectrode
surface was silanized by incubation in a 0.1 wt% solution of 3-aminopropyltrimethoxysilane (APTMS) in anhydrous toluene for one hour followed by thorough
rinsing with toluene and water. The electrode surface was subsequently functionalized
with acrylate groups by incubation in a solution of 1 mM acryloyl(polyethyleneglycol)N-hydroxysuccinamide (ACRL-PEG-NHS, MW 400) in 0.1 M HEPES buffer, pH = 8.5
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for 2 hours. Functionalization of electrodes was followed by ultrasonication in Milli-Q®
water for 5 minutes and drying with ultrahigh purity nitrogen.
Immediately following

cleaning,

surface

modification

and

PEG-ACRL

functionalization, the bare platinum microelectrode was dipped into the 3 mol% TEGDA
cross-linked p(HEMA)-based hydrogel light for 5 min using a UV cross-linker (CX-2000
Crosslinker, UVP, Upland cocktail which had been sonicated and sparged with nitrogen.
The thin film was then crosslinked with UV, CA, USA) under an inert nitrogen
atmosphere to yield a hydrogel membrane that was approximately 5 µm thick.
Electropolymerization of pyrrole was used as the principal means for
bioimmobilization of the enzyme on the hydrogel–modified microelectrode [11]. Before
electropolymerization of pyrrole, the hydrogel modified electrode was immersed and
incubated in 5.0 ml of an aqueous Py (0.4 M) / GOx (1 mg/ml) solution, pH = 6.0,
prepared in Milli-Q® water for 1 h to ensure equilibrium between the hydrogel film and
the electropolymerization solution. Finally, potentiostatic electropolymerization was
commenced by the application of 0.75V vs. Ag/AgCl, 3 M KCl to the Pt W.E. leading to
polypyrrole formation within the hydrogel membrane [2] and the concomitant
immobilization of GOx within the hydrogel. This produced an enzyme-loaded,
electroconductive polymer PPy-hydrogel composite (PPy-GOx-Gel|Pt). The enzyme
electrode was subsequently washed with Milli-Q® water and by PBS to remove any
unbound GOx from the hydrogel film. Electropolymerization charge densities of 0.1 –
100 mC/cm2 were explored.
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3.2.5 Electroconductive hydrogel cocktail preparation
A hydrogel cocktail possessing two cross-linkers, TEGDA and MPB, was
prepared. Firstly, a hydrogel monomer cocktail containing 1.5 mol % TEGDA was
prepared by mixing monomer constituents on a mol% basis (detailed in Table 1)
according to a previously described recipe and protocol [131]. Secondly, 1.5 mol %
MPB was separately synthesized via EDC, Sulfo-NHS chemistry in a 1:1 (v/v) solution
of ethylene glycol/water corresponding to 40 wt% of the monomer cocktail by: i)
dissolving PyBA in the ethylene glycol/water (pH ≈ 8) mixed solvent and reacting this
with an equi-molar concentration of EDC for 30 minutes, ii) adding an equi-molar
concentration of Sulfo-NHS and incubating for a further 5 minutes, and iii) adding an
equi-molar concentration of AEMA and incubating for a further 2 hours at room
temperature. Immediately following MPB synthesis all remaining liquid monomer
constituents were added and mixed into the solvent followed by the remaining solid
monomer constituents and the cocktail stirred until thoroughly mixed and clear. The
resulting monomer cocktail was gently ultrasonicated, sparged with nitrogen, and stored
at 4 oC under UV-free conditions until use.
3.2.6 Fabrication of electroconductive hydrogel modified electrodes and devices
Platinum interdigitated microsensor electrodes (IME 1025.3 M Pt) for impedance
measurements, planar indium tin-oxide electrodes (PITOE 150) for UV-Vis spectroscopy
and planar platinum or planar gold electrodes (PME Pt 118, PME Au 118, PME Au MA)
were acquired from Abtech Scientific (Richmond, Virginia, USA). Electrodes were first
ultrasonicated in DI-water, isopropyl alcohol (IPA), DI-water for 5 minutes each.
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Electrode surfaces were placed into a UV-ozone cleaner (Boekel Industries) and
irradiated for 10 minutes followed by a 1 minute ultrasonication in IPA. Plasma
modification of the IME devices to generate hydroxyl groups onto the silicon nitride was
performed under vacuum in the presence of small amounts of water vapor using a Harrick
Plasma Cleaner (Harrick Plasma). Following plasma activation, the bare platinum
microelectrode surface was silanized by incubation in a 0.1 wt% solution of APTMS in
ethanol for 45 minutes followed by ultrasonication in IPA for 5 minutes. Curing of the
silanol was then performed using 20 minute intervals of 40 oC, 110 oC and 40 oC. The
transducer was then immersed in PBS buffer (0.1 M, pH = 7.2), made the working
electrode of a three electrode electrochemical cell and was cathodically cleaned by
sweeping the potential between 0 and -1.2 V (vs. Ag/AgCl, 3 M KCl) at 100 mV/s for 40
cycles.
Polypyrrole was deposited potentiostatically at 850 mV vs. Ag/AgCl onto the
electrode fingers using an electropolymerization solution consisting of 0.2 M Py with 0.1
M repeat units of polystyrene sulfonate as dopant prepared in DI-water and pH-adjusted
to pH=4.75 using 0.1 M NaOH. An electropolymerization charge density of 10 mC/cm2
was applied to produce a seeding layer of polypyrrole. Transducers were then immersed
in a 0.01 M benzophenone solution prepared in ethanol, removed and allowed to air dry
for several minutes followed by UV irradiation (365 nm) for 5 minutes each on the front
and back side of the transducer to initiate hydrogen abstraction and termination of both
the polypyrrole and primary amine groups of the transducer with benzophenone [1].
Transducers were then either spin coated with monomer cocktail or dip cast into
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monomer cocktail while allowing excess to be removed by dripping and touching the side
of transducers to a Kimwipe®. The hydrogel was crosslinked via UV irradiation for 5
minutes. Transducers were placed into a convection oven at 60 oC for 60 minutes to be
annealed. Transducers were then allowed to incubate in the electropolymerization
solution for 1 hour prior to electropolymerization. Electrodes were then subjected to
subsequent chemically induced oxidative polymerization by immersion in 0.01 M ferric
chloride for 15 minutes and/or electropolymerization at 800-850 mV vs. Ag/AgCl to
generate the polypyrrole based electroconductive hydrogels (PPy-ECH). Charge densities
from 10 to 900 mC/cm2 were explored.
3.2.7 Hydration and swelling properties of hydrogels
Bulk property characterization was performed on the hydrogel to determine:
degree of hydration, DoH, density, ρ, and void fraction, ε. Hydrogel disks fashioned
using silicone isolators (664206, Grace Biolabs) as casting molds were placed on a clean,
hydrophobic (surface modified with octadecyltrichlorosilane), glass microscope slide. 31
μL aliquots of the sonicated and sparged monomer cocktail were pipetted into the isolator
wells and a second microscope slide placed over the filled wells. The isolator|slide
apparatus was immediately UV irradiated (365 nm, 2.3W/cm2) for 5 minutes resulting in
polymerization. The uniform hydrogel disks were removed from the isolators and
gradually hydrated to reduce strain-induced cracking by sequential immersion in
ethanol|PBS solutions (75:25, 50:50, 25:75 v/v) for a minimum of one hour each. The
disks were finally placed in pure PBS, which was exchanged 3-4 more times every 12
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hours to extract any remaining, unreacted monomer or solvent. The hydrated disks were
stored at room temperature in PBS buffer until use.
Degree of hydration (DoH) was determined by taking hydrated and dehydrated
weights of the disks. For dehydration, disks were placed in a desiccator, which
maintained a constant humidity and temperature. Dry weight was determined once the
weight remained stable over a 24hr period. Degree of hydration was then determined by
Equation (3.1). Volume measurements were taken by employing a method, described by
Hughes [215], using Archimedes principle. Density was determined using the measured
weight and volume of the hydrated disks and void fraction was determined using
Equation (3.2) [216].

DoH (%) 

M HG  M DG
100%
M HG

  HG 

  solution 

  DoH 

(3.1)

(3.2)

Where Mi is mass of the polymer, HG is the hydrated hydrogel and DG is the
dehydrated hydrogel. The hydration properties of PPy-ECH films were determined from
dimensional changes (z-axis) measured using a thickness profilometer (Tencor Alpha
Step 200). The films were prepared on PME 118-Pt (ABTECH Scientific Inc., Richmond,
VA) with a fixed area of 0.725cm2. DoH was determined by taking hydrated and
dehydrated dimensions of the films and calculated using Equation (3.4), which results
from combining Equation (3.3) with Faraday’s law and a mass balance. Equation (3.3)
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assumes uniform, isotropic swelling normal to the PME area and that the volume of
mixing between the PPy-ECH and solvent (water) is negligible.

DoH  %  

DoH  %  

 sol V
( wt % )  V  DG
Gel

Where

M Gel

M sol
100%
 M PPy  M sol

Gel  Py

QMW PPy A

  sol V
nF

(3.3)

100%

(3.4)

is the density of the solvent, ΔV is the change in volume due to

swelling, wt%Gel is the weight percent of the UV-polymerized hydrogel in the PPy-ECH
composite, V is volume, Q is electropolymerization charge density, MWPPy is the
molecular weight of polypyrrole, A is area of the film, n (2.25) [217] is the number of
electrons per redox event and F is Faradays constant.
3.2.8 Determination of elastic modulus of hydrogels
The elastic moduli of the electropolymerized PPy-ECH films were measured
using a commercial Atomic Force Microscope (MFP3D-BIO-AFM, Asylum Research,
Santa Barbara, CA) installed on an optical microscope platform (Nikon eclipse Ti-U,
Nikon Instruments Inc., Melville, NY). The measurements employed Olympus TR400PB cone-tipped cantilevers with a spring constant of 0.09 N/m. The PPy-ECH films were
prepared on 1.0 cm x 2.0 cm x 0.05 cm platinum planar metal electrodes (PME 118-Pt;
ABTECH Scientific Inc., Richmond, VA, USA) with various charge densities and
imaged under immersion conditions within DPBS buffer filled Petri dishes ( = 50mm).
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Each PPy-ECH film was imaged in five separate 25 μm*25 μm areas that produced a
total of 500 data points. The quantitative elastic modulus was extracted from the forcedisplacement data using the Hertz model for a cone tip.

F

1

3

4 E
R 2δ2
2
3 (1- υ )

(3.5)

F = Force (nN) = Cantilever Deflection (nm) x Spring Constant (0.09 nN/nm), E =
Elastic Modulus, R = Probe Radius = 2.5 µm, δ = Indentation Depth, υ = Poisson’s Ratio
= 0.29 for poly(HEMA) hydrogel [218]. In view of the composite nature of the hybrid
polymers, a Poisson’s Ratio = 0.50 was also explored.
3.2.9 UV-Vis and electrical impedance spectroscopy of hydrogels as a function
of charge density
For UV-Vis spectroscopy, PITO transducers were cleaned and modified with
PPy-ECH composites of varying charge densities and placed within polystyrene cuvettes
containing

PBS buffer at room temperature (25 oC) and pH = 7.2. Each sample was

analyzed by UV–Vis Spectroscopy using a Synergy Mx Monochromator-Based MultiMode Microplate Reader X (BioTek Instruments, Inc., Winooski, VT USA). A spectrum
analysis was performed from 300 to 900 nm wavelengths to determine the peak
absorbance of PPy within the cast ECHs. Electrochemical experiments were performed
using a BAS-100B/W Electrochemical Analyzer with a BAS PA-1 preamplifier module
used to amplify the current and to filter out noise (BAS, West Lafayette, Indiana, USA).
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Electrical impedance spectroscopy was performed using a Solartron 1260
Frequency Response Analyzer (Solartron Analytical). All impedance experiments were
carried out in a co-planar, two-electrode mode to measure the impedance between the
digits of the interdigitated microsensor electrodes. Devices were studied at RT in 1 mL of
PBS buffer at pH = 7.2 using a 10 mV peak-to-peak sine wave over the frequency range
of 10-1-106 Hz.
3.2.10 Cell culture
PC12 and RMS13 cells were purchased from the American Type Culture
Collection (ATCC, Manassas, Virginia). PC12 cells were cultured in F-12K
supplemented with 2.5% fetal bovine serum (FBS) and 15% horse serum (HS), as well as
50 IU/mL penicillin and 50µg/mL streptomycin (Fisher Scientific, Pittsburgh, PA, USA).
RMS13 cells were cultured in RPMI supplemented with FBS (10%) and 50 IU/mL
penicillin and 50µg/mL streptomycin. Cells were seeded and grown on planar gold
electrodes (PME118 or PME MA; ABTECH Scientific, Richmond, VA, USA) that were
modified according to: i) Au*; ii) Au*|Gel; (iii) Au*|PPy; (iv) Au*|Gel-P(Py-co-PyBA).
Trypsinized cells were stained with trypan blue and the final cell density (in a volume
equivalent to that used in the initial cell seeding) determined using a hematocytometer
and inverted light microscope. The morphology of cells attached to the electrode surfaces
was determined following staining with rhodamine-phalloidin and DAPI subsequent to
fixing with 4% paraformaldehyde. A specific cell proliferation assay aimed at confirming
the proliferative state, such as 3H-Thy or BrdU, was not performed as cell numbers were
in many cases larger than the original seeding numbers confirming cell proliferation.
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Imaging of cells for evaluation of morphology was performed using a Nikon confocal
upright microscope.
3.3 Results and Discussion
3.3.1 Preparation and characterization of microdisc electrodes
Platinum microdisc electrodes were cleaned, surface modified with APTMS
(APTMS|Pt)

and

then

chemically

functionalized

with

PEG-ACRL

(ACRL-

PEG|APTMS|Pt) for the eventual attachment of the bioactive hydrogel membrane layer
and subsequent electropolymerization of Py to simultaneously immobilize the enzyme,
GOx, within the hydrogel membrane layer. To confirm the adsorption of the silanol layer
of primary amines on the microelectrodes, following solvent cleaning and surface
modification by APTMS, electrodes were analyzed by cyclic voltammetry in 1:1 50 mM
Fe(CN)63-/4-. Following electrochemical cleaning in 0.5M H2SO4 by repeated cycling over
the range -0.2 to 1.5V (100 mV/s) vs. Ag/AgCl, 3M Cl-, electrodes were again
characterized in 1:1 50 mM Fe(CN)63-/4-. Figure 3.1 shows the voltammograms that were
obtained for  = 25µm) Pt-ME.

89

2.0E-08

Current (A)

0.0E+00

0.0E+00

-1.0E-08

-1.0E-08

-2.0E-08

After polishing

C

Current (A)

2.0E-08
0.0E+00

0
200
400
600
800
Potential (V) vs. Ag/AgCl, 3M Cl-

2.0E-08

cycle1

1.0E-08

cycle10
cycle25

D

0.0E+00

cycle40

-1.0E-08

-2.0E-08

-4.0E-08

-2.0E-08

-6.0E-08
-8.0E-08
-400

After electrochmical
cleaning
After silanization

-3.0E-08
-200

0
200
400
600
800
Potential (V) vs. Ag/AgCl, 3M Cl-

8.0E-08
4.0E-08

-2.0E-08

After electrochemical
cleaning

Current (A)

-3.0E-08
-200

6.0E-08

B

1.0E-08

Current (A)

1.0E-08

2.0E-08

A

100
600
1100
1600
Potential (V) vs. Ag/AgCl, 3M Cl-

-3.0E-08
-200

First electrochemical
cleaning
Second electrochemical
cleaning after silanization

0
200
400
600
800
Potential (V) vs. Ag/AgCl, 3M Cl-

Figure 3.1. Cyclic voltammograms of the Pt-ME ( = 25µm) in 10mM PBS at pH 7.0 in the presence of
5mM Fe[CN]63-/4- performed at a scan rate of 100 mV/s. A) A direct comparison of an alumina polished
electrode (RED) with one electrochemically cleaned in 0.5M H 2SO4 by repeated cycling over the range -0.2
to 1.5V vs. Ag/AgCl, 3M Cl- at 100 mV/s (BLUE). B) A comparison of electrochemically cleaned
electrode (BLUE) with one that was surface modified by APTMS (RED, APTMS|Pt). C) Multiple cycles
associated with electrochemical cleaning. D) A comparison of an electrochemically cleaned electrode
(BLUE, |Pt) with an electrode that was surface modified with APTMS (RED, APTMS|Pt) and subsequently
electrochemically cleaned as in A above.

Panel A of Fig. 3.1 shows that the electrochemical cleaning protocol improves the
microelectrode characteristics in Fe[CN]63-/4-; producing a voltammogram that
approaches microelectrode ideality. Panel B shows the result of APTMS silanol surface
modification to be a passivated microelectrode with little access of the redox couple to
the electrode. Panel C shows the application of 40 cleaning cycles over the range -0.20 to
1.50 V (vs. Ag/AgCl, 3 M KCl) at 100 mV/s until a steady state cyclic voltammogram
was obtained. Panel D shows the result of the characterization repeated following the
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electrochemical cleaning protocol to return the electrode to a condition similar to the
originally cleaned ideal microelectrode behavior.
Figure 3.2 shows the effect of this electrochemical cleaning protocol on the
electrochemical behavior of the probe molecules, Fe(CN)63-/4- and FcCOOH, at the
electrochemically cleaned and as-modified Pt macrodisc electrode Pt-ME ( = 100µm).
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Figure 3.2. Cyclic voltammograms of the Pt-ME ( = 100µm) performed at 100 mV/s. A) A comparison of
an alumina polished and electrochemically cleaned electrode (BLUE, |Pt) with one that was surface
modified with APTMS (RED, APTMS|Pt) as tested in 10mM PBS at pH 7.0 in the presence of 5mM
Fe[CN]63-/4-. B) A comparison of an alumina polished and electrochemically cleaned electrode (BLUE, |Pt)
with one that was surface modified with APTMS (RED, APTMS|Pt) as tested in 10mM PBS at pH 7.0 in
the presence of 5mM FcCOOH.

Panel A of Fig. 3.2 shows a modest increase in the peak potential of the APTMS
surface modified Pt macroelectrode compared to cleaned bare electrode in the Fe(CN)63/4redox system. At a pH of 7 it is expected that the immobilized amine functional groups of
the APTMS chemisorbed layer will carry some fraction of associated positive charges
[219]. The electrostatic attraction of APTMS is likely increasing the electrode boundary
concentration of the negatively charged Fe(CN)63-/4- causing the observed increase in
peak oxidation reduction current. The shift in the reduction potential for the Fe(CN)63-/4can be expected for the APTMS coated electrode as it is less likely to transfer electrons to
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the higher concentration of negatively charged ferricyanide in conjunction with
electrophilic tertiary amine groups at the electrode surface. The system with ferrocene
monocarboxylic acid did not show any peak shifts or changes in peak currents, but rather
generated similar currents with the APTMS electrode when compared to the bare
electrode. Most important however is the implication that on the microelectrode scale the
chemisorbed silanaol layer is contiguous and passivating while on the macroelectrode
scale the chemisorbed layer lacks the integrity to serve as a passivation layer and is likely
discontinuous and establishes that at Pt-ME ( = 100µm) redox active molecules can gain
access to the macroelectrode surface.
3.3.2 Bioanalytical performance of the immobilized GOx biotransducers
Following hydrogel casting, the immobilized enzyme electrodes were prepared by
electropolymerization of pyrrole in the presence of GOx leading to entrapment of GOx
within the hydrogel and the fabrication of a bioactive, electroconductive hydrogel. The
preparation of glucose responsive biotransducers by the immobilization of GOx via
electropolymerization of Py is well documented in the literature [132, 200, 220-223].
Electropolymerization to confer enzyme biospecificity to the Pt-supported hydrogel
membrane may be accomplished at different values of electropolymerization charge
density. It has previously been established that electropolymerization of Py within
electrode-supported hydrogels is initiated at the electrode-hydrogel interface and
progresses outwards, being more dense at the electrode-hydrogel interface and
progressively less towards the hydrogel-solution interface [224]. The amperometric
enzyme-based biotransducers are Type 1 (or generation 1) devices that involve the

92

measurement of the rate of hydrogen peroxide formation that is linked to enzyme activity.
Each type of micro-biotransducer was investigated by generating a dose response curve
to glucose in aerated buffer solution at RT. Electrodes were then stored in glucose free
buffer solution at 4 °C and periodically analyzed as before by reproducing the dose
response curve.
Firstly, a comparison was made of the performance of biotransducers prepared
using the current hydrogel method (PPy-GOx-Gel|Pt) to that of biotransducers prepared
by entrapping enzyme directly to the surface of a cleaned platinum electrode with
electropolymerized polypyrrole (PPy-GOx|Pt). Figure 3.3(A) shows the dose-response
curves obtained for systems of PPy-GOx|Pt and PPy-GOx-Gel|Pt where the former was
prepared by the electropolymerization of Py in the presence of 1.0 mg/ml GOx at a
cleaned

and

unmodified

electrode

and

the

latter

was

prepared

by

the

electropolymerization of Py in the presence of 1.0 mg/ml GOx at a hydrogel-coated (ca.
5.0 µm) electrode. Both biotransducers were prepared using a charge density of 10.0
mC/cm2. Biotransducers showed monotonically increasing current responses to infusions
of glucose. The chronoamperometric response was stable under gentle stirring conditions
with steady state currents being reached and maintained at response times ranging from
10-70 seconds. It is clear that the non-hydrogel system displays a fourfold higher
sensitivity (50 pA/mM) compared to the hydrogel modified biotransducer (12 pA/mM).
Secondly, the hydrogel modified biotransducer displays a change in slope and thus shows
two linear regimes. Secondly, a comparison was made of the performance of
biotransducers prepared by the current hydrogel method when using different
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electropolymerization charge densities, Figure 3.3(B). The bioanalytical performance of
the various transducers studied is summarized in Table 3.1.
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Figure 3.3. Glucose dose–response curves of biotransducers ( = 100µm) PPy-GOx|Pt (RED) and PPyGOx-Gel|Pt composite membrane (BLACK). A) A comparison of PPy-GOx|Pt (RED) and PPy-GOxGel|Pt at 10 mC/cm2 and B) A comparison of PPy-GOx-Gel|Pt at various electropolymerization charges.
Table 3.1. Bioanalytical performance of PPy-GOx|Pt and PPy-GOx-Gel|Pt biotransducers as a function of
electropolymerization charge density measured after 7 days of storage in PBS 7.2 at 4 °C.
PPyGOx|Pt

PPy-GOx-Gel|Pt

Charge density
(mC/cm2)

10

0.1

1

10

20

100

Sensitivity
(nA/mM/cm2)

596 (1-10
mM)

39 (1-15
mM)

281 (1-15
mM)

146 (1-6
mM)
61 (6-10
mM)

84 (1-6
mM)
29 (6-10
mM)

45 (1-5
mM)
6 (8-33
mM)

1 – 10,

1 – 15,

1 – 15,

1 – 6,

1 – 6,

1 – 5,

-

-

-

6 – 10

6 – 10

8 – 33

Response Time (s)

20

20

50

50

70

2-8

Detection Limit
(mM)

0.004

0.621

0.033

0.020

0.030

0.098

KM (mM)

11.65

29.2

33

6

4.6

0.57

Imax (µA/cm2)

12.7

1.7

13.2

1.9

0.7

0.6

Linear Dynamic
Range (mM)

Hydrogels of implantable biotransducers are a needed component for conferring
their ability to impart biocompatibility through reduction in protein fouling [131],
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reduction to the inflammatory and foreign body responses [225], and reduction to fibrous
encapsulation [3]. The response of the freshly prepared (10 mC/cm2) glucose biosensors
based on PPy-GOx-Gel|Pt composite was linear over the range 1 to 6 mM, with a
sensitivity of 153 nA/mM/cm2 and a response time of 25s. The sensitivity of the freshly
prepared (10 mC/cm2) glucose biosensor without hydrogel film (PPy-GOx|Pt) was linear
in the range 1 to 10 mM with a sensitivity of 637 nA/mM/cm2 and a response time of 18s.
The presence of the hydrogel improved the linear dynamic range but reduced sensitivity
and response time. This could be due to the enzyme loading in the PPy-hydrogel and/or
to the diffusion limitation of glucose through the interpenetrating network of PPy within
the hydrogel. The observed difference in response time would have no practical impact
on performance. Both polypyrrole and the hydrogel are shown to have an effect on
enzyme affinity and stability [226]. The apparent Michaelis–Menten constant KM and the
maximum current response, Imax, were calculated from the slope and the intercept of the
Lineweaver–Burk plots [227, 228]. For PPy-GOx-Gel composite KM= 11.4 mM and Imax=
3.3 µA/cm2 and for PPy-GOx composite KM= 7.6 mM and Imax= 9.1 µA/cm2. In both
cases the value of the KM was higher than that independently determined using
spectrophotometry in solution (KM= 6 mM).
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3.3.3 Effect of electropolymerization charge on the response of ECH modified
biotransducers
The charge density dependence of electropolymerized PPy on the sensitivity of
the biotransducer was examined. After 7 days of storage at 4.0 ºC in PBS 7.2 buffer, the
sensitivity of 0.1, 1, 10, 20, and 100 mC/cm2 current densities used for GOx
immobilization onto biotransducers were compared. Biotransducers with charge densities
ranging from 0.1-20 mC/cm2 were prepared on a platinum microelectrode and the
biotransducer with a charge density of 100 mC/cm2 was prepared using a microdisc
electrode array that has previously been reported [12, 70]. Amperometric responses were
normalized to electrode surface area. The linear dynamic range was shown to be
influenced by the charge density. Increasing the total charge density decreased the
effective linear dynamic range. Improved linear range has previously been attributed to
higher porosity of low charge density polypyrrole [229]. Increasing the overall applied
charge density led to an increase in the response time of biotransducers. This result was
expected as additional polypyrrole will lead to a decrease in permeability of the bioactive
membrane [230]. Average pore radius of mesoporous polypyrrole films has been shown
to be approximately 17-19 Å [231]. Low charge densities of electropolymerized
polypyrrole have been observed to have higher specific capacitances which subsequently
decrease with further applied charge density [232]. For polypyrrole systems, higher
specific capacitances are attributed to higher porosity networks that increase permeability
of electrolytes through the mesopores [233]. Blockage of these nano-features may result
due to the overgrowth of polypyrrole [207, 234].
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Other findings have shown that

increasing polypyrrole charge density decreases response time of the amperometric
biosensor, but no explanation was proposed as to why this may be occurring [230].
We observed an initial rise followed by a decrease in sensitivity with the
maximum sensitivity being observed at 1 mC/cm2, Figure 3.4. Very similar trends have
been observed for cholesterol oxidase and glucose oxidase biotransducers fabricated with
overoxidized polypyrrole [230, 235, 236]. Decreases to sensitivity have been attributed to
decreases in permeability of hydrogen peroxide as polypyrrole thickness increases [235].
Polypyrrole film morphology is highly dependent upon the electropolymerization charge
density [237] and as a result may be having more influence on the activity of the
enzymes. Thicker polypyrrole layers also allow more enzymatic reactions to take place
closer to the solution/bioactive-membrane interface with subsequent diffusion of
hydrogen peroxide into bulk solution rather than to the surface of the transducer [235,
236, 238].
Fructose dehydrogenase immobilized by polypyrrole has also been shown to have
a maximum amperometric current response at a charge density of 1 mC/cm2 for fructose
biosensors [239]. The inflection of maximum sensitivity for glucose was at a lower PPy
charge density or thickness when compared to some other findings [240, 241]. This
indicates that PPy generated within the pHEMA hydrogel reaches saturating levels more
quickly than PPy deposited directly onto electrodes, consistent with other previously
reported findings [224]. Incorporation of the hydrogel diminishes sensitivity by a factor
of four and increases the response time by a factor of two. This was shown to be the case
at a charge density of 10 mC/cm2 for PPy-GOx electrodes which had a sensitivity of 596
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nA/mM/cm2 when compared to PPy-GOx-Gel electrodes having a sensitivity of 146
nA/mM/cm2, Table 3.1. Polypyrrole based enzyme immobilization onto bare electrodes
does not typically reach diffusion limiting levels until polymer thickness reaches >250
nm or a charge density of >100 mC/cm2 indicating that the hydrogel has an appreciable
influence on biosensor performance [238, 242].
The hydrogel utilized was crosslinked with 3 mol% TEGDA, making it a highly
tortuous network even prior to the formation of the interpenetrating network of PPy
[216]. It has been shown that the void volume and tortuosity increase dramatically by
increasing crosslink density of pHEMA hydrogels [181]. This can lead to both decreased
diffusivity of glucose and hydrogen peroxide. Loss of enzyme activity due to the
immobilization process cannot be ruled out. For the lower charge densities KMapp equals
approximately the Michaelis-Menten coefficients for GOx in solution [243]. The amount
of polypyrrole incorporated into the hydrogels may be influencing the bound to free
water ratio which can account for the observed trend in KMapp. Bound water has been
shown to decrease in similar hydrogel systems with increasing TEGDA crosslink density
[216]. We observed that the overall enzyme activity decreased for charge densities >1
mC/cm2 but increased in apparent substrate affinity, Table 3.1.
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Figure 3.4. Trends in the amperometric current density for 5 mM glucose and the apparent MichaelisMenten enzyme affinity constant, KMapp, as a function of electropolymerization charge density (mC/cm2).
The charge density of 100 mC/cm2 was determined using a microelectrode array.

It is clear that optimizations of biosensor performance parameters will require
choosing the combination of cross-link density and electropolymerization charge density
that achieves the best sensitivity, linear dynamic range and lowest detection limit. For
example, the crosslink density (mol % TEGDA) may be decreased to accommodate
additional interpenetrating network formation via pyrrole electropolymerization. The
systems design of an implantable amperometric biosensor in this body of work has shown
to have a predictable properties based on electropolymerization of polypyrrole. One of
the major drawbacks is the decreases in sensitivity of PPy-GOx-Gel composites. Even so,
there are appreciable added benefits in using a PPy-hydrogel composite for biosensing
purposes. The PPy-hydrogel composites have been shown to have superior cell viability
in vitro compared to PPy or hydrogel alone [201]. Other studies have shown polypyrrole
to be positively biocompatible with central nervous tissues [244] and peripheral nervous
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tissues [245] and polypyrrole particles have been shown to not illicit inflammation to
peritoneal cells after a 6 week period [246].
3.3.4 Ascorbic acid interference and effects of the applied potential
Ascorbic acid (AA) is a negatively charged endogenous interferent that is known
to perturb biosensor response in vivo. Ascorbic acid, along with other negatively charged,
redox-active interferents must be screened in order to prevent their non-specific
oxidation. Failure to take this into account may lead to significant errors during in vivo
sensing. A relevant range of oxidative potentials for the oxidation of hydrogen peroxide
was examined using a hydrogel coated, 10 mC/cm2 PPy biotransducer. It was noted that
for a clinically relevant concentration of AA [247] only 3-5% of the total current
response was contributed by AA at the low concentration of 5 mM glucose, Figure 3.5.
Even at the highest applied potential of 700 mV the biotransducer maintained a
reasonable screening ability.
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Figure 3.5. Glucose dose–response curves of biotransducers ( = 100µm) PPy-GOx |Pt (RED) and PPyGOx-Gel|Pt composite membrane (BLACK). A) A comparison of PPy-GOx|Pt (RED) and PPy-GOxGel|Pt at 10 mC/cm2 and B) A comparison of PPy-GOx-Gel|Pt at various electropolymerization charges.
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Polypyrrole is known for its interferent screening capability by anion exclusion
after overoxidation thereby preventing the diffusion of negatively charged ascorbic acid,
uric acid, and acetaminophenol [200, 248]. Polypyrrole used with similar hydrogel
systems have been able to suppress interferents of ascorbic acid and L-cysteine at twice
the physiological levels found in serum by maintaining their deviations to less than 5% of
a glucose responsive biosensor [249]. Polypyrrole shows a consistency in its screening
ability for interferents in bioactive pHEMA-based hydrogel membranes. Thicker
polypyrrole layers with less incorporated enzyme will have the drawback of decreased
sensitivity and linear range but increased screening capability of interferents [250].
3.3.5 Time dependence of performance – stability
Figure 3.6 shows the amperometric sensitivity of two biotransducers (1.0 and 10
mC/cm2) that was observed over time. An overall trend of increasing biotransducer
sensitivity as a function of storage time was noted. The biotransducer of 1.0 mC/cm2
plateaued at approximately 21 pA/mM at 15 days of storage. The biotransducer at 10
mC/cm2 had a similar trend but was not observed beyond 10 days of storage. The most
dramatic changes in stability of PPy-GOx biosensors have been shown to occur within
the first 5 days of storage [241]. Typically biotransducers are characterized by a decrease
in sensitivity and maximum current with increasing storage time [251]. Amperometric
biotransducers utilizing PPy have been shown to have 21 days of stability but a very
sharp decrease in sensitivity thereafter [208]. Ideally no changes to sensitivity or
maximum current should occur over time. Stability of up to 20 days, with no changes in
sensitivity, has been observed for PPy-GOx systems using electrochemical surface
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plasmon resonance [252]. Given proper calibration, the stability of the polypyrrole based
enzyme amperometric biosensors have a reasonably long lifetime of use.

Figure 3.6. Temporal changes in the sensitivity of stored PPy-GOx-Gel|Pt biotransducers prepared with 1
and 10 mC/cm2 as a function of days of storage in PBS 7.2 at 4 °C.

The apparent Michaelis-Menten constant (KMapp) for the charge density of the
electroconductive hydrogel prepared with an electropolymerization charge of 1.0 mC/cm2
was found to fluctuate over time, Table 3.2. For biorecognition membranes prepared
with an electropolymerization charge of 10.0 mC/cm2 the apparent Michaelis-Menten
constant (KMapp) did not change as dramatically, Table 3.3. Enzyme stability and affinity
appeared to be maintained considerably higher over time for membranes prepared with
10 mC/cm2, indicating that the additional polypyrrole introduced more enzyme and aids
in maintenance of enzyme activity. Michaelis constants ranging from 2.7 - 6.1 mM
indicate that affinity increases for polypyrrole entrapped GOx compared to native GOx
under aerated conditions which typically have KMapp of approximately 11 mM [253,
254].
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Table 3.2. Bioanalytical performance and apparent enzyme kinetic parameters of a
PPy/GOx/Hydrogel|Acrylate-PEG-APTMS|Pt biotransducer following preparation using an
electropolymerization charge density, Q = 1.0 mC/cm2 and measured at RT after 7, 10, 11, 15, 16 and 18
days of storage in PBS 7.4 at 4 °C.

Days stored

7

10

11

15

16

18

Sensitivity (nA/mM)

11.6

17.5

18.3

22.1

18.6

21.2

Linear dynamic range
(mM)
Response time (s)

1-8

1-10

1-15

1-15

1-15

1-15

50

50

50

50

50

50

Apparent MichaelisMenten constant
(mM)
Maximum current
(nA)

18.6

152

56

33

31.4

104

0.29

2.90

1.33

1.04

0.84

2.7

Table 3.3. Bioanalytical performance and apparent enzyme kinetic parameters of a
PPy/GOx/Hydrogel|Acrylate-PEG-APTMS|Pt biotransducer following preparation using an
electropolymerization charge density, Q = 10.0 mC/cm2 and measured at RT after 3, 4, 7, 8 and 10 days of
storage in PBS 7.4 at 4 °C.

Days stored

3

4

7

8

10

Sensitivity (pA/mM)

6.4

3.6

8.5

10.6

12.8

Linear dynamic range (mM)

0-7

0-7

1-10

1-10

1-15

Response time (s)

50

50

50

50

50

Apparent Michaelis-Menten
constant (mM)

2.7

2.1

4.9

6.0

6.1

Maximum current (pA)

45.5

30

100

147

170

It is expected that most of the enzyme molecules that were incorporated through
entrapment would somehow have their native conformation and active site perturbed.
Changes in protein structure as a result of immobilization may increase or decrease
enzyme affinity for substrates. However, it has been shown that substrate specificity of
GOx is unaffected by the immobilization through electropolymerization of pyrrole [222].
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Polypyrrole has been shown to protect entrapped enzymes from leaching out in some
cases as well as protecting and stabilizing their activity [222, 223, 255]. Higher charge
density entails a thicker layer of polypyrrole grown upon the electrode surface allowing
greater immobilization and stabilization of enzyme resulting in more consistent enzyme
affinity. Upon reaching a diffusion limited state, the current response of biosensors
become mass transport controlled. This is usually characterized by a decrease in
maximum current and sensitivity with increasing film thickness [238]. Assuming a
uniform current distribution to the working electrode, potentiostatic growth of
polypyrrole films grown at a charge density of 45 mC/cm2 onto planar platinum
substrates will produce films of 0.1 µm thickness [242]. Thus, the charge densities
utilized in this work effectively generate polypyrrole films that are 2.2 nm and 22 nm in
thickness for charge densities of 1.0 and 10.0 mC/cm2 respectively which are well below
the polypyrrole diffusion limiting thickness of 250 nm.
It is uncertain as to why a maturation process occurs for the investigated PPyGOx-Gel composite biotransducers. One possibility is that hydration of the polypyrrole
matrix is occurring over time. The applied potential of 400 mV vs. Ag/AgCl during
interrogation is believed to be high enough to induce degradation of polypyrrole [256],
however, the polypyrrole of the current biotransducers are already overoxidized. There is
the possibility of some partial enzyme unfolding during electro-immobilization that may
be accompanied by refolding within the hydrogel during storage leading to more of the
entrapped enzymes to become active, increasing the enzyme efficiency of the
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biotransducer. Experimental determination of enzyme secondary structure using FT-IR
and circular dichroism may be performed in the future to determine if this is the case.
3.3.6 Interrogation of biotransducers with ferrocene monocarboxylic acid
The dose-response of the transducer modified with OO-PPy showed a decreased
average sensitivity to FcCOOH with 28 ±31 nA/mM, a reduction of 92%, Figure 3.7.
This was significantly different (p = 10-6) when compared to cleaned/bare electrodes
which had an average sensitivity to FcCOOH of 350 ±25 nA/mM. The drastic loss of
current response is likely due to anion exclusion of the negatively charged FcCOO- (as
the anionic form of FcCOOH, pKa = 4.2) [257] is electrostatically repulsed by dopant
anions within the positively charged OO-PPy film. When comparing the sensitivities of
the bare electrode response to the polypyrrole coated electrode response, this ratio is
approximately 12:1. This represents effective interference shielding (a rejection ratio of
12:1) of anionic interferents, such as ascorbic acid, that plague amperometric biosensors.
These results can be confirmed through amperometric response of OO-PPy transducers to
FcCOOH as a function of buffer pH that result in shifts of anionic to neutral forms of
FcCOOH.
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Figure 3.7. The dose response of cleaned/bare and OO-PPy MDEA 5037 electrochemical cells (for both
populations n=4) interrogated in two electrode mode using a 700 mV bias potential of working versus
counter electrodes; Error bars portray 95% confidence intervals.

3.3.7 UV-Vis characterization of PPy-ECH composites as a function of charge
density
To confirm and monitor electropolymerization of PPy within the bioactive
electroconductive hydrogel films, spectrum analysis was performed from 300 to 900 nm
wavelength for all samples, Figure 3.8. Increasing electropolymerization charge density
led to an increase in absorbance over the wavelengths range. Very low charge densities
(<20 mC/cm2) had very similar absorbance spectra. Limited discrimination at these low
charge densities within the PPy-ECH arises because of the presence of the polypyrrole
seeding layer needed for the covalent attachment of the PPy-ECH film to the transducer.
Polypyrrole absorbs broadly with peaks at wavelengths of ca. 435 nm (Eg = 2.81 eV) and
900 nm [258] respectively, and this was also observed for the PPy-ECH|PITOEs for all
charge densities. Peak absorbance was taken at these values for each charge density,
Figure 3.8 insert. Absorbance increased linearly with increasing charge density within

106

the PPy-ECH having a linear correlation coefficient of 0.98 for both the 430 and 900 nm
wavelengths. This confirms that the PPy-ECH composite may be fabricated with fine
control and predictability of its composition and that its optical absorbance can be tuned
via electropolymerization. Furthermore, the linearity of the dependence implies a uniform
distribution of the PPy within the hydrogel matrix.
3.5
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3.0
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2.5

75
50

2.0

ABS

30
20

1.5

10

1.0
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1

0.5

0
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0.0

300
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600

700

800
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Wavelength (nm)
Figure 3.8. Absorbance spectra of PPy-ECH modified PITOEs at varying charge densities of
electropolymerized polypyrrole measured in PBS buffer (pH = 7.2). Insert. Absorbance values at 430 nm
and 900 nm as a function of applied charge density in the electropolymerization of pyrrole to form the PPyECH.

3.3.8 Hydration properties of Py-hydrogel and PPy-ECH composites
Parameters of percent hydration, void fraction and density for freshly cast, UV
cross-linked hydrogel, with and without electropolymerized polypyrrole, were
determined, Figure 3.9. The density of the hydrogel was found to be 1.11 (±0.09) g cm-3,
slightly higher than that of water. The degree of hydration for the as-cast hydrogel
averaged 68.6 (±0.8)% (n=3) and had a void fraction of 76.4 (±6.8)%. For the freshly
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cast, UV cross-linked hydrogel, the total crosslink density was 1.5 mol%, established by
the presence of TEGDA. The degree of hydration of the free-standing hydrogel disc
measured by the standard gravimetric technique was compared to that for the electrodesupported hydrogel measured using the thickness profilometer (66.4%) and was found to
be in good agreement. The observed degree of hydration as a function of crosslink
density was similar to values that were previously reported [216]. The void fraction was
very high when compared with non-pyrrole containing pHEMA hydrogels previously
characterized that had void fractions ranging from 25-75% [12, 216]. Hydrogels based on
alginates have been shown to have void fractions ranging from 45-78% [259, 260].
Overall, these hydration and void fraction characteristics are consistent with the
incorporation of and hosting of biomolecules such as drugs, peptides, proteins and
enzymes [216, 261]. Biomolecule immobilization can be performed by direct
incorporation into the monomer cocktail [262], specifically through the covalent
attachment to the backbone of the hydrogel via conjugation to free pendant primary
amine or carboxylic acid groups [263], and by electrostatic entrapment during
electropolymerization of polypyrrole [1, 4, 262].

108

120%

Degree of Hydration (Average)

100%
DI
80%

PBS

60%
40%
20%
0%

-20%
0

50

100

150

200

250

Electropolymerization Charge Density (mC / cm2)
Figure 3.9. A) Thickness of PPy-ECH composite measured by stylus profilometry using a Dektak (n=3),
and B) Degree of hydration (%) calculated from dimensional change in PBS 7.2 at RT (n=3) as a function
of electropolymerization charge density (mC/cm2); error bars show ±STDev.

For the electropolymerized PPy-ECH composites, the total crosslink density was
3.0 mol%, being 1.5 mol% by TEGDA and 1.5 mol% by MPB. The degree of hydration
was measured using the thickness profilometer (n=5) both in PBS and DI water, Figure
3.9. In both cases, the initial degree of hydration of 68.6 (±0.8)% fell rapidly as PPy was
added to the hydrogel. The addition of 1 mC/cm2 of PPy resulted in a fall of the DoH
from 66.4% to 24%. Further addition of PPy produced hydrogel composites with
progressively decreasing degrees of hydration and which by 100 mC/cm2 was essentially
0 %. Since the degree of hydration is reflective of the free water content that occupies
voids within the hydrogel [213], the loss of hydration suggests that the PPy is causing the
expulsion of free water and may be growing within the voids of the hydrogel.
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3.3.9 Modulus of PPy-ECH composites as a function of charge density
Nano-indentation measurements to reveal elastic modulus were taken from 500
randomly chosen points on each PPy-ECH modified transducer, Figure 3.10. Modulus
values were determined for each charge density of electropolymerized polypyrrole and
are summarized in Table 3.2. Freshly cast Py-hydrogel (0 mC/cm2) had a minimum of
1.5 mol% crosslink density via TEGDA with up to a maximum additional 1.5 mol%
crosslink

density

via

MPB

following

electropolymerization.

Following

electropolymerization of polypyrrole within the hydrogels the resulting PPy-ECH total
crosslink density ranged from 2.5 - 4.5 wt% crosslinker. Hydrogels containing the
electropolymerizable monomer had an elastic modulus of 56 (±32) kPa, which is in
accord with that of a low crosslink density pHEMA hydrogel [213]. Modulus values for
pHEMA at a pH of approximately 7.0 have been determined to range from 30-4000 kPa
for crosslinker concentration ranging from 0.2 - 5.0 wt% [264]. Stiffness of the PPyECHs was shown to be tunable by controlling the charge density of electropolymerized
polypyrrole. Monotonically increasing average elastic modulus was observed as
electropolymerization charge density of polypyrrole was increased. Such increase in
elastic modulus was similar in trend to that observed for increasing cross-link density
[213]. Modulus values plateaued at 100 mC cm-2 and averaged 499 (±293) kPa.
Depending on the dopant used and charge density applied, the morphology and elastic
modulus of bulk polypyrrole can vary greatly. Reported values of Young’s modulus for
electrochemically formed, high charge density (>1 C cm-2, ≈10 µm thickness)
polypyrrole range from 10-1000 MPa [265, 266]. The low charge densities used in this
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study generated PPy thickness equivalents on the nanometer scale (<250 mC cm-2, <100
nm thickness). Therefore, we would not expect to observe an elastic modulus that was
different than that of p(HEMA). We undertook some sensitivity analysis around the
Poisson’s ratio, which for p(HEMA) is 0.29 and for PPy is 0.38 [266]. We find that for a
Poisson’s ratio as large as 0.5 there is no significant difference in the measured modulus
of the ECH.

Figure 3.10. The elastic modulus of PPy-ECH modified PME-Pt at varying charge densities of
electropolymerized polypyrrole measured in PBS buffer (pH = 7.2) as determined by nano-indentation (n =
500 for each sample). Insert: Optical micrographs of the PPy-ECH on planar platinum electrodes.
Table 3.2. The elastic modulus of PPy-ECH composites as a function of varying electropolymerization
charge density of polypyrrole used in the synthesis of the composite.

Charge density of
polypyrrole
(mC cm-2)

Average elastic
modulus
(kPa)

Standard
Deviation
(kPa)

0

49

27

1

146

79

10

172

99

20

266

136

100

422

207

250

448

293
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3.3.10 Electrical impedance spectroscopy of PPy-ECH composites as a function
of charge density
The electrical impedance of the PPy-ECH composites was measured as a function
of electropolymerization charge density over the range 0 - 900 mC/cm2. Equivalent
circuit modeling converged on a Randles-like network model that comprised a solution
resistance, Rs, that represented the resistance of the PPy-ECH membrane (henceforth,
RM) in series with a constant phase element, CPE, that represented the capacitance of the
co-planar arrangement of interdigitated electrodes, which was itself in parallel with a
charge transfer, Rct, that represented electron transfer events. Two different constructs
were studied. The first was based on the presence of the seeding layer of PPy/PSSA that
was directly formed on the platinum digits (bare Pt) of the IME device [Pt|PPy]. The
seeding layer was typically fabricated by the application of 10 mC/cm2 of
electropolymerization charge density.
The resulting PPy/PSSA film served to provide a highly adherent layer on the
metal from which surface initiated atom transfer polymerization to covalently attach the
hydrogel layer proceeded. This layer was explored at different thicknesses. Figure
3.11(A) shows the trend in interfacial impedance magnitude and phase as increasing
amounts of Py was electropolymerized. It is apparent that 10 mC/cm2 was sufficient to
dramatically change the interfacial impedance of the Pt microelectrodes of the IME
device. Additional electropolymerization charge did not appreciably change the
interfacial impedance until the application of 600 mC/cm2. Finally, by 900 mC/cm2 the
film is established as a fully contiguous layer between the electrodes that produces a
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purely Ohmic behavior and a frequency independence of the impedance magnitude. Thus
10 mC/cm2 was established as a suitable electropolymerization charge density to achieve
a reduced interfacial impedance and subsequent hydrogel attachment.
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Figure 3.11. Magnitude, |Z| (), and phase angle,  (degrees), of the electrical impedance as a function of
electropolymerization charge density (0 - 900 mC/cm2) for two different conductive polymer constructs on
the electrodes of the IME 1025.3 M Pt. (A) The seeding layer of PPy on the platinum IME electrode
[Pt|PPy] and (B) The growth of electropolymerized polypyrrole within a covalently attached hydrogel layer
[Pt|PPy|PPy-ECH(EP)].

The second construct examined was electropolymerized PPy grown within the
hydrogel layer covalently attached to the 10 mC/cm2 seeding layer [Pt|PPy|PPy-ECH].
Figure 3.11(B) shows the trend in interfacial impedance as increasing amounts of Py was
electropolymerized within the hydrogel beginning from 0 mC/cm2 (i.e. Pt|Py-Gel) to 900
mC/cm2 (i.e. Pt|PPy-ECH). The presence of the hydrogel layer dramatically changed the
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electrical

dispersion

characteristics

and

the

impedance

model.

Further

electropolymerization reduced the DC impedance confirming the addition of an
electronically conductive component. The results of the equivalent circuit modeling
produced the parameters summarized in Table 3.3 and Table 3.4.
Table 3.3. Equivalent circuit parameters for cleaned platinum IMEs as a function of electropolymerized
polypyrrole charge density (Parentheses show ± 95% confidence interval of n = 3).
Charge density
(mC cm-2)

Rs (Ω)

error
(%)

Rct (kΩ)

error
(%)

CPE-T
(µF)

error
(%)

CPE-P

error
(%)

0 (Bare Pt)

69.3 (0.3)

2.09

4.8E+10
1.9E+07
(1E12)

0.13
(0.01)

1.85

0.94
(0.007)

0.27

10

102.9

2.30

9.9E+10

3.1E+08

4.94

2.59

0.81

0.60

50

85.0

1.00

1.5E+10

1.5E+08

16.89

1.45

0.80

0.38

100

80.5

0.65

9.7E+09

1.0E+08

23.16

0.94

0.78

0.26

150

78.8

0.69

4.9E+02

19.64

23.29

1.15

0.77

0.32

300

82.1

0.69

1.3E+01

2.20

45.66

1.69

0.80

0.46

600

77.2

0.58

4.6E-01

1.08

104.93

4.24

0.72

1.00

900

74.4

0.48

7.9E-02

1.24

178.77

9.57

0.67

2.06

Table 3.4. Equivalent circuit parameters for Py-Gel and PPy-ECH modified platinum IMEs as a function of
electropolymerized polypyrrole charge density (Parentheses show ± 95% confidence interval of n = 2).
Charge density
(mC cm-2)

Rs (Ω)

error
(%)

Rct (kΩ)

0 (Py-Gel)

79.4 (7.7)

1.45

1.4E+10
(3E+10)

10

77.0 (4.9)

0.82

50

73.2 (5.5)

1.07

100

72.5 (4.8)

0.53

150

72.0 (6.3)

0.51

300

71.5 (6.9)

0.49

600

69.6 (6.8)

0.51

900

68.5 (6.2)

0.57

error
(%)

CPE-T
(µF)

6.5E+07 3.15 (0.10)

6.0E+10
1.1E+08 7.26 (0.83)
(6E+09)
7.0E+09
18.62
5.2E+07
(1E+10)
(0.58)
2.3E+01
24.28
1.49
(9E+00)
(1.21)
4.6E+00
22.71
0.86
(7E-01)
(7.00)
4.6E-01 (3E52.74
0.81
01)
(6.86)
6.2E-02 (2E111.51
1.43
02)
(2.29)
1.8E-02 (9E153.13
3.58
04)
(22.83)
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error
(%)

CPE-P

error
(%)

1.65

0.79
(0.019)

0.34

1.07
1.78
1.22
1.79
3.92
12.79
39.37

0.83
(0.006)
0.83
(0.013)
0.82
(0.003)
0.82
(0.001)
0.81
(0.009)
0.77
(0.027)
0.77
(0.021)

0.24
0.45
0.30
0.38
0.79
2.40
6.65

Bare platinum transducers had a capacitance of 0.13 (±0.01) µF. Applying even a
low charge density of PPy (10 mC/cm2) directly onto the platinum electrodes increased
the capacitance parameter, CPE-T, by over an order of magnitude, Figure 3.12(A).
Modification with PPy-ECH resulted in significantly higher capacitance for all charge
densities when compared to bare platinum (p < 0.003). Capacitance is known to increase
in proportion to polypyrrole film thickness [267]. The difference in capacitance between
[Pt|PPy] and [Pt|PPy|PPy-ECH] became negligible at charge densities ≥100 mC/cm2. The
porous structure of polypyrrole provides a high surface area and behaves as an
electrochemical double layer capacitor with counter ions screening charge [268, 269].
The constant phase element deviated from an ideal capacitor was determined by the
decreasing CPE-P parameter after application of a polypyrrole seeding layer and
modification with PPy-ECH at all charge densities. The CPE-P value being less than 1
(ideal capacitor) for the bare platinum IME is likely due to the co-planar geometry of the
transducer electrodes vs. the traditional parallel plate arrangement.
Seeded Pt
PPy-ECH

Membrane Resistance, RM. (Ω)

Capacitance, CPE-T, (µF)
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Figure 3.12. A) Capacitance (CPE-T) and B) Membrane resistance (RM) as a function of
electropolymerized polypyrrole charge density applied to the bare platinum and PPy-ECH modified
interdigitated microsensor electrodes (IME 1025.3 M Pt).
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1000

The membrane resistance parameter, RM, of the electrochemical interface is a
likely mix of ionic and polaronic conductivity and thus a function of electrolyte
concentration, temperature, intrinsic resistance of the active material, the dimensions of
the electrodes and cell, and the contact resistance between materials [270]. The true RS
defined as the bulk solution resistance, was determined from use of the bare Pt IME and
found to be 69.3 (±0.3) . Since temperature (25 oC) and electrolyte concentration were
kept constant, any variation in RM () may be attributed to changes in electrode
dimensions and/or changes in the conductivity of the membrane materials. As seen in
Figure 3.12(B), the presence of the Py-Gel membrane increases the resistance relative to
that of the solution resistance (RM(Py-Gel) = 80  and RS = 69.3 (±0.3) ). This was
expected as the ionic conductivity of the solution is higher than that of the hydrogel.
However, following initiation of electropolymerization, the resistance of the Pt|PPy
construct becomes immediately higher than that of the Pt|PPy|PPy-ECH(EP) construct.
For low charge densities (<100 mC/cm2) we observed higher membrane resistances for
Pt|PPy that extend beyond the 95% confidence intervals of Pt|PPy|PPy-ECH(EP). These
results indicate higher conductivity for PPy-ECH compared to PPy. The apparent
membrane resistance for both constructs approached the original bulk solution resistance
as the electropolymerization charge density was increased. This evidence suggests the
presence of high conductivity pathways being formed within the ECH.
The impedance magnitude in the low charge density domain was shown to be
primarily a function of the double layer capacitance and solution resistance. No charge
transfer was observed on bare, low charge density seeded, Py-Gel and/or PPy-ECH
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transducers indicating an absence of redox events to support charge injection into and out
of the membrane. The % error for charge transfer resistance indicated a good fit at charge
densities ≥300 mC/cm2 and ≥100 mC/cm2 for the Pt|PPy and Pt|PPy|PPy-ECH(EP),
respectively. The change in Rct indicates a change in impedance response from being
purely capacitive double layer charging to direct charge transfer across the Pt|PPy or
PPy|Electrolyte interface. Visual inspection of the IME surfaces confirms the efficiency
in bridging the fingers of the platinum IME device with polypyrrole for PPy-ECH
modified transducers compared to PPy seeded platinum transducers, Figure 3.13, as was
previously reported [224]. These results indicate that the transition from ionic to
polaronic conduction occurs earlier in the PPy-ECH construct and that hydrogel
facilitates long-range electrical conductivity and interconnectivity of the formed
interpenetrating network of polypyrrole.
0 mC/cm2

150 mC/cm2

300 mC/cm2

600 mC/cm2

900 mC/cm2

A

B

Figure 3.13. Optical micrograph showing the bridging of polypyrrole, or lack thereof, between the
electrode digits as a result of increasing electropolymerized polypyrrole charge density for IMEs with (A)
polypyrrole seeding and (B) PPy-ECH modification.
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The rapid decrease in charge transfer resistance of PPy-ECHs may be due to the
dimensionality of the polypyrrole structure formed within the void spaces of the hydrogel
during electropolymerization. The decreased hydration and void volume of the PPy-ECH
as charge density increases supports this observation. Conduction via Mott’s variable
range hopping (VRH) has been well established as the dominant mechanism of polaronic
charge transport for polypyrrole, and the conduction mechanism in pristine polypyrrole is
three dimensional VRH where electrons hop in a probabilistic manner between localized
polaron states in all directions [175, 176, 271-273]. Forming composite materials with
polypyrrole have been shown to lead to one dimensional VRH with faster intra-chain
charge hopping [273]. Highly ordered CEP chains with few inter-chain links will have
less instances of inter-chain charge hopping and more intra-chain charge hopping leading
to greater conductivity. Future studies focused on the temperature dependence of
conductivity for the electroconductive hydrogels may be performed to evaluate the
mechanism of conduction and dimensionality of electron hopping [272].
3.3.11 Anchorage-dependent cell growth on Py-hydrogels and PPy-ECH
hydrogel composites
In previous work we have reported the considerable growth and proliferation of
anchorage-dependent

human

muscle

fibroblasts

(RMS

13)

and

murine

pheochromocytoma cells (PC12) on electroconductive blends of poly(HEMA-coPEGMA-co-HMMA-co-SPMA) and poly(Py-co-PyBA) [102]. In that work, PC12 and
RMS13 cells were seeded onto Au*|Gel, Au*|PPy, and Au*|PPy-ECH surfaces with
electropolymerization times on the order of 5, 25 and 50 s corresponding to 11, 87 and
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250 mC/cm2 (an asterisk identifies a functionalized gold surface). The PC12 cell line
showed strong positive correlation between proliferation and the extent of
electropolymerization. A concern has been whether or not the observed growth and
proliferation arose from the evolving modulus of the PPy-ECH membrane or of the
evolving electrical properties.

A

B

Figure 3.14. A) The percent change in cell proliferation of RMS 13 and PC12 cells following four-day
incubation on Au*|hydrogel, Au*|PPy, and Au*|PPy-ECH plotted alongside the elastic modulus of the three
surfaces. B) The percent change in cell proliferation of PC12 cells following four-day incubation on
Au*|hydrogel, Au*|PPy, and Au*|PPy-ECH of different electropolymerization charge densities [5s
(11mC/cm2), 25s (87mC/cm2) and 50s (250 mC/cm2) plotted alongside the elastic modulus of the various
surfaces. Cell seeding density was 4.9+/-0.7 x105 cells/ml.

Figure 3.14(A) shows the percentage change in both RMS13 and PC12 cell
numbers after four days of culture on the various surfaces plotted alongside the elastic
modulus. Both RMS13 and PC12 cell lines revealed a decrease in cell numbers on the
Au*|Gel and Au*|PPy surfaces, while both cell types showed increases on the Au*|PPyECH (50 s or 250mC/cm2). For RMS13, there was a 50 to 70% decrease in cell density
after 4 days on the Au*|Gel and Au*|PPy surfaces respectively, while there was a nearly
80% increase in cell density on the Au*|PPy-ECH (50 s or 250mC/cm2). For the PC12,
there was a 70 to 90% decrease in cell density after 4 days on the Au*|Gel and Au*|PPy
surfaces, while there was a 12% increase in cell density on the Au*|PPy-ECH (50 s or

119

250mC/cm2). PC12 cell proliferation on Au*|PPy-ECH was nearly 70% less than
RMS13. The reason for this difference is unclear, but it may be related to differences in
how these two cell lines attach to the substrate surface and/or differences in their rates of
cell division. A two-tailed student’s t-test indicated a statistically significant change in
both RMS13 and PC12 cell populations from Day 0 to Day 4 (p<0.05) for all samples
with the specific exception of PC12 on Au*|PPy-ECH (50s) (corresponding to 250
mC/cm2), which had a p-value of 0.26. This indicates that there was little to no
proliferation of PC12 during the 4 day incubation period on this particular surface. From
Figure 3.14(A), one also sees that the elastic modulus of the Gel-PPy film is nearly an
order of magnitude greater than either the native hydrogel (Gel) or polypyrrole (PPy).
The positive correlation between cell proliferation and elastic modulus of the film
exemplified herein suggests that stiffness of the substrate plays an important role in cell
attachment and subsequent cell division. A critical threshold in the elastic modulus is
likely necessary to be surpassed in order for positive cell proliferation to occur, and may
also be dependent on cell type. This critical threshold is yet to be determined; however a
suggested threshold value is reported later in this text.
As in Figure 3.14(A), Figure 3.14(B) also shows the percentage change in PC12
cell numbers measured following trypsinization after four days of culture on the various
surfaces plotted alongside the elastic modulus. In this instance, however, proliferation
was investigated as a function of Gel-PPy electropolymerization times - 5, 25 and 50 s,
corresponding to 11, 87 and 250 mC/cm2 to further validate the hypothesis that
proliferation is directly correlated to substrate stiffness. For the native hydrogel (Gel) and
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PPy films, there was a 70-80% decrease in the number of PC12 cells four days following
the initial cell culture, which is consistent with observations made in the previous
experiment, Figure 3.14(A). On the Gel-PPy films (ECH films), however, an increase in
cell density of about 5% was observed for Au*|PPy-ECH (50s) and 40-60% for Au*|PPyECH (5 and 25s). A two-tailed student’s t test indicated a statistically significant change
in the PC12 cell population from Day 0 to Day 4 (p<0.05) for all samples with the
exception of Au*|PPy-ECH (50s) (corresponding to 250 mC/cm2) which had a p value of
0.737. This is also consistent with the results observed for PC12 in the previous
experiment, Figure 3.14(A). The increasing elastic modulus of the electroconductive
hydrogel with electropolymerization charge density is a direct indication of the increase
in % PPy content of the ECH (also seen in the UV absorbance spectrum, Figure 3.8).
However, the cell proliferation studies appear to indicate that there are fundamental
differences in the material properties experienced (seen) by the cells as they attempt to
attach to the surfaces of the hydrogel, PPy and PPy-ECH respectively and that these
differences are not captured solely by the elastic modulus. Although the ECH has been
described as a hybrid material combining the poly(HEMA)-based hydrogels with the
conducting polymer polypyrrole, it appears that the surface of the ECH may have a
different molecular make-up from either the native poly(HEMA)-based hydrogel or the
polypyrrole. In the case of both the Au*|PPy-ECH (5s) and Au*|PPy-ECH (25s), there
was a statistically significant net increase in cells, while there was a net decrease for
Au*|Gel and Au*|PPy. If the PPy-ECH samples were truly homogeneous, isotropic
hybrids of both the hydrogel and PPy, one would expect that in all these cases, there
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would be a net decrease in cell density, since these component materials have been
shown to resist protein adsorption and consequently inhibit cell attachment and
proliferation. However, there is a clear increase in the Au*|PPy-ECH (5s) and Au*|PPyECH (25s) samples which might be associated with the increased elastic modulus
(stiffness) of the composite conducting hydrogel films. As the % PPy content of the ECH
increases beyond a certain threshold, the stiffness may play less of a role and its attributes
for cell anchorage diminished compared to the material properties afforded by the PPy.
This elastic modulus threshold necessary for PC12 cell proliferation should at least fall
between 150 and 300 kPa, according to Figure 3.14(B). The fact that there was no
appreciable cell proliferation on the final sample, Au*|PPy-ECH (50s) likely indicates
that the surface properties of the material, at this point, are more similar to PPy than to
the ECH composite material and that the PPy dominated molecular make up of this
material likely overcomes the ability of the elastic modulus to influence cells to
proliferate. It is unlikely that surface topography (roughness) is at play, since
profilometry results (not shown) reveal little variability across ECH films of different
electropolymerization charge densities.
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Figure 3.15. Schematic illustration of the possible role of the elastic modulus of the PPy-ECH on the
growth and proliferation of attachment dependent cells.

Figure 3.15 provides a schematic illustration of how we conceptualize the
competing influences of the cellular response to the elastic modulus or stiffness of the
substrate with the competing response of the PPy-ECH growth. During the early stages of
electropolymerization (1-50 mC/cm2) the PPy is electropolymerized within void spaces,
normally occupied by water, within the hydrogel. Hence, the hydration properties of the
hydrogel are rapidly compromised as bulk water is expelled. During the middle stages of
electropolymerization (50-100 mC/cm2) the PPy interpenetrates the hydrogel network.
During the late stages of electropolymerization (100-250 mC/cm2) the PPy begins to
grow on the surface of the hydrogel layer and reestablishes its cell-surface interaction but
displaces a modulus reminiscent of the composite beneath.
3.3.12 Effects of a polypyrrole seeding layer on analytical performance of
biotransducers
To create effective, stable and reproducible biotransducers, it is necessary to
establish an intimate and stable interface between the biorecognition membrane layer and
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the underlying physicochemical transducer, in this case, the electrode. To achieve this we
developed an approach based on the fabrication of a nano-dimensioned seeding layer of
pristine polypyrrole-polystyrene sulfonate (PPy(PSSA)) on to which a biosmart hydrogel
can be covalently coupled. The effects of seeding transducers with PPy(PSSA) prior to
subsequent electropolymerization and entrapment of enzymes was explored. A low
charge density of 10 mC/cm2 was used as a seeding layer prior to applying 100 mC/cm2
of PPy/GOx. The enzyme kinetic parameters of biotransducers were determined using
Lineweaver-Burke analysis. Unseeded biotransducers had a sensitivity of 0.77 (±0.35)
µA cm-2 mM-1, an Imax of 16.8 (±6.5) µA cm-2, a linear dynamic range maximum of 15.8
(±2.8) mM, a KMapp of 11.1(±4.3) mM, and a limit of detection of 0.07 (±0.05) mM.
Seeded biotransducers had a sensitivity of 1.44 (±0.78) µA cm-2 mM-1, an Imax of 35.3
(±18.3) µA cm-2, a linear dynamic range maximum of 19.4 (±1.0) mM, a KMapp of 11.8
(±0.3) mM, and a limit of detection of 0.04 (±0.03) mM.
60
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Figure 3.16. The effects of the PPy(PSSA) seeding layer (10 mC/cm2) on the enzyme kinetic parameters of
biotransducers fabricated at 100 mC/cm2 (error bars show 95% confidence intervals, n ≥ 5). * = P < 0.05;
** = P < 0.01.
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Figure 3.16 shows the effects of the PPy(PSSA) seeding layer (10 mC/cm2) on
the enzyme kinetic parameters of biotransducers fabricated at 100 mC/cm2. Both the
sensitivity and the apparent Michaelis-Menten enzyme kinetic parameters were
statistically equivalent suggesting no deleterious influence of the adhesion promoting
seeding layer on biotechnical performance. The linear range of an amperometric
biosensor system is typically a function of analyte diffusivity through the bioactive
membrane [274]. The linear dynamic range of seeded biotransducers was not
significantly broader than for the unseeded. The nano-thin PPy(PSSA) layer was not
enough to serve as a barrier to diffusion for hydrogen-peroxide in order to increase the
linear range or adversely affect other enzyme kinetic parameters. The KMapp values
determined show that no changes to enzyme affinity occurred as a result of the seeding
layer. Seeded biotransducers showed less variability in KMapp indicating good
reproducibility of enzyme affinity compared to unseeded transducers. For amperometric,
enzyme-based biosensors, the maximum current is related to total enzyme activity [1].
The nearly 2-fold increase in maximum current was statistically significant (p = 0.045).
These results are a good indication that the seeding layer serves to better preserve enzyme
active site structure and function but does not lead to an increase in the number of
enzymes entrapped as sensitivity does not significantly increase. It is likely that the
seeding layer acts as a soft milieu onto which enzymes may then be adsorbed and
entrapped within a PPy|PPy interface after subsequent electropolymerization. Polypyrrole
is known to have a stabilizing influence on enzymes [223]. Enzymes being immobilized
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onto an unseeded electrode will be entrapped within a mechanically disparate interface of
PPy|Pt that may not preserve the structure of immobilized enzymes as effectively.
The principal role of the seeding layer was to be an interface for hydrogel casting.
However, the seeding layer was shown to significantly decrease the average
biofabrication time from 68 (±22) min for the unseeded biotransducer to 35 (±6) min for
the seeded biotransducer (p = 0.007); a reduction of 50%. Electropolymerization
efficiency is an important biofabrication parameter. Enzymes require a hydrated,
protective environment in order to function in vivo [4]. Hydrogels provide the necessary
protective hosting for biomolecules [275] and the in vivo biocompatibility for the
protection of the biotransducers [4]. However, hydrogel modified transducers require
considerable overpotential for electropolymerization; as much as 1,000 mV vs. Ag/AgCl
and the polymerization times are comparable to that of unmodified electrodes [12].
3.3.13 Enzyme monomerization and sulfonization
Lysine groups of glucose oxidase were covalently coupled to either pyrrole
butyric acid (PyBA) or sulfobenzoic acid (SBA) using EDC-NHS coupling chemistry,
Figure 3.17. The amperometric dose response of biotransducers to glucose was measured
for i) covalently conjugated systems: PPy(SBA-con-GOx), P(Py-co-PyBA-con-Gox), ii)
non-covalently conjugated systems: PPy(SBA)-GOx, P(Py-co-PyBA)-GOx, and iii)
control systems: PPy-GOx. The covalently conjugated systems with a 10:1 molecular
ratio of PyBA:GOx or SBA:GOx are depicted in Figure 3.18. The approach to covalent
coupling considered in this work is intended to be a simple and effective means of
enzyme conjugation that can be performed in a single solution and immediately utilized
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for electropolymerization without need for separations. Monomerized enzymes were
prepared with the intent of having them be directly incorporated into the backbone of the
forming electropolymerized polypyrrole. Sulfonized enzymes were prepared in order to
have them act as more effective dopants and be electrostatically entrapped within the
positively charged polypyrrole backbone. Biosensor performance parameters for all
systems are summarized in Table 3.5.
Step 1:
10:1 molecular
ratio of
PyBA:Enzyme

pH = 4-5

Pyrrole Butyric Acid
(PyBA)

Add EDC = moles PyBA

1 hr

Step 2:
Unstable o-Acylisourea
intermediate

Add NHS = # moles EDC

5 min

Step 3:

Monomerized Enzyme

Amine-reactive
NHS Ester
Combine with enzyme
primary amines

24 hr

Figure 3.17. Scheme of enzyme modification using EDC-NHS coupling chemistry to monomerize glucose
oxidase with PyBA; Sulfonization of enzymes with SBA was performed in a similar fashion.
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PyBA : GOx = 10 : 1

SBA : GOx = 10 : 1

Figure 3.18. Subunit of glucose oxidase from Aspergillus niger with Lysine groups in red (top),
monomerized enzymes used for preparing P(Py-co-PyBA-con-Gox) (bottom left) and sulfonized (bottom
right) enzymes used for preparing PPy(SBA-con-GOx) with 10:1 ratio of PyBA or SBA conjugation to
enzymes.

3.3.14.1 Effects of enzyme modification on kinetics of electropolymerization
The kinetics of electropolymerization (time to reach 100 mC/cm2 of charge) were
compared for all systems. The control systems of PPy-GOx had an electropolymerization
time of 68 22 min. Enzyme systems P(Py-co-PyBA)-GOx and P(Py-co-PyBA-con-Gox)
both had significantly greater (p<0.03) electropolymerization times compared to PPyGOx. Enzyme systems PPy(SBA)-GOx, PPy(SBA-con-GOx) had significantly lower
electropolymerization times compared to all other systems (p<0.02). Sulfobenzoic acid is
a highly mobile dopant capable of screening charge and making electropolymerization
kinetics more facile for polypyrrole [276]. No significant difference in kinetics was noted
between covalent and non-covalent conjugation for either PyBA or SBA systems. A
decrease in variability in electropolymerization time was observed for the covalently
conjugated systems when compared to the non-covalently conjugated systems. There is
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likely competition in doping of the formed polypyrrole between adsorbed glucose
oxidase and PyBA/SBA in the non-covalent systems, whereas for covalently conjugated
systems the dopant becomes solely the adsorbed monomerized or sulfonized enzyme.
Table 3.5. Dose response (PBS, pH = 7.2, 25 oC) performance parameters for biotransducers fabricated
with covalently modified enzymes, non-covalently modified enzymes and control systems having no
modification (± standard deviation is shown).
PPy-GOx
(n = 4)

PPy(SBA)GOx
(n = 4)

PPy(SBAcon-GOx)
(n = 2)

P(Py-coPyBA)-GOx
(n = 2)

P(Py-coPyBA-conGox) (n = 2)

68 22

23 19

15 5

204 37

230 132

0.87 0.04

1.8 1.2

1.9 0.2

4.8 0.9

0.99 0.28

41 21

17 9

18 5

17 5

14 5

0.50 0.30

0.01 0.01

2.2E-3 1.8E3

0.05 0.03

0.02 0.01

KMapp (mM)

14.1 3.1

8.2 2.6

11.1 5.6

7.2 2.6

19.7  3.9

Imax (µA/cm2)

23.3 3.1

30.6 18.8

39.2 11.7

77 25

28.9 4.0

Linear range
(mM)

17.4 7.0

9.4 2.6

10.2 3.2

9.5 2.8

25.6 5.6

[E] = 1.0
mg/mL
Polymerizaton
time to 100
mC/cm2
(min)
Sensitivity
(µA/mM/cm2)
Response time
(s)
Detection limit
(mM)

3.3.14.2 Biotransducer performance with sulfonized enzymes
The covalently sulfonized system, PPy(SBA-con-GOx), had a sensitivity of 1.92
0.2 µA/mM/cm2, a response time of 18 5 s, a detection limit of 2.2E-3 1.8E-3 mM, a
KMapp of 11.1 5.6, a maximum current of 39.2 11.7 µA/cm2 and a linear range of 10.2
3.2 mM. The PPy(SBA-con-GOx) system was significantly more sensitive (p<0.0002)
than the PPy-GOx system. It also had the best limits of detection of all the systems with
significantly better (p=0.002) resolution compared to P(Py-co-PyBA-con-Gox).
Response times were found to be similar for all systems. The non-covalently coupled
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SBA system, PPy(SBA)-GOx, had a sensitivity of 1.8 1.2 µA/mM/cm2 which was not
found to be different from PPy-GOx controls. Electropolymerized polypyrrole glucose
biotransducers prepared with GOx conjugated to poly(2-acrylamido-2-methylpropane
sulfonic acid) polyanion dopants have been shown to have sensitivity ranging from 180270 nA/mM/cm2 with a linear range of 20-26 mM and a Michaelis-Menten constant of
46.7 mM [277, 278]. Overall the covalent sulfonization process successfully yielded
biotransducers with higher sensitivity but at the cost of decreased linear dynamic range
when compared to the GOx-polyanion system found in literature.
3.3.14.3 Biotransducer performance with monomerized enzymes
The non-covalently P(Py-co-PyBA)-GOx system had a sensitivity of 4.8 0.9
µA/mM/cm2, a response time of 17 5 s, a detection limit of 0.05 0.03 mM, a KMapp of
7.2 2.6, a maximum current of 77 25 µA/cm2 and a linear range of 9.5 2.8 mM. Its
sensitivity was significantly greater than every biotransducer (p<0.045) other than
PPy(SBA-con-GOx). P(Py-co-PyBA)-GOx

had the highest maximum current of all

systems but was only significantly greater (p<0.01) than PPy-GOx systems. Covalently
monomerized GOx did not perform statistically different from PPy-GOx systems.
Glucose oxidase that is lysyl modified with an N-substituted 1H-Pyrrole-1-propionic acid
have been shown to have higher electrode activity compared to native GOx in
polypyrrole membranes [279]. Chemical modification of GOx lysine groups with 3carboxymethyl pyrrole has also been shown to exhibit higher enzyme activity and storage
stability than systems using N-substituted pyrrole [280]. Our results show that
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incorporation of PyBA without covalent coupling is sufficient for increasing biosensor
performance with respect to higher sensitivity and overall enzyme activity.
3.4 Conclusions
It is highly feasible to fabricate amperometric enzyme biotransducers using the
procedure of Py electropolymerization to ensnare GOx and immobilize it within hydrogel
membrane layers that were covalently anchored onto surface modified platinum
electrodes. The electropolymerization charge density dependence of ECH-modified
biotransducer sensitivity and enzyme activity revealed a maximum sensitivity of 281
nA/mM/cm2 and an apparent KM of 33 mM at an applied charge density of 1.0 mC/cm2.
Screening of ascorbic acid was consistent with previously reported results. Following
electropolymerization at low charge density the partitioned and adsorbed enzymes within
the hydrogel may become trapped, have more enzyme active sites available for reaction,
less diffusional constraints, but will be more unstable. Electrodes of 10 mC/cm2 gels were
capable of entrapping enzymes within the hydrogel and polypyrrole, maintain their
affinity, but also lead to an increase in diffusional barriers for enzyme substrate and
products. A tradeoff between enzyme stability over time and magnitude of current
response over time appears to be necessary. It is concluded that enzyme incorporation
into hydrogels via electropolymerization of polypyrrole is an effective means of
imparting bioactivity to a transducer, but the biotransducer becomes more sensitive to the
mass transport limitations imparted by the overoxidized polypyrrole. This study
optimized biotransducer performance as a function of electropolymerized polypyrrole.
There is need to investigate and optimize the relationship between the crosslink-density
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and the electopolymerization charge density in order to achieve a strategic balance been
the compromise in sensitivity and the benefits of interference screening, biocompatibility
and long term enzyme stability. When modified with over-oxidized polypyrrole, the
transducer was shown to reject access of the negatively charged FcCOOH, analogous to
interference shielding of ascorbic acid.

A temporal improvement in biotransducer

sensitivity, regardless of charge density of fabrication, was associated with the presence
of the hydrogel membrane layer. Such increases in sensitivity indicate increases in
immobilized enzyme activity over time.
An interpenetrating co-network of a pHEMA-based hydrogel possessing a variety
of modifying monomers and conductive, electroactive PPy-co-PyPA was synthesized by
covalently linking the two networks via a hetero-bifunctional monomer, 2methacryloyloxyethyl-4(3-pyrrolyl)butanate (MPB). MPB was synthesized in situ from
the conjugation of PyBA (acid) and AEMA (amine). The elastic moduli of the
electroconductive interpenetrating co-network were larger than either the Py-Gel or PPy
only and the optical density increased linearly while the stiffness increased and plateaued
with electropolymerization charge density. The frequency dependence of the electrical
impedance of the PPy-ECH co-network showed a dramatically different dispersion
compared to the Py-Gel and to PPy. Increasing charge density did not appreciably change
this dispersion. Attachment dependent RMS13 and PC12 cells demonstrate a strong
correlation of their growth and proliferation with the elastic modulus of the
electroconductive hydrogels. No such correlation was observed with respect to either the
membrane resistance, membrane capacitance or charge transfer resistance of the film.
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However, the evolving molecular composition and structure of the surface may also play
an important role in supporting cell growth and proliferation. The interplay among the
elastic modulus and the PPy content may be at work in determining the ability of cells to
proliferate on the PPy-ECH materials.
Seeding platinum electrodes with polypyrrole had no significant effect on
sensitivity, linear range, limits of detection and response time while increasing maximum
current. These results indicate that entrapping enzymes onto polypyrrole seeded
electrodes better maintains activity compared to entrapment directly onto electrodes.
Seeded transducers also had significantly more facile polypyrrole electropolymerization
kinetics. The seeding layer may be a good option for making the polymerization kinetics
more facile with a lesser overpotential in these hydrogel systems when highly mobile
dopants (Cl-, HPO42-) are not available. Sulfonization of enzymes was shown to be a fast
and effective means of improving biotransducer performance. Sulfonization using
sulfobenzoic acid at a 10:1 SBA:GOx ratio was shown to be useful in making
electropolymerization kinetics more facile and doubling biotransducer sensitivity
compared to native enzyme systems. Monomerization of enzymes using pyrrole butyric
acid at a 10:1 PyBA:GOx ratio did not significantly influence biotransducer performance.
Non-covalently incorporated pyrrole butyric acid dramatically increased biotransducer
sensitivity and decreased linear dynamic range.
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CHAPTER FOUR: IN VIVO STUDIES IN A SMALL VERTEBRATE ANIMAL
TRAUMA MODEL

4.1 Introduction
4.1.1 Lethality of trauma and the need for advanced trauma diagnostics
Hemorrhage alone accounts for nearly 50% of deaths within the first 24 hours of
trauma care, Fig. 4.1 [281, 282]. Hemorrhage is also the #1 preventable cause of death
for warfighters [13] and accounts for 68% of all battlefield fatalities. Complications such
as systemic inflammatory response syndrome, compensatory anti-inflammatory response
syndrome, multiple organ failure, and multiple organ dysfunction syndrome will arise in
the re-perfused hemorrhage patient [283]. These complications may further result in
permanent organ damage and possibly death. Caregivers must be judicious in their
resuscitation in order to save the hemorrhaged trauma patient while simultaneously
avoiding these complications [33, 284]. This becomes especially difficult under austere
conditions (highway or battlefield) where first responders have no technology for
diagnosing and monitoring patients (for occult (undetectable) hemorrhagic shock) with
hypotension [21]. A gap exists in diagnostic technology for first responders and care
givers when compared to the capabilities of a trauma center or emergency room [124].
Hemorrhage produces a state of insufficient oxygen delivery or consumption and
decreased cellular perfusion that leads cellular metabolism into anaerobic respiration
[285]. The extent of hypoperfusion depends on the rate of blood loss, total amount of
blood loss, duration of tissue vasoconstriction, the level of perfusion pressure in the blood
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vessels, and the type of vascular bed being affected [25]. Resuscitation with whole blood,
crystalloids or colloids, releases the products of tissue ischemia into systemic circulation
where they affect other host responses and tissues [32, 283]. There is thus pressing need
to develop technology solutions to address the first 24 hours following trauma-associated

Percentage of deaths

hemorrhage in order avoid such outcomes as hemorrhagic shock.

Figure 4.1. Bar chart comparing time and mechanisms of traumatic death. Nearly all deaths due to
hemorrhage occur within the first 24 hours. Major clinical complications of hemorrhage and hemorrhagic
shock such as sepsis, organ failure and multiple organ dysfunction syndrome replace hemorrhage as a
major cause of death [281].

4.1.2 Biosensors as point of care technology for continuous patient monitoring
The use of point-of-care technology to diagnose and stratify trauma victims
beginning at the point of injury is gaining attention and acceptance [3, 117, 286]. Unlike
traditional point of care testing devices, like hand held monitors with test strips and/or
cartridges, fully integrated in-vivo biosensors are special point-of-care testing platforms
upon which biological events may be observed and measured in a continual manner. The
implantable biosensors of the current proposal use means of sensing similar to that
performed at the lab bench, but the (testing) data acquisition is faster, continual, uses a
smaller footprint instrument, is enabled with telemetry capabilities, and is done within the
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patient. A rapidly deployable biosensor system administered by a first responder can
begin immediate and continual monitoring of metabolic vital signs, logging data during
transport and handing this off to a medivac vehicle, then to the hospital trauma center in
order to enable monitoring right through to the Intensive Care Unit (ICU).
4.1.3 New patient data trends available to care givers
Rapidly and continually measuring metabolic biomarkers such as glucose and
lactate will permit the consideration of new trends in patient data analysis. Two major
novel data trends include “rate of change in analyte concentration” and “integral
exposure dose above normal concentrations of analytes”. These data trends are not
readily observed using infrequent laboratory blood (stat) analysis in a hospital
environment where turnaround times may be 30-60 minutes [117, 119, 122]. Such data
trends on glucose and lactate simultaneously have yet to be rigorously and prospectively
explored in the musculature during trauma. Though hand-held blood analyzers have the
capability of measuring glucose and lactate at ca. 2-4 minutes per test [122], there is
significant cost for each test (ca. $15) with tests requiring periodic blood sampling of
patients, which is less than ideal for patients who have suffered blood loss [287]. A well
designed implantable biosensor system will be more efficient at capturing data over long
periods of time compared to traditional blood analysis. These new data analysis trends
may be used to develop new resuscitation initiation criteria and regimens for caregivers
to utilize.
During trauma and hemorrhage, blood within the vasculature is in a well-studied
compartment of the body. Less attention has been given to other compartments due to
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their lack of access and the invasiveness required in reaching them. A minimally invasive
biosensor, however, can readily be implanted into skeletal muscle using a large gauge
needle. A biosensor, implanted by the first responder at the point of injury, will enable
immediate and continuous measurement of a trauma patient’s physiological status.
Decisions on care are made based on physical and metabolic vital signs that a patient
presents, knowledge gathered by emergency first responders, and the experience of
medical staff. Data and trends in patient status gathered wirelessly can automatically be
handed off to and integrated with a hospital’s WiFi network.
4.1.4 Use of the MDEA 5037 biosensor system for monitoring the events of
trauma
The dual responsive Electrochemical Cell-on-a-Chip Microdisc Electrode Arrays
(ECC MDEA 5037) is a recently developed transducer for use in a wireless, implantable
biosensor system for the continuous measurement of interstitial analytes. Preliminary
studies with the MDEA 5037 in a rat hemorrhagic shock model have shown discordance
between blood and interstitial lactate levels, Figure 4.2 [3]. Lactate can accumulate more
readily in the muscles especially during periods of compensation and increased peripheral
resistance during moderate to severe hemorrhage as blood oxygen delivery will be even
further reduced, thus causing a rapid spike in interstitial lactate levels. Given knowledge
of the Cori cycle, this lactate will diffuse back into the blood and eventually make its way
to the liver [130, 288]. It is hypothesized that under conditions of diminished peripheral
perfusion, lactate levels in the tissues will be discordant with systemic lactate levels, and
that the amount and duration of the tissue lactate levels will be a better indicator of the
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extent of hemorrhagic shock in the trauma patient. Continued examination of interstitial
compartments using biosensors will aid in understanding the temporal relationships
among markers of stress in these environments and how they relate to shock-like states.

ECC MDEA 5037

B

A

Figure 4.2. A) The ECC MDEA 5037 is a dual channel biotransducer that is interfaced with a wireless
potentiostat. B) In preliminary studies, intramuscularly implanted lactate sensitive MDEA 5037s have
shown the difference between interstitial and blood lactate levels.

The ultimate goal of this research is to change patient survival outcomes for
victims of trauma associated hemorrhage. Trauma is a leading cause of death among our
youth, both on our highways and on our battlefields. The aim is to deploy an in vivo
(intramuscular) biosensor system (The PSM Biochip) that will allow immediate and
continual pre-hospital monitoring of lactate and glucose to inform patient specific
interventions that will improve survivability from hemorrhage (and hemorrhagic shock),
Fig. 4.3. The following work is a preliminary study of wireless biosensor systems in vivo
to evaluate initial functionality.
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Figure 4.3. An implantable biosensor for continual monitoring will improve trauma outcomes by engaging
pre-hospital monitoring, providing adjunct metabolic vital signs to first responders, and enabling more
physiologically based care and patient specific interventions. Such a system can be rapidly deployed by
emergency medical services (EMS) during mass impatient care (MIC) from natural disasters and in the
theater of war by combat medics (WAR).

4.2 Materials and Methods
4.2.1 Chemicals and reagents
Poly(styrene sulfonic acid) (PSSA) was purchased from Polysciences, Inc.
Dulbecco’s phosphate buffer saline, Pyrrole monomer (reagent grade 98+%), 4-(3Pyrrolyl)butyric acid (PyBA), Glucose oxidase (GOx, E.C. 1.1.3.4 from Aspergillus
niger), Lactate oxidase (LOx, 1.13.12.4 from Pediococcus sp), β-D(+)-glucose, Lithium
lactate, and all other common solvents were purchased from Sigma Aldrich Co. (St.
Louis, MO, USA). Pyrrole monomer was purified by double passage through an alumina
silicate column. Solutions were prepared in deionized water prepared by purifying
distilled water through a Milli-Q® plus (Millipore Inc.) ultrapure water system. The
glucose stock solutions of 1.0 M and 3.0 M were prepared and allowed to mutarotate
overnight.
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4.2.2 Biosensor components
The MDEA 5037 transducers were acquired from ABTECH Scientific, Inc.,
Richmond, Virginia. The 8100-K1 fixed frequency wireless dual potentiostat system was
purchased from Pinnacle Technology (Lawrence, KS). The kit contained the Pinnacle
8151 wireless dual potentiostat, the voltage programmer, and a receiver base station
(model 8106) with USB cables. Software for data acquisition (PAL) was also included in
the kit.
4.2.3 Cleaning of transducers
The MDEA 5037 transducers were first ultrasonicated in DI-water, IPA, and DIwater for 5 minutes each. Next they were placed in a UV-ozone cleaner (Boekel
Industries) and irradiated for 10 minutes followed by 1 minute of ultrasonication in IPA.
Transducers were then immersed in PBS buffer, made the working electrode of a three
electrode electrochemical cell and electrochemically cleaned by sweeping the potential
between 0 to -1.2 V (vs. Ag/AgCl, 3 M KCl) at 100 mV/s for 40 cycles. Transducers
were finally thoroughly rinsed in flowing DI-water before use.
4.2.4 Conferring biospecificity to MDEA 5037 transducers
Working electrode arrays of MDEA 5037 transducers were first seeded with a
thin electropolymerized film of PPy. This adherent film was formed with an impressed
potential of 750 mV vs Ag/AgCl (3M KCl) using a charge density of 10 mC/cm 2 from an
aqueous solution of 0.2 M Py and 0.05 M (repeat units) PSSA. Biospecificity was then
conferred to the working electrode arrays through further electropolymerization in
solutions containing 0.175 M Py, 0.025 M PyBA and 1 mg/mL of GOx or LOx prepared
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in DI-Water with pH adjustment to 4.5-5.5 using 1 M NaOH. Electropolymerization for
entrapping enzymes proceeded at 850 mV vs Ag/AgCl (3M KCl) for 100 mC/cm 2.
Before use, enzyme-modified microelectrodes were over-oxidized (OO-PPy) by
repeatedly cycling the electrode in PBS (100 mM, pH 7.2) between -200 to 1300 mV vs.
Ag/AgCl (3M KCl) for 40 cycles.
4.2.5 In vitro biosensor calibration prior to in vivo implantation:
Biotransducers were interfaced with the 8151 wireless potentiostat via a custom
connector. Two electrode electrochemical detection of glucose or lactate was utilized
with the on-board working electrode array serving as the working electrode and the onboard counter electrode serving as the shorted counter and reference. Bias potential of
0.65 V was programmed into the 8151 and applied to the working electrode array of the
MDEA 5037 with respect to the onboard counter electrode. To ensure functionality prior
to implantation an in vitro calibration of MDEA 5037s were performed no longer than 8
hours prior by placing biotransducers in PBS buffer at 37 oC followed by standard
glucose and lactate infusions. Steady state amperometric current produced was measured
and the sensitivity of the device was determined from the slope of the calibration plot. In
vitro calibrated sensitivity (So) is determined by the ratio of the resulting change in
current (I) to change concentration of analyte in buffer (Go for glucose, Lo for lactate) in
units of µA/mM/cm2. Time dependent estimations of intramuscular glucose, Go(t) and
lactate, Lo(t) were made based on this reference sensitivity after implantation of the
device. The kinetic parameters were determined using Lineweaver-Burk (LWB) analysis
of biosensor amperometric response. The apparent Michaelis–Menten constant KMapp and
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the maximum current response, Imax, were calculated from the slope and the intercept of
the Lineweaver–Burk plots [227, 228]. Limits of detection were calculated by dividing
3*STDev of the steady-state, blank solution current response by the calculated
sensitivity.
4.2.6 Implantation of biotransducers into trapezius muscles of rats
Sprague-Dawley rats weighing between 250-450 g were shaved, sterilized and
placed under anesthesia on a warming pad. An incision was made above the trapezius
muscle on the back to expose the fascia and muscle. Fascia was spread apart using blunttipped scissors to expose the muscle. A small pocket was formed by spreading the muscle
tissue apart using microtweezers. The MDEA 5037 was carefully inserted into the pocket
by hand. The muscle tissue was closed over working region of the biotransducer and
secured with a suture, Figure 4.4(A). Fascia was secured over the muscle tissue with a
suture and the wound was closed with surgical staples, Figure 4.4(B). After implantation
the MDEA 5037 was interfaced with the 8151 potentiostat and allowed to reach steady
state for an hour. The rat was observed during this time to ensure stability.
A

B

Figure 4.4. Sprague-Dawley rat under anesthesia with A) the MDEA 5037 biotransducer implanted into
trapezius muscle and secured into place with a suture, and B) the incision closed and secured around the
MDEA 5037 with surgical staples.
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4.2.7 In vivo biosensor sensitivity and response time to bolus infusion of
analytes:
After biosensor response reached a steady state baseline measurement of
intramuscular analytes, measurements of blood analytes from the saphenous vein were
made. Blood glucose was measured using a test strip based Alpha TRAK glucose meter
(Abbott Laboratories). A bolus of solution consisting of 3 M glucose and 0.4 M lactate
prepared in 1X PBS (pH = 7.4) was infused (up to 0.5 mL) through the tail vein.
Interstitial analytes were measured for up to 3 hours. Additional blood analyte
measurements and bolus infusions were made at 30 min intervals. Changes in
amperometric response deviating from steady state were observed after the bolus
injection of glucose and lactate into venous blood. Estimated interstitial analyte responses
measured by biosensors calibrated in vitro were compared to basal analyte concentrations
in the blood. Interstitial concentrations of glucose in non-diabetic rats have been shown to
have a good 1:1 correlation to plasma glucose concentration at the basal state [289].
Sensitivity was determined based on in vivo responsiveness to exogenously changing
levels of glucose and lactate. Clarke error grid analysis was performed to compare
interstitial and blood analytes [290]. Rats were subsequently euthanized after procedures
and the trapezius muscle surrounding the biotransducer was resected in order to safely
recover biotransducers
4.2.8 Mechanisms of failure and functional life time of biotransducers
Resected biotransducers were characterized in vitro to assess the functionality and
lifetime of the device in vivo. Biosensors may cease to function as intended due to
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component-based and biocompatibility-based failures [291]. The following mechanisms
of failure for the explanted biosensors were analyzed: lead detachments, electrical shorts,
component delamination and degradation, biofouling, electrode passivation, and fibrous
encapsulation. Upon explantation the base current, sensitivity and response time of
biosensors was evaluated in PBS buffer. Resected biotransducers were considered
functional if sensitivity and maximum current are maintained non-significantly different
from freshly prepared sensors, can detect the physiologically relevant range of glucose or
lactate, and have a response time of approximately 1 minute.
4.3 Results and Discussion
4.3.1 Performance of freshly prepared lactate biosensors
Biotransducers were characterized immediately after their preparation and again
immediately after being resected from the trapezius muscle. Lactate biosensors using
lactate oxidase, an FMN-based enzyme, were prepared in the same fashion as glucose
biosensors using glucose oxidase, an FAD-based enzyme.

Lactate sensors were

successful in producing a dose response, but did not produce adequate current densities in
response to analytes in vitro and were therefore not considered for in vivo analysis. Dose
response to lactate and biosensor performance parameters are shown in Figure 4.5 and
Table 4.1.

The lactate sensors had a good sensitivity of 0.36 0.15 µA/mM/cm2.

However, there was insufficient current density generated to produce a meaningful dose
response using the Pinnacle 8151 wireless potentiostat. Response lactate was linear for
nearly the entire range of interrogated concentration with a linear dynamic range of 6.6
0.9 mM. Based on the observed Imax and KMapp the lactate biosensors did not adhere well
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to LWB analysis in addition to seeing the dose response having a linear trend. Given the
detection limits of 7.9 5.6 mM, lactate biosensors could only accurately discern changes
in interstitial lactate concentration larger than that which is clinically relevant
(hyperlactatemia ≈ [lactate] > 4 mM) [65, 66].
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Figure 4.5. Dose response of lactate MDEA 5037 biotransducers at 650 mV bias working electrode array
versus on-board counter electrode after being freshly prepared (PBS buffer, pH = 7.2, 25 oC).
Table 4.1. Dose response (650 mV bias, PBS, pH = 7.2, 25 oC) performance parameters for lactate
biotransducers freshly fabricated (± standard deviation is shown).

Sensitivity (µA/mM/cm2)

Freshly prepared
biotransducers
(n = 3)
0.36 0.15

Response time (s)

86 26

Detection limit (mM)

7.9 5.6

KMapp (mM)

-9.1 15.8

MDEA 5037, Pt|PPy(PSSA)|p(Py-co-PyBA)-LOx
[E] = 1.0 mg/mL

Imax (µA/cm )

-1.9 5.8

Linear range (mM)

6.6 0.9

2
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4.3.2 Performance of freshly prepared and resected glucose biosensors
Glucose biosensors successfully produced dose response curves to analytes in
vitro. The dose response of glucose sensitive MDEA 5037s are shown in Figure 4.6. The
changes in glucose biosensor performance parameters are summarized in Figure 4.7 and
Table 4.2. The MDEA 5037 biotransducers were implanted in muscle tissue for up to 3
hours. The overall performance of resected biotransducers was diminished compared to
when they were freshly prepared which was expected. Sensitivity decreased from 0.68
0.40 to 0.22 0.17 µA/mM/cm2 (p = 0.08), response time increased from 41 18 to 244
193 s (p = 0.08), detection limits increased from 0.05 0.03 to 0.27 0.27 mM (p =
0.17), KMapp increased from 7.3 3.4 to 74 130 mM (p = 0.35), Imax decreased from 11.7
6.5 to 8.8 9.3 (p = 0.30), and linear range increased from 7.2 5.9 to 14.1 11.6 (p =
0.34). Biotransducers were subject to blood and protein adsorption as well as the acute
inflammatory response during their relatively short implantation period. The dramatic
increase in response time and KMapp is likely due to proteins adsorbing from the
interstitial fluid to the biotransducer surface. Protein adsorption has been shown to have a
negative influence on glucose diffusion for implantable and continuous biosensor systems
[138, 292]. No deterioration of the MDEA 5037 transducer was observed and none of the
resected biotransducers had a spurious response indicating that neither instrumentation
problems nor transducer compromises were causing the changes in performance. Limits
of detection were maintained at adequate levels to discern changes in glucose using the
biosensor system. Production of hydrogen peroxide has been identified as the primary
agent for short-term enzyme degradation in vivo [293]. The lack of significant change in
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maximum current shows that the original enzyme activity is still present in the system
after short-term use in vivo, supporting these previous findings. Overall the MDEA 5037
biotransducers maintained their activity after short-term implantation with respect to
sensitivity, maximum current, range of response and response time.
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Figure 4.6. Dose response of glucose MDEA 5037 biotransducers after being freshly prepared and after
resection from rat trapezius muscle (650 mV bias, PBS buffer, pH = 7.2, 25 oC, ± standard deviation is
shown).
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Figure 4.7. Glucose biosensor performance parameters of freshly prepared and resected biotransducers
(650 mV bias, PBS buffer, pH = 7.2, 25 oC, n = 4, ± standard deviation is shown).
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Table 4.2. Dose response performance parameters for biotransducers freshly fabricated and resected from
trapezius muscle after c.a. 3 hours of implantation (650 mV bias, PBS, pH = 7.2, 25 oC, ± standard
deviation is shown).

MDEA 5037, Pt|PPy(PSSA)|p(Py-co-PyBA)-Gox
[E] = 1.0 mg/mL

Freshly prepared
biotransducers
(n = 4)

Resected
biotransducers
(n = 4)

Sensitivity (µA/mM/cm2)

0.68 0.40

0.22 0.17

Response time (s)

41 18

244 193

Detection limit (mM)

0.05 0.03

0.27 0.27

KMapp (mM)

7.3 3.4

74 130

Imax (µA/cm2)

11.7 6.5

8.8 9.3

Linear range (mM)

7.2 5.9

14.1 11.6

4.3.3 In vivo response of MDEA 5037 biosensors to exogenously changing
analytes
Steady state current was allowed to be reached for one hour after implantation of
the biotransducer into the trapezius muscle. Three MDEA 5037 biosensors were tested in
vivo (MDEA-1, MDEA-2 and MDEA-3). The amperometric responses of the sensors in
vivo are shown in Figures G1, G2 and G3. MDEA-1 and MDEA-3 were prepared
having a glucose sensitive cell (Channel 1) and a lactate sensitive cell (Channel 2).
Response of Channel 2 for these biotransducers was omitted for clarity. MDEA-2 utilized
two glucose sensitive cells (Channel 1 and 2) to compare differences in response to
glucose on the same biotransducer. Intramuscular glucose via the biosensor was
compared to venous blood glucose from the saphenous vein measured with the Alpha
TRAK. Interstitial glucose has been shown to lag blood glucose by approximately 5
minutes [294]. Over the implantation time periods there was sufficient time for interstitial
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glucose to follow blood glucose measurements. The first sensor, MDEA-1, came to a
stable base-line current, and interstitial glucose concentrations did not vary much
between 1.91-2.23 mM, Figure 4.8 and Table 4.3. This seemed reasonable as blood
glucose did not vary, remaining between 5.49-5.88 mM. One of the sensors (MDEA-2,
Channel 2) showed a sustained increase in interstitial glucose after tail vein infusions of
glucose, Figure 4.9 and Table 4.4. For the case of MDEA-2, both channels were
sensitive to glucose. However, only one of the channels (Channel 2) showed a change in
interstitial glucose while the other (Channel 1) did not. MDEA-3 showed a decreasing
trend of interstitial glucose concentration with a rapid increase and subsequent fall within
minutes after a tail vein infusion, Figure 4.10 and Table 4.5. Interstitial and blood
glucose concentrations in anesthetized rats at the basal level are typically statistically
similar, but insulin has been shown to cause up to a 60% difference between the two
compartments within 30 minutes [295]. Glucose concentrations have been shown to
change significantly faster in the blood of anesthetized rats with a rate of 6.8 2.0
mg/dl/min compared to subcutaneous fluid having a rate of 3.9 1.3 mg/dl/min [295].
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Figure 4.8. MDEA-1 Amperometric response at 650 mV bias to glucose in vivo in the trapezius muscle of
a male Sprague-Dawley rat of 412 g (infusions were of 3 M glucose in PBS).
Table 4.3. MDEA-1 Biosensor and saphenous glucose comparison.

Time (s)

Saphenous glucose (mM)

Biosensor glucose Ch1 (mM)

4360

5.49

2.23

6330

5.72

1.91

8380

5.88

1.92

150

Figure 4.9. MDEA-2 Amperometric response at 650 mV bias to glucose in vivo in the trapezius muscle of
a male Sprague-Dawley rat of 408 g (infusions were of 3 M glucose in PBS).
Table 4.4. MDEA-2 Biosensor and saphenous glucose comparison.

Time (s)

Saphenous glucose
(mM)

Biosensor glucose Ch1
(mM)

Biosensor glucose Ch2
(mM)

3531

10.21

0.67

5.01

4837

9.93

0.74

5.97

5982

10.88

0.71

7.95

7111

11.27

0.67

8.54
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Figure 4.10. MDEA-3 Amperometric response at 650 mV bias to glucose in vivo in the trapezius muscle of
a female Sprague-Dawley rat of 265 g (infusions were of 3 M glucose in PBS).
Table 4.5. MDEA-3 Biosensor and saphenous glucose comparison.

Time (s)

Saphenous glucose (mM)

Biosensor glucose Ch1
(mM)

3736

13.65

3.55

5344

19.65

0.44

6381

16.26

1.28

4.3.4 Clinical accuracy of the MDEA 5037 wireless biosensor system
The correspondence between the two systems is summarized in Figure 4.11.
Intramuscular glucose measurements were consistently lower than blood glucose
measurements. Clarke’s error grid analysis was utilized to assess the clinical significance
of difference between the MDEA 5037 biosensor and the Alpha TRAK reference, Figure
4.12. Zone A represents glucose values that deviate no more than 20% of reference
values, and the values within this range are considered to be clinically exact. Zone B are
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considered to be benign errors. Values in zones A and B are considered clinically
acceptable, whereas values in zones C-E are considered dangerous [296]. The MDEA
5037 biosensors had a total of 0 points in zone A, 7 points in zone B, 1 point in zone C, 0
points in zone D, and 6 points in zone E. Although none of the biosensors agreed exactly
with the reference, the MDEA 5037 and Pinnacle 8151 wireless biosensor system had a
clinically acceptable accuracy of 50%. Background current could not be fully accounted
for with these biosensors due to both electrochemical channels being used for
simultaneous analyte detection. Accuracy of continuous monitoring can be improved by
correcting for background current [297]. Background current stability of biosensors is
known to drift in vivo [298]. The background current of MDEA 5037 biotransducers can
increase by two orders of magnitude from 0.5 nA to 20 nA after a week of storage in 0.1
M PBS (pH = 7.2) buffer at 25 oC (data not shown). Future studies will need to take into
consideration background current immediately prior to implantation. Electroconductive
hydrogel modified biotransducers will also be utilized in future studies, which will likely
have better stability in vivo compared to just polypyrrole modified biotransducers. The
biosmart hydrogels have been shown to mitigate protein adsorption [131] which may lead
to better short-term performance in vivo. The inclusion of hydrogels will be necessary for
the protection of enzymes and mitigation of fibrous encapsulation for long-term
implantation of biosensors.
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Figure 4.11. Comparison of intramuscular (MDEA 5037 biosensor) to venous blood (Alpha TRAK
handheld) glucose measurements.

Figure 4.12. Clarke’s error grid analysis of implanted MDEA 5037 biosensors with respect to hand-held
glucose monitor Alpha TRAK measuring venous blood as a reference.

4.4 Conclusions
The MDEA 5037 and Pinnacle 8151 wireless biosensor system was successfully
prepared and characterized in vivo. Both glucose and lactate biosensors were prepared
and interrogated in vitro prior to implantation. Lactate biosensor performance was
insufficient for characterization in vivo as the limits of detection were not small enough.
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Glucose biosensors performed as expected based on previous characterization in vitro.
MDEA 5037 Biosensor systems maintained functionality after 3 hours of implantation in
the trapezius muscle of Sprague-Dawley rats. Non-significant decreases in sensitivity and
maximum current were observed after biotransducers were resected. Protein adsorption
onto the MDEA 5037 biotransducer surface after short-term use in vivo is likely the cause
for dramatically increased response time and KMapp. The biosensor system had a clinically
acceptable accuracy of 50% when comparing interstitially measured analytes to a
reference hand held glucose monitor. To improve both short-term and long-term
performance in vivo the biotransducers will be coated in hydrogel in the future to mitigate
protein adsorption. Background current will also need to be taken into consideration for
improving in vivo accuracy of MDEA 5037 biosensor systems. This may be
accomplished by either utilizing sensors non-specific to analytes during measurement or
measurement of steady state current in an interstitial fluid/buffer immediately prior to
implantation.
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CHAPTER FIVE: FUTURE WORK AND COMMENTARY ON IMPLANTABLE
AMPEROMETRIC BIOSENSORS

5.1 Introduction
This last chapter highlights areas of ongoing research with respect to implantable
biosensors. There are a number of avenues for future work and research when it comes to
implantable devices and specifically biosensors like the MDEA 5037 system. The
primary goal for future work on implantable amperometric biosensors will be continued
investigation of methods and approaches to influence in vivo performance. Other
important avenues include developing oxygen independent systems, determining the
usefulness of biosensor vital signs for healthcare professionals, integration of biosensor
vital signs with established physical vital signs, systems integration, and internal
calibration.
5.2 Improving the current generation of implantable amperometric
biosensors
For an indwelling biosensor, such as an intramuscularly implanted biosensor, the
temperature of the surrounding tissue bed will have influence on the amperometric
current response based on the Arrhenius relationship [299]. For a biosensor used in the
monitoring of vital signs of a trauma patient, onset of events such as hypothermia will
have ramifications for the performance of the biosensor. Physiological and metabolic
changes in the body will also accompany changes in temperature. Temperature has
shown to have effects on the catalytic activity of the enzymes, permeability of analytes
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through substrates, and the water solubility of oxygen [300]. Future iterations of
implantable biosensors will need to account for temperature and thereby reduce
uncertainty in the basis for changes of the amperometric response.
Signal processing procedures necessary for implantable sensors have been
outlined and include low-pass filtering, DC offset adjustment, and amplification [70].
Raw signals from biosensors have been considered as a convolution of an analytespecific function and a series of interference functions such as temperature changes and
mechanical instabilities of the implanted device [301]. Algorithms have been developed
for real time management of raw data, providing compensation electrical and mechanical
perturbations, temperature fluctuation, enzyme inactivation, and nonlinearity of analyte
dose response [301]. Interference functions that are mechanical or electrical in origin, are
filtered using a process known as clipping, which is the suppression of rapid signal
variations that are faster than the fastest physiological changes in analyte concentration
[301].
Another approach to address interferences is to use interrogation potentials that
are displaced from the redox signals of the interferents. This is accomplished by the use
of surface confined electrocatalysts such as poly(neutral red) / flavin adenine dinucleotide
(FAD) hybrid films [188], lead pentacyanonitrosylferrate [302], Prussian Blue and its
hybrids [303] or molecular redox mediators. Decreases in biosensor signal are expected
to occur over time (drift). For any such decrease in signal over time, fifty percent of the
total decrease can be attributed to inactivation of enzyme, thirty percent attributed to
leaching of mediators, and twenty percent attributed to decreases in background current
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leading to only an apparent loss of signal [300]. Hence emphasis must be placed on
reducing enzyme denaturation, eliminating the use of mediations, and eliminating
background currents.
Prussian blue (PB) is a well-known, highly stable, highly selective catalyst for
hydrogen peroxide reduction. Reduction of H2O2 can be performed at a PB modified
surface using potentials as low as 0 V vs Ag/AgCl with better effectiveness than
peroxidase enzyme modified surfaces [304]. Utilizing such a low potential would
mitigate many interfering responses. Heterogeneous rate constants for peroxide reduction
of 0.015-0.02 cm/s have been reported [305]. In comparison the kinetic constant for
peroxide oxidation at platinum electrodes is three orders of magnitude lower than this
[306]. Prussian blue and polypyrrole can both be electrodeposited onto electrodes [307].
This technique will be explored in future iterations of the ECH-modified MDEA 5037
biotransducer to maximize response to hydrogen peroxide generated by glucose oxidase
and lactate oxidase. Underpotential deposition of platinum and gold onto MDEA 5037
electrodes to form nanoparticles will also be explored. Gold and platinum nanoparticles
can be used to achieve similar catalytic oxidation and reduction of hydrogen peroxide at
low operating potentials [308, 309].
5.3 Optimizing electroconductive hydrogels for enzyme stability in vivo
Enzyme stability in a biosensor application can be defined as the reproducibility
of analytical response or signal to analyte (substrate) over a period of time. Factors
influencing signal reproducibility include the exact activity of immobilized enzymes
[310], possible enzyme denaturation during immobilization onto electrodes [311],
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enzyme degradation over time by reactive oxidative species [312], and protease
degradation of the immobilized enzyme [313]. It has been well established that stability
of enzymes will be directly affected by the immobilization technique used and the
microenvironment into which the enzymes are immobilized [314]. Conventional
immobilization techniques include physical adsorption [182], biomolecule entrapment
with or without covalent tethering such as within a hydrogel [2, 183, 184], covalent
cross-linking using homo- and hetero-bifunctional cross linkers [186], and direct covalent
bonding to the electrode’s surface [185]. Entrapment is one of the most appropriate
techniques for implantable devices as it is safe and easy to perform, requires little to no
toxic chemicals, and maintains enzymes in a confined area near an electrode without
chemically perturbing their native structure [315].
To address the needs of the system, we have developed soft, condensed,
biomimetic but otherwise inherently electronically conductive materials to address the
challenge of interfacing solid state devices with the electronics of the body, which is
predominantly ionic [316]. These electroconductive hydrogels offer the potential for
biocompatibility while sustaining electrical fidelity across the biological-to-solid state
interface. Electroconductive hydrogel coating of biotransducers has shown to be
beneficial for mitigating protein adsorption, fibrous encapsulation, enzyme stability and
control of transport properties of biomolecules. The current drawback to using ECH
modified systems is low current densities due to diffusion limitation of analytes to the
electrode surface. While sophisticated potentiostat technology can be utilized to
circumvent these issues by implementing low current modules, it becomes more difficult
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to produce a small, wireless system with the same amplification and filtering capabilities.
Increasing the degree of hydration by lowering the overall crosslink density of hydrogels
to improve current densities will be a future work in optimizing ECH-modified
biotransducers. This may serve to effectively increase the free water content of the
system to better facilitate enzyme entrapment, and decrease diffusional barriers and
tortuosity. The stiffness of the ECH will also need to be considered during the
optimization as it will have an effect on cell viability and proliferation.
5.4 Second generation biosensors and use of mediators for electron transfer
Mediators are molecules, moieties of polymers, complexes, and inorganic layers
that mediate electron transfer between the redox active co-factors of immobilized
enzymes and the electrode. A key requirement of the mediator is to provide a high
electron transfer rate constant (kET) with the prosthetic group of the enzyme as well as
with the electrode in order to obtain high currents, lowered limits of detection and
increased sensitivity. As a result, the necessary applied potential can be reduced to values
where fewer potentially interfering electroactive species are non-specifically oxidized or
reduced. Other requirements for mediators are that they be suitably soluble in aqueous
media, have well-characterized reversible redox behavior, possess chemical stability in
both the oxidized and the reduced forms, be of an appropriate redox potential to allow
mitigation of the effect of interfering substances, be un-reactive with the targeted enzyme
substrate, its product or other substances, be insensitive to pH and ionic strength effects,
and most of all be non-cytotoxic. Mediators are crucial for implantable sensors where
oxygen levels are significantly reduced (hypoxia) and/or highly variable, such as during a
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state of tissue ischemia. Oxygen is a highly competitive molecule against other mediators
for the oxidation of reduced enzymes. Glucose oxidase has a turnover rate of
approximately 1000 s-1 in the presence of oxygen [138].
Molecular mediators such as ferrocene, and electroactive polymers such as
poly(vinlyferroence) have been explored but found wanting. Polymers based on Os2+/3+
complexes 2,2’-bipyridine (bpy) of type [Os(2,2'-bipyridyl)2LL'] and [Os(4,4'-dimethyl2,2'-bipyridyl)2LL'] (where LL are ligands) form stable, reversible, redox couples and
have shown tremendous promise but have not been fully evaluated in vivo [317].
Electroconductive polymers such as polypyrrole, polythiophene and polyaniline have also
be used as mediators wherein electrons are transferred between the enzyme redox center
and the polymer chain allowing for bias potentials as low as 0.0 V vs. Ag/AgCl to be
used [318]. However, peroxide generated by enzymes will overoxidize the polypyrrole
network over time, diminishing its electroconductive and mediating properties. Future
work will include tethering of osmium and ruthenium complexes into hydrogel networks
to

improve

oxygen

independence

of

biosensor

systems.

The

intramuscular

biocompatibility of mediator loaded hydrogels will also need to be examined.
5.5 Third generation biosensors and direct electron transfer
Generation III biotransducers allow direct electron transfer between the redox
active co-factor of the oxidoreductase enzymes and the underlying electrode. In this
respect they obviate the need for molecular oxygen and/or molecular mediators. Carbon
nanotubes (CNTs) and graphene with their high chemical stability, high surface area,
excellent mechanical properties, and high electrical conductivity are now being
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extensively investigated for the construction of nanobiosensors [319-321]. The electrical
and electronic properties of CNTs enhances electron transfer, making them suitable for
the preparation of electrode materials and for use in chemical and biological sensors [322,
323]. The use of CNTs for biosensor electrode applications has been demonstrated [320,
324] and their application towards electrochemical sensors and biosensors has gained
significant momentum [320, 325]. Covalent functionalization changes the chemical
properties of nanotubes dramatically. However, this has allowed covalent and ultrasonic
non-covalent conjugation [326] to redox proteins and so allows for the efficient
immobilization of glucose oxidase; allowing the CNTs to simultaneously act both as an
immobilization matrix and as a redox mediator or electrocatalyst [327, 328]. Direct
electron transfer has been demonstrated, however, the dose response to glucose for these
systems has been less efficient in deoxygenated conditions compared to O2-saturated
conditions [329, 330]. Oxygen independent systems, while currently less efficient than an
oxygen dependent systems, is more valuable especially for trauma monitoring
applications in hypoxic tissues where oxygen tension is very low. Although there have
seen significant research to produce glucose biosensors with reliability for in vitro or in
vivo applications [331, 332], the recent availability of nanostructured electrodes that
allow direct bio-electrochemical reactions with the buried FAD [330] is promising for the
development of reagentless biosensors, independent of oxygen tension, for eventual
clinical use. In view of their above mentioned properties, carbon nanotubes are under
intensive investigation as potential building blocks for implantable amperometric
biosensors.
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Electrodes used for carbon nanotube immobilizations are typically high surface
area such as electrospun fibrous metal or glassy carbon [329, 330]. Transducers like the
MDEA 5037 utilize platinum and gold for their working electrodes which can be
modified to produce a variety of surface topographies and chemistries. Future work may
encompass depositing carbon nanotubes onto the MDEA 5037 working electrode
surfaces for immobilizing carbon nanotubes to be used for conjugation with enzymes. For
polypyrrole

immobilized

single-walled

carbon

nanotubes

(SWCNT)

via

electropolymerization, preliminary studies have shown that either nanotubes and/or GOxSWCNT conjugates are providing conduction between the solution and platinum
electrode through the nano-thin polypyrrole layer, Figure 5.1. Approximately 80% of the
original electrode area is blocked by PPy-GOx whereas only 25% of the original
electrode area is blocked by PPy-GOx-SWCNT. Blocking and insulation of the electrode
to Ferrocene Carboxylic acid (FcCOOH) by polypyrrole was expected [12]. Having
immobilized SWCNTs onto MDEA 5037 transducers there is now potential for direct
electron transfer between subsequently immobilized enzymes and electrodes.
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Figure 5.1. (Left) Cyclic voltammetry of bare platinum, PPy-GOx and PPy-GOx-SWCNT systems in 1
mM FcCOOH in PBS buffer (pH = 7.2) at 100 mV/s. (Right) Peak anodic current as a function of scan rate
(error bars show standard deviation).

5.6 Systems integration
Implantation is motivated by the need to allow the patient or subject the freedom
of motion without being confined to an instrument; implantation allows the subject to
take the instrument with them. Central to an implantable amperometric enzyme biosensor
is its potentiostat. However, for implantation, the potentiostat is closely associated with
two-way telemetry and communications. Three general formats are being pursued. The
first is an implantable but otherwise tethered biotransducer with externally located power,
electronics and communications components with the external components being
mounted outside but on the subject’s body [166]. The second is a fully integrated discrete
but otherwise fully implanted device [333] and the third is an application specific
integrated circuit (ASIC) where all components are likewise fully implanted [334].
Representative examples of these three formats are shown in Figure 5.2. Simple
electrochemical techniques such as fixed-potential amperometry have been successfully
demonstrated. However, further improvements may be made by including additional
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electrochemical techniques such as sweep and pulse voltammetry. Improved filtering and
amplification capabilities of will enable detection of low current densities. The ability to
wirelessly program potentiostats will also be necessary for indwelling devices.

A

B

C

Figure 5.2. Examples that illustrate the three general formats for implantable biosensor systems. A) The
tethered biotransducer with externally located power, electronics and communications components. B) The
fully integrated discrete but otherwise fully implanted biosensor system. C) The application specific
integrated circuit (ASIC).

5.6.1 Device footprint
Cutting-edge, low-profile (small footprint) wireless potentiostats such as the
Pinnacle 8151 have been successful in producing implantable wireless glucose
biosensors. Decreasing the overall footprint of biosensor systems will be necessary in
future iterations. The footprint of an implantable amperometric biosensor is defined by
the volume of space the device takes up and represents the judicious balance between use
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of space and functionality. Ideally, an implantable biosensor system should be as small as
possible, have very low power consumption, and be able to wirelessly transmit data and
be remotely programmed while implanted within living tissues. Major electronic
components include the front-end potentiostat, power modules, microcontrollers, random
access memory, flash memory, RF transmitters, and analog-to-digital converters (ADC)
[335]. Miniaturized potentiostats have been developed which contain microprocessors,
ADC, gain and low-pass filters [153, 336-343]. Continued innovations in potentiostats
are needed. A miniature conformal antennae for implantable telemetry applications has
been developed to help minimize footprint wherein the entire package of the implantable
Bio-Nano-Sensor system is approximately 2477 mm3 (≈2.5 mL) in volume [344]. BioNano-Sensors with electrochemical front-ends have been developed for continuous
monitoring of alcohol [333], glucose, lactate, glutamate, and ATP [345]. Subdermal
identification (RFID- Radio Frequency Identification) chips such as the VeriChip® are
approximately 12-14 mm3, approximately two orders of magnitude smaller. However,
while application specific integrated circuits (ASIC), these devices at not equipped for
bioanalytical measurements. The unequivocal ambition of in vivo bioanalytical and
clinical chemistry is to develop and deploy physiological status monitoring biochips of
similar footprint, along the lines of a large grain of rice, Figure 5.3. The technical and
financial feasibility of this should become more apparent when considering Moore’s law
of increasing number of transistors per unit area of integrated circuits.
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Figure 5.3. The conceptualization of an ASIC design for an implantable biochip capable of bioanalytical
measurement.

5.6.2 Wireless architecture
Wireless biosensor systems are important for continuous monitoring of analytes at
the molecular level in both animal models and human patients [346]. Wireless
implantable biosensor systems must perform the following functions: i) manage power
for all components of the system, ii) acquire and condition analog signals, iii) digitize
analog signals, iv) store readings and operational parameters, v) support communication
to and from a base station, and vi) be able to switch between an active and low-power or
sleep state [335]. The Texas Instruments (TI) MSP430 ultra-low power and mixed signal
microcontrollers are readily matched with AD converters, wireless transceivers and
application specific circuitry to provide a valuable development platform. The CC1110
(TI/Chipcon) is a small, surface mounted integrated circuit (IC) that been determined to
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be one of the best solutions for a discrete implantable system as it has a fully
implemented microprocessor, RF transceiver, and ADC [335]. A low-power, high-speed,
ultra-wideband (UWB) transmitter in a wireless transmission test platform for
implantable biosensors has been developed. Occupying 420 μm2, the integrated
transmitter consists of a compact pulse generator and a modulator [347]. The transmitter
generates 1ns pulse widths at pulse rates of 90-270 MHz and achieved 14 Mbps data rate.
At a 50% data duty cycle, power ranged from 10-21 mW over a transmission distance of
3.2-4.0 meters. The site of implantation and the environment of operation of the
biosensor will determine the requirements of the RF transceiver in terms of frequency of
operation. The MAX4039 (Maxim integrated products) is a commercially available IC
that has already been utilized in implantable biosensors for animal modeling [345]. Novel
low power IC designs and power harvesting circuits have also been employed in some
select case studies [348]. New wireless architecture enables data processing on hand-held
devices such as mobile phones and by cloud computing. The ability to save history and
trends of patient physiologic status can facilitate powerful retrospective analysis with
respect to patient outcomes. This will come with issues of latency, response time and
wireless security that will need to be considered.
5.6.3 Power requirements
Implantable amperometric biosensor systems, because of their analog front ends
and the need for mixed signal electronics, processing, and communications, are power
demanding devices. Acknowledged power sources are batteries, inductively coupled
power sources, or an internally sustainable source of energy such as a biofuel cell.
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Batteries have thus far failed to deliver the combined power density and footprint
required of fully implantable bioanalytical devices. Inductively powered sources based on
novel stacked spiral antenna designs are beginning to emerge and are providing sufficient
power to meet the demands of implantable bioanalytical devices [349]. Micro-biofuel
cells based on enzyme reactivity represent a clear sustainable possibility [350]. Facile
methods to develop lithium-ion batteries comprised of anode materials of SnO2nanocrystal/grapheme-nanosheets have been explored for potential use in biosensor
applications, but are still in the nascent stages of development and optimization [351]. In
any case, power management will become central to the performance of wholly
implantable biosensors.
5.7 Usefulness of data to caregivers
The format for presenting data can affect decision making [352, 353]. In general,
the faster directed resuscitation efforts are performed the better opportunity patients have
for survival [354]. While under development, it is important to understand and delineate
the suitability and applicability of an implantable device to the real world need.
Determining how to appropriately present data in a fast-paced, data-rich environment
requires judicious attention to the decision support needs and the context of use for each
group of end users (e.g. EMS, emergency physician, surgeons, RNs). It will be
paramount to identify i) what physiological status data, if any, is currently available to all
healthcare professionals (e.g. EMTs, emergency physicians, trauma surgeons, and nurses)
that care for the trauma patient from site of accident through recovery, ii) the key
physiological parameters that are useful in making patient care decisions, iii) the data
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needs during transition from prehospital to hospital based care between ambulance and
emergency department/trauma center, operating theater, and ICU, and iv) the variability
among two admitting centers. It will also be important to identify all participants in the
chain of patient custody throughout the time course of trauma. Future studies will include
conducting interviews with pre-hospital personnel, nurses and physicians, and developing
plans for biosensor handling between these personnel. This will be necessary in order to
produce a clear chain of care that does not violate privacy guidelines or compromise the
integrity of the device and associated data. The goal is to develop a display system that
presents data in a way such that it supports the cognitive work (sensing and perceiving
information,

decision-making,

problem

solving,

adapting,

etc.)

of

healthcare

professionals. Thus the biosensor display may act as a cognitive aid to reduce potential
decision-making and communication errors, reduces decision-making time, increases
system efficiency and potential survival rate of trauma patients.
5.8 Metabolic markers of trauma and integration with existing vital signs
It has been shown that combinations of vital signs are better at predicting trauma
patient outcome and need for lifesaving intervention better than individual vital signs
[355]. The Wireless Vital Signs Monitoring (WVSM) system by Athena GTX has shown
that a holistic understanding of physical vital signs is more accurate in predicting
outcomes than monitoring single physical events individual. These types of combination
vital signs have been used to produce close-loop resuscitation systems [356]. Future work
in monitoring trauma physiology will involve determining the predictive capability of
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combined biosensor vital signs with well-known physical vital signs such as heart rate,
pulse pressure and systolic blood pressure.
5.9 Internal calibration systems
A major challenge with indwelling biotransducers of the enzyme amperometric
type is the need for and approach to in vivo calibration of the device. It is commonplace
to conduct in vitro calibrations via standard additions when the sample matrix is complex.
Such techniques are generally not accessible in vivo. Accordingly, in vivo amperometric
biosensors must be designed to perform with a simple one-point calibration. One-point
calibration is generally based on blood derived from a single finger prick. One point
calibrations are inherently fraught with error and are notoriously inadequate when errors
are more complex than systemic and/or random. Multi-point calibrations of in vivo
biotransducers is possible by the administration of a bolus of glucose or lactate to the
patient or animal subject, and is often done in animal studies and may be done in a
clinical setting [9, 298]. However, this is not generally possible or recommended in the
chronically monitored patent. Moreover, this approach assumes that interstitially or
subcutaneously monitored analytes are at the same concentration as their systemic
circulating counterparts, or at least they are consistently proportional due to transport
barriers. While under homeostasis, the latter may be true, however the dynamics of the
physiological changes suggest otherwise, such as during hemorrhage [3]. In order to get
the most accurate interstitial analyte readings, future studies will investigate the best
possible calibration method for the MDEA 5037 biosensor prior to implantation.
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5.10 Conclusions
The ultimate goal of this work is to decrease the number of deaths due to trauma
related hemorrhage. Enzyme based amperometric biosensors are currently the dominant
in vivo format for the specific detection of biomolecules and are showing great promise in
their ability to be translated into an advanced diagnostic platform for trauma. We are
guided by critical analysis to the value of glucose and lactate as biomarkers of trauma and
hemorrhage. Enhancing biosensor performance for the measurement of glucose and
lactate will serve to develop this novel trauma diagnostic, and it will serve the need for
sustained research of numerous other implantable devices. The small size of
microfabricated biotransducers and their many possible modes of implantation open up
unexplored avenues for physiologic status monitoring. Opportunities include, but are not
limited to, measurement of i) lactate in the heart for predicting outcomes and endpoints of
cardiovascular surgery [357], ii) acetylcholine in the brain to measure brain seizure
activity [358] or observing effects of drugs on learning and memory [359], and iii)
observing hepatic glycogenesis in response to hyperglycemia and hyperinsulinemia for
diabetes research [360]. The potential for in silico modeling of biological transport
phenomena between the compartments also exists. The continued integration of
transducers, potentiostats, enzymes, hydrogels, physiology and nanotechnology will
guarantee the sustained research and development in this field.
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APPENDIX A: Electrode Geometries for Amperometry

Table A.1: Disc, Microdisc and Microdisc array geometries of implantable amperometric electrodes, their
associated forms of the Cottrel’s equation and schematics of the diffusive mass transport field associated
with each type of electrode.
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Table A.2: Disc, Microdisc and Microdisc array geometries of implantable amperometric electrodes, their
associated forms of the Cottrel’s equation and schematics of the diffusive mass transport field associated
with each type of electrode.
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